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ABSTRACT 
 
Epilepsy is a complex neurological disease composed of two or more unprovoked 
seizures that occur due to aberrant neuronal hyperexcitability. Detailed analysis of the 
mechanisms involved in epilepsy is required since there is a lack of adequate preventive 
therapies and one third of epileptic patients are pharmaco-resistant. Theiler’s murine 
encephalomyelitis virus (TMEV) infection induces a well-characterized experimental 
model of epilepsy. In response to intracerebral (I.C.) injection of DA or BeAn strain of 
TMEV in C57BL/6 mice, there is an unregulated immune response that has detrimental 
effects on neurons, and contributes to acute seizures, rendering mice susceptible to 
epilepsy. However, the specific contributions of virus and innate immune components to 
epileptogenesis need to be elucidated. For the first objective, we compared the in vivo 
neurovirulence of two variants of the DA strain, small (DA-DS) and large (DA-CL) 
plaque forming variants, by infecting C57BL/6 mice IC with either DA-DS or DA-CL 
variant. For the latter two objectives, we investigated the function of Nlrc5 and Nlrc3 
genes as positive or negative regulator of anti-viral immunity and epilepsy by infecting 
age-matched C57BL/6 wild type, Nlrc5-/-, and Nlrc3-/- mice with BeAn strain of TMEV. 
The infected mice were monitored for seizures, sickness, weight loss, and cognitive and 
behavioral deficits during the course of infection. Brains and spinal cords from infected 
mice were collected to determine viral titers, histopathology, and characterization of 
cellular infiltration.  
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We identified that DA-DS-infected mice exhibited significantly more seizures, sickness 
behavior, anxiety, weight loss, viral burden, neuroinflammation, and neuronal damage 
than DA-CL- infected mice. Thus, DA-DS variant was found highly neurovirulent, while 
DA-CL variant was attenuated in epilepsy.  
 
With respect to NLRs we found that Nlrc5-/- infected mice had significantly fewer 
seizures, lower sickness scores, weight loss and neuroinflammation, than wild type mice. 
In contrast, Nlrc3-/- infected mice were found hypersusceptible to acute seizures, 
epilepsy, and anxiolytic behavior. Furthermore, we determined that chronic seizures 
were not the consequence of persistent inflammation. We infer that Nlrc5 significantly 
upregulated anti-viral inflammation and seizures, while Nlrc3 significantly 
downregulated acute seizures and chronic epilepsy in C57BL/6 mice. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Overview of epilepsy  
 
Epilepsy and its clinical relevance 
Epilepsy is the fourth most common neurological disease in the USA following 
migraine, stroke, and Alzheimer’s disease 1. Recently, the International League against 
Epilepsy (ILAE) proposed a new definition of epilepsy to better suit its clinical 
relevance. They recommended, “epilepsy be considered to be a disease of the brain 
defined by any of the following conditions: (1) At least two unprovoked (or reflex) 
seizures occurring >24 h apart; (2) one unprovoked (or reflex) seizure and a probability 
of further seizures similar to the general recurrence risk (at least 60%) after two 
unprovoked seizures, occurring over the next 10 years; (3) diagnosis of an epilepsy 
syndrome” 2. Further, ILAE defined seizures as “a transient occurrence of signs and/or 
symptoms due to abnormal excessive or synchronous neuronal activity in the brain” 3.  
The current statistics from the Center for Disease Control and Prevention (CDC), 
estimates 4.1 million adults who have had a diagnosis of epilepsy or seizure disorder, 
including 2.3 million adults with active epilepsy in the USA 4, and this number escalates 
to approximately 70 million people in the world. Epilepsy affects people of all ages, but 
is more frequently seen during childhood and older adulthood, and among people from 
low- and middle-income countries, possibly due to their increased susceptibility to 
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cerebral infections and trauma 5. Currently available anti-epileptic drugs (AEDs) provide 
only symptomatic relief to patients, may lack efficacy and have several undesirable 
effects. Non-availability of adequate preventive therapy and pharmaco-resistance among 
one third of epileptic patients necessitates further understanding of the mechanism of 
epilepsy 6,7. 
According to the ILAE, epileptic seizures can be classified into two groups. The first are 
generalized seizures where both cerebral hemispheres of the brain are involved. 
However, the location and lateralization of each seizure onset may vary. The second 
group includes focal seizures where seizures originate from one focal region of the brain, 
and each seizure type share the same site of ictal onset. There is no distinct classification 
of epilepsy, but being a multi-factorial disease, it could be characterized based upon its 
etiology: (a) genetic, where the cause of the epileptic seizures is a known or presumed 
genetic defect(s) such as Dravet syndrome; (b) structural/metabolic, where epileptic 
seizures are caused by an acquired central nervous system (CNS) lesion such as by an 
infection or trauma; or (c) of unknown cause, where the trigger for epileptic seizures is 
unidentified 8. 
Viral infection-induced seizures or epilepsy 
Patients who suffer from encephalitis accompanied with acute seizure(s) have an 
increased risk of developing epilepsy, and this risk is known to be 10% by 5 years and 
22% by 20 years after the onset of the CNS infection. Moreover, patients with viral 
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encephalitis have a 16-fold increased risk of developing epilepsy, and this risk can 
persist for about 15 years after the occurrence of the initial viral infection 9. In most 
cases of viral encephalitis, the patients may experience seizure(s) during viraemic phase, 
and 4-20% of the patients, who survive the encephalitic phase, may regress to develop 
epilepsy 10.  
There are a number of viruses that may alter the neuronal circuits of the brain especially 
in the hippocampus. West Nile virus (WNV), Japanese encephalitis virus, Herpes 
simplex virus-1 (HSV-1), Enterovirus, Epstein-Barr virus, etc., are some of the common 
viruses that may cause seizures or epilepsy in humans and/or animals. Most of these 
viruses may cause generalized tonic-clonic seizures, which is characterized by the loss of 
consciousness and stiffening of the muscles followed by repetitive jerking movements of 
arms and/or legs. The viral infection could be a direct or indirect cause, as the virus itself 
and/or host immune responses developed against the virus may trigger seizures or 
epilepsy 10. In many cases of viral-induced epilepsy, the etiology remains unidentified. 
This could be due to a short period of viremia, lack of adequate viral diagnostic tests 
and/or unavailability of the affected brain tissue through biopsy 11.   
Use of the animal models to study seizures & epilepsy 
There are various animal models that could be used to study the cellular and molecular 
mechanisms of epilepsy and seizures. Existing animal models have been crucial in the 
development of currently available therapies. Yet, there is a need for new and improved 
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experimental models due to lack of any existing preventive therapy or “cure” 6. Most of 
the available animal models mimic only the acute phase of the disease or lack the 
development of spontaneous recurrent episodes of epileptic seizures; others may be 
costly, laborious, non-specific, non-reproducible or may involve long latent periods, 
lower number of epileptic animals or high animal mortality 12,13.  
 
Nevertheless, different forms of epilepsy with their variable pathophysiologies add 
complexity to the validation of new AEDs. A single model of epilepsy cannot 
recapitulate all the clinical signs and symptoms of human epilepsy. Therefore, 
understanding the mechanisms of epilepsy from different aspects requires studying 
multiple experimental epilepsy models 14.  
 
The immune responses in epilepsy 
The immune system plays a pivotal role in protecting the host against foreign pathogens 
or toxins. The innate immune responses aid in protecting the host against pathogens, and 
provide the signals for the activation of the adaptive immune cells. The CNS resident 
immune cells, microglia and astrocytes (glial cells) share a bidirectional relationship 
with each other. Their activation and localization near the site of injury/lesion is the 
hallmark of inflammation in various neurological diseases including epilepsy. But, the 
prolonged activation of microglia and astrocytes may have detrimental effects on the 
viability of neurons and the integrity of the blood-brain barrier (BBB). The glial cells 
can secrete several chemical mediators that affect each other’s activation and 
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recruitment, and the recruitment of peripheral immune cells into the CNS. The damaged 
BBB further allows the infiltration of peripheral immune cells (macrophages/monocytes, 
granulocytes, T cells, etc.) into the CNS, thereby exacerbating neuroinflammation 15-18.  
Activated microglia, reactive astrocytes and infiltrating macrophages can secrete various 
pro-inflammatory cytokines such as tumor necrosis factor (TNF-α) and interleukin (IL)-
1β, IL-6, which further contribute to inflammation by inducing neuronal cell death 16,19-
21. Microglia can also upregulate the expression levels of the major histocompatibility
complex (MHC) class I molecules on neurons through the secretion of various chemical 
mediators. Besides, microglia and macrophages themselves act as the professional 
antigen presenting cells (APCs) by expressing the MHC class II molecules on their 
surface 16. In addition to secreting pro-inflammatory cytokines, reactive astrocytes may 
become dysfunctional or lose their typical function of maintaining K+ and glutamate 
(excitatory neurotransmitter) homeostasis, thus further contributing to seizure 
development 19,22.  
Cells of the adaptive immune system also play a role in epilepsy. During viral 
encephalitis, CD8+ (cytotoxic) T cells secrete cytotoxic granules to kill virus-infected 
cells. These cytotoxic granules can also induce over-activation of glutamate receptors 
(N-methyl-D-aspartate [NMDA] receptors) leading to neuronal degeneration and 
seizures 10. Interestingly, epileptic patients have been found to have a significant 
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increase in the circulating levels of Natural Killer (NK) and CD8+ T cells during their 
transition from the ictal to the post-ictal phase 18. 
Apart from microglia, macrophages, and astrocytes, pro-inflammatory cytokines can 
also be produced by cerebral endothelial cells, and in some cases, by neurons 19. 
Development of epilepsy could be due to increased expression level of cytokine(s) or an 
imbalance between pro- and anti-inflammatory cytokine levels. For instance, elevated 
expression of IL-1β may affect seizure activity by increasing the extracellular 
concentration of glutamate (major excitatory neurotransmitter) and/or by increasing the 
function of glutamate receptors (NMDA receptors). Furthermore, IL-1β can dampen the 
inhibitory current transmission by inhibiting gamma-amino butyric acid (GABA)-
mediated Cl- fluxes thus further increasing neuronal excitability. Besides IL-1β, TNF-α 
can also increase the neuronal expression of glutamate receptors (α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid [AMPA] receptors) 19,23. Moreover, TNF-α can 
stimulate its own production (autocrine effect), and can promote the production of other 
pro-inflammatory cytokines such as IL-1β and IL-6. Additionally, it can activate 
microglia in an autocrine and paracrine fashion, and has a positive- feedback effect on 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) signaling 16.  
Thus, excessive and prolonged neuroinflammation may promote seizures, contribute to 
epileptogenesis, and may favor seizure recurrence by allowing the activation of resident 
  7 
immune cells and the infiltration of peripheral immune cells into the brain through the 
damaged BBB 18.   
 
Theiler’s murine encephalomyelitis virus  
 
Introduction to virus 
Theiler’s murine encephalomyelitis virus (TMEV) is a non-enveloped, positive-sense 
ssRNA virus. It belongs to the Cardiovirus genus of the Picornaviridae family. 
Picornaviruses are cytolytic in nature and may cause tissue damage either by inhibiting 
host transcription and translation machinery and/or by altering the apoptotic machinery 
of host cells. TMEV is a natural pathogen of mice and is thought to be transmitted by the 
fecal-oral route 24-26.  
 
Based on the neurovirulence, different strains of TMEV can be classified into two 
subgroups, GDVII and Theiler’s original (TO). The GDVII subgroup consists of highly 
neurovirulent strains, GDVII and FA, that cause acute fatal polioencephalomyelitis in all 
strains of mice including SJL mice, and fatal encephalitis associated with seizures in 
C57BL/6 mice upon intracerebral infection (I.C.). The TO subgroup is comprised of less 
virulent strains, DA, BeAn 8386 (BeAn), WW, Yale, and TO4. Among the TO strains, 
I.C. injection of DA or BeAn strain induces non-fatal but different neurological diseases 
depending upon the genotype of mice used in the study 24,27-32,33-35  
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TMEV-induced demyelinating disease of the CNS 
In the SJL strain of mice, TMEV causes T helper (Th1/Th17) cell-mediated chronic 
demyelinating disease of the CNS within 2-3 months post infection (p.i.). TMEV causes 
a biphasic disease in SJL mice where the polio-encephalomyelitis-like symptoms appear 
during the acute phase, and inflammatory demyelination and axonal degeneration in the 
spinal cord occur during the chronic phase of the disease. In this experimental model, the 
virus first infects neurons and later persists in astrocytes, microglia and 
oligodendrocytes. At this stage, the host’s autoreactive T cells and antibodies attack the 
mouse myelin protein resulting in demyelination of the CNS. The TMEV-induced 
mouse model of demyelinating disease mimics human multiple sclerosis (MS), hence is 
commonly used to study the mechanism of MS 24,26,29,30. 
 
TMEV-induced epilepsy 
Disease pathogenesis 
Libbey et al. were the first group to report that TMEV induces epilepsy in C57BL/6 
mice 34. Intracerebral (I.C.) injection of 3x105 plaque forming unit (pfu) DA or BeAn 
strain of TMEV induces acute symptomatic, afebrile seizures in approximately 65% of 
the adult infected C57BL/6 mice. The number of mice suffering seizures increases to 
80% when a higher dose of virus (3x106 pfu) is used 35. The seizures begin from day 3 
p.i. and eventually subside by day 7 p.i. The seized mice usually show severe signs of 
the clinical disease, hence attain the score of 3 or above on the Racine scoring system 
34,35. Following acute seizures, mice acquire increased excitatory post-synaptic currents 
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(EPSCs), permanent reduction in the seizure threshold, and hippocampal sclerosis. After 
an indefinite latent period, 40-64% of acutely seized mice proceed to exhibit 
spontaneous behavioral seizures (epilepsy) and 100% of them exhibit epileptiform 
activity during 2nd, 4th and 7th month p.i. as reported via video-electroencephalogram 
(VEEG) monitoring 36. Thus, the clinical features of TMEV-induced epilepsy model 
resemble that of mesial temporal lobe epilepsy (mTLE), the most common form of 
epilepsy in humans 37. In addition, TMEV infected-seized mice also display anxiety-like 
behavior and cognitive impairment. Such symptoms are often exhibited by human 
epileptic patients 38.  
 
Immune responses in the TMEV-induced model of epilepsy 
During the first week of infection (acute phase), TMEV mainly resides in the 
hippocampal and cortical neurons of C57BL/6 mice brains. In addition, a few infected 
cells are also found in the frontal lobe, caudoputamen, septum, thalamus and 
hypothalamus. The hippocampus from infected mice exhibits excessive elevation in the 
activation of astrocytes and microglia, and increased infiltration of granulocytes, 
macrophages, etc. Additionally, there is pronounced damage to hippocampal neurons, 
which could be the cumulative result of infection, seizures, and/or inflammation 34,35,39. 
 
C57BL/6 mice attain viral clearance within 2-4 week p.i., with the help of MHC class I-
restricted CD8+ T cells and MHC class II-restricted CD4+ T cells. The virus is mainly 
cleared by MHC class I-restricted CD8+ T cells. β2-microglobulin (β2m) knock out 
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C57BL/6 mice that are devoid of MHC class I-mediated CD8+ T cell signaling, develop 
severe pathology in their cerebellum, cortex, brain stem and corpus callosum. Whereas, 
Aβ° knock out mice that lack MHC class II-mediated CD4+ T cell signaling, develop no 
cerebellar damage, and show comparatively less damage in their cortex, brain stem and 
corpus callosum. Both MHC class I- and MHC class II-mediated immune responses are 
important in preventing any damage in the hippocampal and striatal regions of the brain. 
This suggests that the MHC class I-dependent CD8+ mediated immune responses protect 
most regions of the mouse brain against TMEV infection 40. The expression of MHC 
class I molecules is highly upregulated in the choroid plexus of the brain within 1 day 
p.i. and in the gray matter of the brain and spinal cord by day 7 p.i. And after the 
clearance of virus, the MHC class I expression subsides to its normal level as determined 
on day 28 p.i 41.  Moreover, infected C57BL/6 mice that lack β2m do not show any 
clinical signs of the demyelinating disease. But these mice develop inflammatory 
demyelinating lesions, have a slight increase in the infectious viral titers and a 
significant increase in the CD4+ T cell-mediated immune responses in comparison to 
that in wild type mice. This suggests a compensatory role of CD4+ T cells in viral 
clearance in the absence of functional CD8+ T cells. Alternatively, CD8+ T cells 
regulate the proliferation of CD4+ T cells by mediating effective viral clearance from the 
CNS 42,43.   
Following infection of C57BL/6 mice with TMEV, there is increased production of pro-
inflammatory cytokines and chemokines by macrophages, microglia, astrocytes, etc. 39. 
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Although, generation of an anti-viral immune response and viral clearance render these 
mice resistant to the demyelinating disease, development of “bystander” inflammation in 
the brain makes them susceptible to epilepsy 36. Previous studies have shown that 
aberrant activation of complement 3 (C3) and increased production of IL-6 and TNF-α 
by infiltrating macrophages and resident microglia are considered to be the major 
contributors in the development of acute seizures in C57BL/6 mice (Figure 1) 20,44.  
Figure 1 Immune responses in the TMEV-induced model of epilepsy. (1) Upon intracerebral (I.C.) 
injection, TMEV is localized mainly in the hippocampal and cortical neurons. (2) In response to infection, 
the resident cells of the central nervous system (CNS), microglia and astrocytes, become activated and 
secrete several cytokines and chemokines. (3) The increased production of pro-inflammatory mediators 
disrupts the integrity of the Blood-Brain Barrier (BBB), and allows the infiltration of peripheral innate 
immune cells, monocytes/macrophages, neutrophils, into the CNS. (4) The overzealous inflammation 
within the CNS causes severe damage to hippocampal neurons, resulting in neuronal hyperexcitability and 
symptomatic seizures within a week p.i. (5) The T cell-mediated viral clearance occurs within a month 
p.i., (6) but the acute phase events subsequently lead to the development of epilepsy after an undefined
latent period.  
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Strengths and limitations of TMEV-induced epilepsy model 
The TMEV-induced epilepsy model proves to be clinically relevant to study structural 
forms of epilepsy, as many cases of human and animal epilepsy are triggered due to 
environmental factors (such as CNS infection). The greatest strength of this model is 
that, unlike other infection-driven epilepsy models, TMEV infection runs a non-fatal 
disease course in C57BL/6 mice, giving investigators the opportunity to understand the 
mechanisms of epileptogenesis, and the acute and chronic forms of seizures. Moreover, 
the seizures observed in this model are mostly of severe intensity and resemble the tonic-
clonic forms of seizures frequently diagnosed in cases of human epilepsy. However, the 
limitation of the current epilepsy model is the phenotypic variability observed among 
TMEV-infected mice, since only ~60% of the infected mice develop acute seizures, and 
a fraction of the acutely seized mice proceed to develop unprovoked seizures (epilepsy). 
Furthermore, this phenotypic variability may mask the true effects of potential AEDs 
tested using the disease model. 
The nucleotide-binding oligomerization domain-like receptors 
Description of NLRs  
The nucleotide-binding oligomerization domain-like receptors (or NLRs) are a family of 
intracellular pathogen sensors or Pattern Recognition Receptors (PRRs). These innate 
immune receptors are expressed by a variety of cell types in the body, including those of 
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both the innate and adaptive immune system. There are 22 types of NLRs in humans and 
34 types in mice 45,46.  
NLRs serve diverse functions. They may aid in the activation of inflammasomes (multi-
protein inflammatory complexes), inflammatory transcription factors and/or MHC 
molecules or in the inhibition of inflammatory signaling pathways 47. NLRs can be 
categorized as pro-inflammatory or anti-inflammatory depending upon their stimulatory 
or inhibitory effect(s) on the immune responses. The pro-inflammatory NLRs promote 
immune response against inflammatory stimuli (pathogen-associated molecular patterns 
[PAMPs]) by either activating the NF-κB signaling pathway (as in case of NLR, domain 
containing 1 [NOD1], NLR, domain containing 2 [NOD2]) or by forming an 
inflammasome (as in case of NLR family, pyrin domain containing 3 [NLRP3]), which 
further activates the production of NF-κB and pro-inflammatory cytokines. On the other 
hand, the anti-inflammatory NLRs (such as NLR family, pyrin domain containing 12 
[NLRP12], NLR family member X1 [NLRX1]) can attenuate inflammation by directly 
or indirectly inhibiting the activation of inflammatory pathways such as NF-κB and/or 
type I IFN signaling pathways 48. Since NLRs have only recently been discovered, many 
of their functions remain unclear.  
The role of NLRC5 gene in inflammation 
The NLR family, caspase activation and recruitment (CARD) domain containing 5 
(NLRC5), also known as NOD27, NOD4 or CLR16.1, is a member of the NLR family. 
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It has a tripartite domain that consists of a caspase activation and recruitment domain 
(CARD) at the N-terminus, a nucleotide-binding domain (NBD) at the center and 
leucine-rich repeats (LRR) at the C-terminus. The LRR domain of NLRC5 consists of 
1,855 amino acids, which makes it the largest protein in the NLR family. Most of the 
NLR proteins are localized in the cytoplasm but NLRC5 can shuttle between the nucleus 
and cytosol depending on its activation state. NLRC5 is most closely related to MHC 
class II transactivator (CIITA) based on its structure and function 46.  
NLRC5 is highly expressed in hematopoietic cells with its highest expression in 
lymphocytes (CD4+ T cells, CD8+ T cell, CD19+ B cells, NK cells, NKT cells) and 
moderate expression in CD14+ cells (monocytes) and CD11b+ splenic myeloid cells. 
IFN-γ is a potent stimulator of NLRC5 expression, which is dependent on the signal 
transducer and activator of the transcription 1 (STAT1) signaling pathway. The 
expression of NLRC5 can also be upregulated in response to viral infections, 
polyinosinic:polycytidylic [poly (I:C)], lipopolysaccharide [LPS] and Type I IFN (IFN-
β) 46.  
The MHC class I molecule is expressed by all nucleated cells. Its expression is critical 
for antigen presentation and activation of CD8+ T cells. In turn, the expression of MHC 
class I molecule is tightly regulated by NLRC5, hence NLRC5 is known as the major 
transactivator of the MHC class I gene (CITA). NLRC5 upregulates the expression 
levels of MHC class I gene, non-classical MHC class I gene and MHC class I accessory 
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genes such as β2m, LMP2 (low molecular mass proteasome) and TAP1 (transporter 
associated with antigen processing 1). It does not affect the expression of MHC class II 
or its accessory genes, thereby maintaining its exclusivity in the regulation of genes 
involved in the antigen presentation and processing in MHC class I pathway.  Thus, by 
regulating the expression of MHC class I genes, NLRC5 plays an important role in 
immune regulation 45,49-52. 
Although, the function of NLRC5 as the MHC class I transactivator has been well 
defined, its function as the positive or negative regulator of antiviral immunity and 
inflammation is still unclear. Certain groups have reported NLRC5 as a pro-
inflammatory NLR as it mediates immune responses against influenza virus 53, Sendai 
virus (SeV) 54, Cytomegalovirus (CMV) infected human foreskin fibroblast (HFF) 55, 
and poly (I:C) stimulated human acute monocytic cell line (THP-1) and human dermal 
fibroblasts 54. Other researchers have reported NLRC5 to have anti-inflammatory role in 
response to vesicular stomatitis virus (VSV) infection, where it downregulates NF-κB 
and Type I IFN signaling pathways, production of proinflammatory cytokines and 
antiviral immunity 56,57. While the third group of researchers have reported that NLRC5 
may be dispensable for NF-κB and Type I IFN signaling pathways 50, and may play no 
role in Toll-like receptor [TLR], retinoic acid inducible gene-1 [RIG1] -like receptor, or 
DNA (Newcastle disease virus) sensor signaling 58. In addition, NLRC5 has been 
suggested to regulate the activation of inflammasome in response to bacterial PAMPs 
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and crystals 59, and/or partly regulate the activation of NLRP3-mediated inflammasome 
against intracellular infections 50.    
 
Most studies describing the role of the Nlrc5 gene have been conducted in vitro or ex 
vivo. The conflicting results obtained from the above mentioned studies could be due to 
the use of different types of cell lines, cell lines obtained from different species, cell 
lines with variable expression levels of NLRC5, different gene deletion strategies, and/or 
variable doses and duration of stimuli 53.  
 
The role of NLRC3 gene in inflammation 
The NLR, caspase activation and recruitment (CARD) domain containing 3 (NLRC3), 
also called NOD3 or CLR16.2, belongs to the NLR family of PRRs. Like most NLRs, it 
is localized in the cytoplasm. It has a tripartite domain consisting of LRR at the C-
terminus, NOD/NBD at the center and a less developed CARD3 domain at the N-
terminus 60. It is highly expressed in human T cells and NK cells and mouse T cells. 
Additionally, human and mouse B cells also express some amount of NLRC3 61.  
 
NLRC3 is evolutionary conserved. Its expression has been determined in the leukocyte 
cell lines (including macrophage, cytotoxic T cell and B cell) and various tissues (head 
kidney, trunk kidney, intestine and spleen) of channel catfish (Ictalurus punctatus) 62, 
where it contributes to innate immunity in response to various bacterial and viral 
infections 63. A homologue of NLRC3 in the nervous system of the leech (Hirudo 
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medicinalis), has been suggested to participate in CNS injury and infection in the 
invertebrates 64. The NLRC3-like NLR, which shares similarities with the human 
NLRC3, have been shown to be important for the development of microglia from 
primitive macrophages during embryogenesis, and in regulating systemic inflammation 
in zebrafish in the absence of inflammatory stimuli 65.  
In vitro studies have shown that NLRC3 expression significantly reduces upon T cell 
receptor complex (TCR)- and CD28-mediated T cell activation. However, exogenous 
NLRC3 can attenuate T cell signaling, and reduce the expression levels of IL-2 and 
CD25 genes, the genes that are important for T cells activation and in preventing T cell 
anergy. NLRC3 also downregulates the activation of NF-κB transcription factor by 
either delaying the degradation of inhibitor of kappa B (IκB) a 61 or by blocking the 
ubiquitination of  TNF receptor associated factor 6 (TRAF6). In the resting phase, 
association of NLRC3 with TRAF6 prevents the activation of NF-κB and production of 
inflammatory cytokines. However, under pathological conditions, expression levels of 
NLRC3 decrease resulting in the activation of NF-κB -dependent inflammatory pathway. 
Nonetheless, NLRC3 expression restores to its normal levels after the resolution of 
inflammation, suggesting its role in negatively regulating inflammatory responses 66. 
NLRC3 may also impair activation of other transcription factors, such as activating 
protein-1 (AP-1) and nuclear factor of activated T-cells (NFAT), that activate upon T 
cell stimulation 61.  
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Additionally, interaction between NLRC3 and Toll-like receptor 4 (TLR4) has been 
studied using Nlrc3 deficient (Nlrc3-/-) mice. One hour following LPS (TLR4 agonist) 
stimulation, peritoneal macrophages obtained from Nlrc3-/- mice had increased 
expression of pro-inflammatory cytokine-encoding genes and no significant changes in 
the expression of Tlr4 and Traf6 in comparison to wild type cells. But, the expression 
levels of these genes were found to be similar between the two groups at later time-
points. This study suggests a role of NLRC3 in negatively regulating TLR4-mediated 
inflammation, specifically at earlier time-points 66. Furthermore, NLRC3 has been 
reported to downregulate the production of stimulator of interferon genes (STING)-
dependent type I IFN, IL-6 and TNF-α, thereby delaying viral clearance. This response 
is exclusively seen in the case of DNA virus infections (such as HSV-1) but not with 
RNA virus infections (such as SeV, VSV) or viral mimic poly (I:C) stimulation 67. 
NLRC3 may also negatively regulate pro-IL-1β maturation by inhibiting the activation 
of NLRP3-inflammasome. NLRC3 achieves this by replacing NLRP3 and forming its 
own complex with apoptosis-associated speck-like protein containing a CARD (ASC) 
and caspases 1 and 5. The resultant (NLRC3-ASC- caspases 1 and 5) complex, however, 
does not follow the typical functions of inflammasome in activating pro-inflammatory 
pathways 60.  Recently, Nlrc3 has been reported to provide partial protection to mice 
against colitis-associated colorectal cancer by reducing the activation of mechanistic 
target of Rapamycin (mTOR)-signaling pathways at earlier time-points, thus decreasing 
cellular proliferation and stem-cell-derived organoid formation at later time-points. 
Nlrc3 expression significantly decreases in tumor tissue of wild type mice. However, 
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Nlrc3-/- mice show increased susceptibility to colitis and colorectal tumorigenesis due to 
increased expression levels of innate immune cells, pro-inflammatory cytokines and 
chemokines, and increased activation of immune signaling pathways in colon tissue 68. 
These studies suggest that NLRC3 negatively regulates both innate and adaptive immune 
responses by targeting several immune-signaling pathways. Consequently, NLRC3 may 
have a protective role in preventing autoimmune diseases and inflammatory disorders. 
Objective of this dissertation 
Overall hypothesis: We hypothesize that viral persistence and viral infection-driven host 
immune responses are crucial for causing seizures in TMEV-induced murine model of 
epilepsy. 
The viral infection-driven host immune responses are critical in causing acute neuronal 
damage and seizures in TMEV-induced murine model of epilepsy. Therefore, it is 
interesting to investigate the influence of distinct virus-variants and inflammatory 
components on disease pathogenesis. The first aim of this dissertation is to characterize 
the genomic differences between the two plaque-sized variants, DA-CL and DA-DS, of 
the DA strain of TMEV, and to determine their virulence and pathogenicity in epilepsy. 
In the latter aims, we examine the independent roles of Nlrc5 and Nlrc3 genes in 
regulating inflammation and epileptogenesis, using BeAn (TMEV strain)-infected  
Nlrc5-/- and Nlrc3-/- mice on C57BL/6 background.  
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CHAPTER II  
CHARACTERIZATION OF PLAQUE-SIZED VARIANTS OF DANIEL’S (DA) 
STRAIN IN TMEV-INDUCED EPILEPSY 
Introduction 
Theiler’s murine encephalomyelitis virus (TMEV) is a single stranded RNA virus that 
belongs to the Picornaviridae family 24. It is found naturally in the enteric system of 
mouse 27,69. TMEV is divided into two serologically related but biologically and 
neuropathologically distinct subgroups, GDVII and Theiler’s original (TO). The GDVII 
subgroup contains highly neurovirulent GDVII and FA strains, while the TO subgroup 
contains less neurovirulent DA, BeAn 8386 (BeAn), WW, Yale, and TO4 strains 24,27-
29,33,70. 
Intracerebral (I.C.) infection with TMEV induces different neurological diseases in mice 
based upon either the virus strain or mouse strain used 24,30-32,34,70-74. The GDVII 
subgroup causes acute fatal polioencephalomyelitis in all strains of mice including SJL 
mice 30,70, and acute fatal encephalitis accompanied with seizures in C57BL/6 mice 34,73. 
DA and BeAn are the two most commonly studied virus strains in the TO subgroup. 
DA- or BeAn- infected SJL mice develop biphasic disease characterized by early (weeks 
1-2 post-infection [p.i.]) mild poliomyelitis and late (~ 2 months p.i.) demyelinating 
disease 24,71.  In this strain of mice infectious virus is not cleared and persists at low titer, 
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primarily in the spinal cord 24,75-77. In contrast to developing demyelinating disease, DA- 
or BeAn- infected C57BL/6 mice develop acute (within a week p.i.) seizures 34 that 
progress into epilepsy after an indefinite latent phase (~1-2 months p.i.) 78. In C57BL/6 
mice infectious virus is cleared from the CNS within a month p.i. 79. Interestingly, tonic-
clonic seizures or hyperexcitabilty were also observed in FA-, and occasionally in 
GDVII- infected Swiss mice 30. However, like the SJL mice, DA-infected Swiss mice 
develop demyelinating disease 31,72. This suggests some phenotypic overlap among the 
TMEV strains, and among the mouse strains, in spite of their genotypic differences.  
 
TMEV subgroups also differ from one another based upon their in vitro characteristics. 
The GDVII viruses form large plaques (1 to 5 mm), whereas the TO viruses usually 
form small plaques (0.2-1 mm) on baby hamster kidney (BHK) cells 28,70. Dr. Leibowitz 
and colleagues observed that their DA strain of TMEV produced a mixture of large and 
small sized plaques when assayed on L2 cells. The large plaques were 1.51±0.16 mm, 
while small plaques were 0.75±0.13 mm in size. The genetically stable, large and small 
sized plaques forming variants of the DA strain were isolated and called DA-CL and DA-
DS, respectively 80.  
 
The growth kinetics and neurovirulence of DA-CL and DA-DS plaque variants have been 
well documented in TMEV-induced demyelinating disease. The DA-CL variant yields 
higher titer in vitro, but replicates to lower titers in the CNS and is unable to induce any 
clinical disease in SJL mice even though it is able to persist in the CNS. In contrast, the 
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DA-DS variant yields lower titers in vitro, but replicates efficiently in the CNS and 
induces demyelinating disease in SJL mice. Following infection with DA-DS, there is 
higher viral growth in the CNS and increased severity of demyelinating disease 
compared to the parental DA virus. 80. However, no further studies have been carried out 
to determine the relative virulence of these DA variants in TMEV-induced epilepsy 
model.  
 
The TMEV-induced epilepsy model is the first viral infection-driven animal model 
developed to understand both the acute and chronic forms of seizures. Infection in 
C57BL/6 mice with the DA or BeAn strain of TMEV stimulates a vigorous host immune 
response (central and peripheral) that targets the virus but could also cause damage to 
the pyramidal neurons of the hippocampus in the process.  The unregulated host immune 
response and neuronal damage triggers hippocampal excitability, acute seizures, and 
reduced seizure threshold. The T cell-mediated virus clearance occurs within a month 
p.i. Nonetheless, the acute phase events pave the way for the development of recurrent 
spontaneous seizures (epilepsy) in the chronic phase 20,21,34,78,81,82.  
 
Here, we characterized the genetic differences between the two plaque variants, DA-CL 
and DA-DS, and their neurovirulence and pathogenesis in the epilepsy model. We 
showed that the DA-CL variant was relatively avirulent as it induced reduced 
neuroinflammation, neuropathology and minimal seizures in infected mice. Conversely, 
the DA-DS variant was highly neurovirulent as it provoked pronounced 
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neuroinflammation, hippocampal damage and seizures in infected mice. Thus, DA-C 
was attenuated in both the epilepsy and late demyelinating models. Moreover, our results 
suggest that the neurovirulence of the DA variants is independent of the genotype of SJL 
and C57BL/6 mouse strain. A sequence 83 comparison of the DA-CL and DA-DS genome 
sequences revealed two differences between the two variants resulting in three coding 
differences at the protein level, in the L, L*, and 2C proteins.  
Materials and methods 
Figure 2 Experimental timeline. The acute phase of disease is defined as up to day 7 p.i., during which 
seizures, non-epileptic clinical illness, weights, viral burden, inflammation and CNS pathology were 
determined. The chronic phase is defined as from week 2 to 11 p.i. or until the termination of mice. 
Chronic phase measures included clinical scores (spontaneous seizures), weights, elevated plus maze test 
(EPMT), novel object recognition test (NORT), novel object location test (NOLT), and histological 
analyses of the CNS. 
Mice 
Three-week-old female C57BL/6 mice were purchased from Envigo Laboratories 
(Indianapolis, IN). They were caged in groups of four or five, under constant room 
temperature of 70±0.5° F and relative humidity of ~50% with 12 hours of light and dark 
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cycle. Ad libitum feed and water were provided to the mice throughout the experiment. 
Mice were given a week to acclimate to their housing environment prior to infection. All 
animal experiments (Figure 2) were conducted in accordance with the protocols 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
Comparative Medicine Program at Texas A&M University. 
Virus 
The DA-CL (large) and DA-DS (small) plaque variants of the DA strain of TMEV have 
been described previously 80. The plaque variants were grown in BHK cells and stored at 
-80°C, until used for infection.  Virus titrations were performed as described previously 
77
Infection  
Mice were placed into 3 groups according to the virus used for infection: controls, DA-
CL, and DA-DS. Mice in the infected groups were injected I.C. with 2.0 x 105 plaque 
forming units (pfu) of either DA-CL or DA-DS plaque variant in 20 μl of Dulbecco’s 
modified eagle medium (DMEM) (Sigma, Life Science, St. Louis, MO). Mice in the 
control group were injected I.C. with 20μl of sterile 1x Phosphate Buffer Saline (PBS). 
All injections were performed under isoflurane (IsoFlo, North Chicago, IL) anesthesia.  
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Body weight measurement  
Mice were weighed daily until day 7 p.i. (acute phase), and then once a week until the 
termination of the experiment (chronic phase). % weight loss was calculated as percent 
of daily or weekly weights of mice compared to their baseline weights i.e. weights at day 
0 p.i.  
Clinical scores 
For clinical scores, mice were observed twice daily for two hours between 9 AM to 6 
PM until day 7 p.i. (acute phase). Additionally, two cages of infected mice (n=9/infected 
group) were video recorded 24/7 and the resulting videos analyzed for acute seizures.  
Mice were scored for seizures based on the Racine scoring system; (1) Mouth and facial 
movements; (2) Head nodding; (3) Forelimb clonus; (4) Rearing; and (5) Rearing and 
falling progressing to tonic-clonic seizure 84. For non-epileptic clinical signs, mice were 
scored as: score (0) no clinical signs; score (1) mildly ruffled, hunched, and/or ataxic; 
score (2) moderately ruffled, hunched, and/or ataxic; score (3) severely ruffled, hunched, 
and/or ataxic; score (4) paralysis; and score (5) moribund. Moreover, three cages of mice 
were kept for chronic phase studies until week 5 or 11 p.i. In the chronic phase, mice 
were observed once weekly for spontaneous seizures and symptoms of demyelinating 
disease.    
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Tissue isolation 
For tissue isolation, mice were euthanized with 150 mg/kg beuthanasia-D special 
(Schering-Plough Animal Health Corp. Union, NJ) and perfused intracardially with 10 
ml of sterile PBS. For plaque assay experiments, brains and spinal cords were collected 
at day 7 p.i., snap frozen and stored at -80°C until use. For immunohistochemistry 
(IHC), brains were collected at day 7 p.i., fixed in freshly prepared 4% 
paraformaldehyde (PFA) for 24-48 hours at 4°C, and cryoprotected in 30% sucrose for 
72 hours at 4°C. Then brains were embedded in optimum cutting temperature (OCT) 
compound (Tissue-Tek 4583, Torrance, CA) and stored in -80°C until they were ready 
for sectioning. For histology, brains and spinal cords were collected at days 3 and 7, and 
weeks 5 and 11 p.i., fixed in 10% formaldehyde for 4-5 days at room temperature, 
processed and embedded in paraffin wax. Each brain was cut to obtain coronal sections 
containing dorsal hippocampus and each spinal cord was sectioned to retrieve at least 
one transverse slice from the cervical to sacral segments. For flow cytometry, brains 
were collected at day 3 p.i. in ice cold RPMI 1640 (Gibco, Life Technologies, Grand 
Island, NY), and immediately processed to analyze leukocyte populations as described 
later.  
Brain weight 
Increased brain weight could be indicative of neuro-edema. For this, brains were 
collected from control (n=3) and infected mice (n=19/group) at day 7 p.i. and weighed. 
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Plaque assay 
Brains and spinal cords were collected separately and 10% w/v homogenates in DMEM 
were prepared and sonicated by three 20 second pulses in a cup sonicator (Heat Systems, 
Sonicator Ultrasonic Processor, model XL2020). Homogenates were centrifuged at 
2000-3000 rpm for 10 minutes at 4°C, and the supernatant containing virus was titrated 
by plaque assay as described previously 80,85. 
Immunohistochemistry (IHC) 
10-micron (μm) coronal sections were cut from OCT blocks of mouse brain (n=4/ 
infected group) on a cryostat (Leica CM 1950). Serial sections containing dorsal 
hippocampus were collected on plus-charged coated slides, and stored at -80°C until 
further use. For each immunostain, four rostral-caudal matched sections were analyzed 
per mouse.  
Before staining, the cryosections were incubated for 1 hour at 37°C, hydrated with PBS, 
and blocked for 1 hour with 5% goat serum (16210-064; Gibco, Life Technologies, 
Grand Island, NY) and 0.1 or 0.3% Triton X-100 (9002-93-1; Sigma-Aldrich, St. Louis, 
MO) in PBS. The cryosections were incubated overnight at 4°C with primary antibodies 
for astrocytes, chicken anti-glial fibrillary acidic protein 86 [1:500, AB5541; EMD 
Millipore, Temecula, CA], or for TMEV-antigen positive cells, rabbit anti-TMEV 87 
[1:50; Welsh lab]. The next day, cryosections were washed and then incubated for 1 
hour with either Alexa Fluor 488 goat anti-chicken IgG [1:1000, A11039; Invitrogen, 
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Life Technologies, Eugene, OR] or Alexa Fluor 594 goat anti-rabbit IgG [1:1000, 
A11037; Invitrogen, Life Technologies, Eugene, OR]. Later, cryosections were washed, 
counterstained with Hoechst 33342, trihydrochloride, trihydrate [1:1000, H3570; Life 
Technologies, Eugene, OR] and mounted with Fluoromount-G (0100-01; 
SouthernBiotech, Birmingham, AL). All images were acquired using a HRD076-NIK 
camera attached to OLYMPUS VANOX AHBS3 microscope. Activated astrocytes and 
TMEV-antigen positive cells were enumerated both in the left and right hippocampi and 
totaled.     
 
Histology: brain 
Four μm paraffin-embedded sections of brains from control (n=3) and infected mice 
(n=4-5/group) from acute (days 3 and 7 p.i.) and chronic (weeks 5 and 11 p.i.) phase 
were stained with H&E. To determine the extent of acute (day 7 p.i.) inflammation in 
hippocampus, we enumerated and totaled the number of inflammatory foci and 
perivascular cuffs in right and left hippocampi from each mouse. Previous studies have 
shown that acute neuronal loss in TMEV-infected C57BL/6 mice mainly occurs in the 
CA1 and CA2 regions of the hippocampus 81. Therefore, we estimated the percent loss 
of CA1 and CA2 neurons and ranked it on a scale of 0 to 10. Scores from the left and 
right hippocampi were totaled, such that the highest possible cumulative score for each 
mouse was 20 88. H&E stained brain sections from day 3 and weeks 5 and 11 p.i. were 
examined for the progression of neuropathology in the hippocampus. 
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Histology: spinal cord 
Four μm paraffin-embedded transverse sections of the spinal cords from control (n=3) 
and infected mice (n=4-6/group) from acute (days 3 and 7 p.i.) and chronic (weeks 5 and 
11 p.i.) phase were stained with H&E. The cervical, thoracic, lumbar and sacral 
segments of the spinal cords were examined for the presence of inflammatory foci, 
axonal/neuronal degeneration, and/or meningitis. Each spinal cord segment was graded 
separately on a scale of 0 to 4: score (0) the absence of any pathology; score (1) minimal 
pathological lesions (<10%); score (2) mild pathological lesions (10% to <30%); score 
(3) moderate pathological lesions (30% to <70%); and score (4) severe pathological 
lesions (≥ 70%).                                                                    
 
Flow cytometry 
Whole brains (n=5/control group and n=13/infected group) were homogenized in RPMI 
1640, filtered using 70-μm FALCON cell strainers (21008-952; VWR, Sugarland, TX), 
and centrifuged at 500 x g for 5 min at room temperature. After discarding the 
supernatant, each pellet was suspended in 10 ml of 30% Percoll (17-0891-01; GE 
healthcare, Uppsala, Sweden) in PBS. This solution was gently overlaid onto 2 ml of 
70% Percoll in PBS, and centrifuged 500 x g for 30 min at 18°C. The buffy coat 
containing leukocytes was collected from the interphase of the 30% and 70% Percoll 
layers, washed, and suspended in flow buffer containing 2% fetal bovine serum (FBS) 
[16000-044; Gibco, Invitrogen, Grand Island, NY] in PBS. Cells were treated with Anti-
Mouse CD16/CD32 (1:100, 14-0161-82; eBioscience, San Diego, CA) for 10 min at 4°C 
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to prevent any non-specific binding. For phenotyping, cells were stained with the anti-
mouse antibodies as indicated below for 30 min at 4°C, washed and fixed with 2% PFA 
prior to flow cytometric analysis on a Beckman Coulter MoFlo® Astrios™ High-Speed 
Cell Sorter machine. Data were analyzed using FlowJo® software V10.0.8r1 (Mac OS X, 
FlowJo, LLC, Ashland, OR). Ly-6G (Gr-1) was detected with clone RB6-8C5 (1:500, 
12-5931-82; eBioscience, San Diego, CA). CD11c was detected with clone N418 (1:250, 
17-0114-81; eBioscience, San Diego, CA). NK1.1 was detected with clone PK136 
(1:500, 12-5941-63; eBioscience, San Diego, CA). CD11b was detected with clone 
M1/70 (1:500, 101224; BioLegend, San Diego, CA). CD45.2 was detected with clone 
104 (1:100, 109805; BioLegend, San Diego, CA). CD8a was detected with clone 53-6.7 
(1:250, 100711; BioLegend, San Diego, CA). CD4 was detected with clone GK1.5 
(1:500, 100428; BioLegend, San Diego, CA). Cell viability was assessed with Ghost dye 
Red 780 (1:100, 13-0865; Tonbo Biosciences, San Diego, CA). For compensation 
controls, UltraComp eBeads (01-2222-41; eBioscience, San Diego, CA) were used 89.  
Behavioral and cognitive tests 
Behavioral and cognitive tests were conducted at week 4 p.i., since C57BL/6 mice are 
known to clear TMEV by this time 81. Experiments were performed in an isolated room 
with dim lighting to minimize environmental distractions. Mice were given 30 min to 
acclimate to the room prior to any testing. All experiments were performed during the 
day. 
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Elevated Plus Maze test (EPMT) 
EPMT was performed by the standard protocol as previously described by Komado et al. 
with some modifications. The elevated plus maze was made of black Plexiglass. It 
consisted of two opposing open (25x5x0.5 cm3) and closed (25x5x16 cm3) arms placed 
in a perpendicular fashion, with a central platform (5x5x0.5 cm3). The maze was kept 
elevated at a height of 50 cm above the floor (Figure 3). 
Mice were individually placed on the central platform with their heads facing towards 
the same closed arm. Each mouse was given a 5-min test period to freely explore the 
maze. During this period, we recorded the number of times the mouse entered the open 
and closed arms. An arm entry was defined as the placement of all four paws of the 
mouse in that arm of the apparatus. The number of entries in open arms was used as a 
measure of anxiety-like behavior in the mice. The number of entries in closed arms was 
used as a measure of locomotor activity. The maze was cleaned with 70% (vol/vol) 
ethanol between the tests to remove any feces, urine or animal odor 90.  
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Figure 3 Schematic diagram of the elevated plus maze. The maze was made of black plexiglass. It 
consisted of two opposing open and closed arms placed in the shape of a plus, and a platform at the 
intersection of the arms. The maze was kept elevated at a height of 50 cm above the ground. 
Novel object recognition test (NORT) and Novel object location test (NOLT) 
Mice were tested for object- and place-recognition memory to determine any seizure-
associated memory loss. We modified the original protocol as described by Jiang et al. 91 
by increasing the period of object exploration time from 5 to 10 min, and retention delay 
from 90 min to 24 h. The open arena (50x50x50 cm3) was made of Plexiglass and 
different sets of objects were used for each test.  
As illustrated in Figure 4, the test was conducted over a period of 5 days. On the first 
day, the habituation phase, mice were individually placed in the open arena and allowed 
to freely explore it for 5 min. On the second day, the familiarization phase for NORT, 
mice were allowed to explore the first set of identical objects. On the third day, the test 
phase for NORT, mice were placed back in the arena with one of the familiar objects 
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replaced by a novel object. On the fourth day, the familiarization phase for NOLT, mice 
were allowed to explore the second set of identical objects in the same arena. On the 
fifth day, the test phase for NOLT, mice were returned to the arena with one of the 
identical objects displaced to a novel location. A retention delay of 24 hours was used 
between the phases. The total time for the familiarization and test phases were 10 min 
for both NORT and NOLT. Touching or sniffing the objects, but not climbing them, at a 
distance of less than 2 cm was considered as an explorative behavior. Objects and arena 
were cleaned with 70% (vol/vol) ethanol between the tests to avoid any olfactory cues.  
Tests were video recorded and later analyzed for the time spent exploring each object 
and discrimination index (DI). DI was calculated as the ratio of time spent on novel 
object or location to the time spent on familiar object or location.  
Figure 4 Schematic diagram of novel object- and novel location- test setup. The open arena made of 
plexiglass, and non-edible, odorless objects were used for the tests. The test was conducted over a period 
of five days, comprising of a 5-min session of habitutation phase, 10 min-session of familiarization phase 
for NORT and NOLT each, a 10-min session of test phase for NORT and NOLT each, with a rentention 
delay of 24 h between the phases. 
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Sequencing of plaque variants 
Tissue culture dishes (60 mm diameter) of confluent L2 cells were infected with DA-DS 
and DA-CL at an multiplicity of infection 92 of 3 and incubated for 16 hours at 37° C and 
total intracellular RNA extracted using the Omega Bio-Tek Total RNA Kit as per the 
vendor’s directions. cDNA synthesis was performed with Superscript III (Invitrogen) 
using the primers listed in, Table 1. The resulting cDNAs were amplified by PCR to 
produce the overlapping amplicons listed in Table 2. PCR was performed with 
ONETAQ DNA polymerase (New England Biolab) and the PCR primers listed in, Table 
2. The most 3’ amplicon was amplified using the 3’RACE procedure 93. The PCR
conditions used for each amplicon were those recommended by the New England Biolab 
web tool (http://tmcalculator.neb.com/#!/) 94 for each primer pair with ONETAQ DNA 
polymerase. Amplified cDNAs were purified by 1% agarose gel electrophoresis, 
visualized on a Clare Dark Reader and recovered from the gel using Bioline PCR and 
Gel Extraction kits, according to the vendor’s instructions. Purified PCR products were 
then sequenced commercially (Eurofins) using the primers shown in, Table 3. Sequences 
were viewed and aligned using Sequencher (version 4.8) and a consensus sequence 
determined. The DA-CL and DA-DS sequences were aligned and compared for 
differences using L-align and ClustalOmega web platforms.   
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Primer Sense and Position Use Primer Sequence* 
 (-) 1170-1151 cDNA synthesis TGG GAA CCA TTC ACC GTC TG 
(-) 2538-2520 cDNA synthesis TGA GGT CGT CGG GAC AGA A 
(-) 3083-3065 cDNA synthesis GGT AGT TTC ACG GGT TCT G 
(-) 4612-4593 cDNA synthesis GGC AAA CTG GGG GAG GAG TA 
(-) 6312-6293 cDNA synthesis CTT ACT ACG ACA GTG GCC CT 
(-) 7835-7813 cDNA synthesis AGT TTC TCT TTA AGT GTT CCT GG 
3’ RACE-OligoT cDNA synthesis GAC TCG AGT CGA CAT CGA (T)17 
Table 1 cDNA Synthesis Primers 
*Primer positions and sequences are from Genbank Accession M20301
Table 2 PCR products amplified for sequencing. 
PCR Primer Primer Sequence cDNA Used for PCR  Amplified 
cDNAs 
(+)123-142 ACT CCC GAC TCC GCA CCC TA DA (-) 1170-1151 123-1170 
(-)1170-1151 TGG GAA CCA TTC ACC GTC TG 
(+)750-769 ACA CAA AGG CAG CGG AAC CC DA (-) 2538-2520 750-1760 
(-)1760-1741 GGG AGA GGA ATG CGG ATG TG 
(+)1087-1106 CCA GAT GTG TGC CCT ATT TG DA (-) 3083-3065 1087-3083 
(-)3083-3065 GGT AGT TTC ACG GGT TCT G 
(+)1862-1881 CTC AAT TTC ACG CCG GCT CT DA (-) 2538-2520 1862-2538 
(-)2538-2520 TGA GGT CGT CGG GAC AGA A 
(+)2806-2825 TCC CCT ACT CAC TAT CGC CA DA (-) 4612-4593 2806-4612 
(-)4612-4593 GGC AAA CTG GGG GAG GAG TA 
(+)2946-2965  GTC TCC GCG GGA GAT GAT TT DA (-) 4612-4593 2946-4612 
(-)4612-4593 GGC AAA CTG GGG GAG GAG TA 
(+)3753-3772  CTT CTT TCC CTG GCC TGT GT DA (-) 6312-6293 3753-5839 
(-)5856-5839 CTC AAC TCT CAC GGG CGA A 
(+)4229-4248 CCC TGT GCA GTC GGT TTT TC DA (-) 6312-6293 4229-6312 
(-)6312-6293 CTT ACT ACG ACA GTG GCC CT 
(+)6031-6050  CCT GAC AAG GCT GAA GTG AC DA (-) 7835-7813 6031-7835 
(-)7835-7813 AGT TTC TCT TTA AGT GTT CCT GG 
(+)6031-6050  CCT GAC AAG GCT GAA GTG AC 3’ RACE 6031-poly(A) 
(-)3’RACE GAC TCG AGT CGA CAT CGA 
(+)6066-6079 GCT CCG TGC CCA CC 3’RACE 6031-poly(A) 6066-poly(A) 
(-)3’RACE GAC TCG AGT CGA CAT CGA 
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Primer Name 
Position 
Polarity Sequence (5’->3’) Length 
DA (+)123-142 +sense ACT CCC GAC TCC GCA CCC TA 20 
DA (-)450-431 -sense TCA CAT AAT CGG GGA GAC AT 20 
DA (-)625-606 -sense AAG GAA GGG GCA ACA CAT AC 20 
DA (+)750-769 +sense ACA CAA AGG CAG CGG AAC CC 20 
DA (+)1087-1106 +sense CCA GAT GTG TGC CCT ATT TG 20 
DA (-)1170-1151 -sense TGG GAA CCA TTC ACC GTC TG 20 
DA (+)1428-1447 +sense CCC CCA AAA CAA CGG ACA AT 20 
DA (+)1737-1756 +sense CTC CCA CAT CCG CAT TCC TC 20 
DA (-)1760-1741 -sense GGG AGA GGA ATG CGG ATG TG 20 
DA (+) 1862-1881 +sense CTC AAT TTC ACG CCG GCT CT 20 
DA (-) 2538-2520 -sense TGA GGT CGT CGG GAC AGA A 19 
DA (+)2806-2825 +sense TCC CCT ACT CAC TAT CGC CA 20 
DA (+)2946-2965 +sense GTC TCC GCG GGA GAT GAT TT 20 
DA (-)3083-3065 -sense GGT AGT TTC ACG GGT TCT G 19 
DA (-)3538-3520 -sense CAG CAC CGA CGA GCC ACA T 19 
DA (+)3753-3772 +sense CTT CTT TCC CTG GCC TGT GT 20 
DA (-)3905-3886 -sense CCG TGA ACC TTG TAG TCA AA 20 
DA (+)4229-4248 +sense CCC TGT GCA GTC GGT TTT TC 20 
DA (-)4612-4593 -sense GGC AAA CTG GGG GAG GAG TA 20 
DA (+)4740-4759 +sense ACG TGA GGC CAA TGA AGG TT 20 
DA (-)5328-5309 -sense AAC AGC AGG GTA ATG GGC AA 20 
DA (-)5856-5837 -sense CTC AAC TCT CAC GGG CGA A 19 
DA (+)6031-6050 +sense CCT GAC AAG GCT GAA GTG AC 20 
DA (-)6312-6293 -sense CTT ACT ACG ACA GTG GCC CT 20 
DA (+)6660-6679 +sense TCA TGA TGT TTT CCA ACC CA 20 
DA (+)7766-7787 +sense CTC AAA TGG ATG CTG TCA ACT T 22 
DA (-)7835-7813 -sense AGT TTC TCT TTA AGT GTT CCT GG 23 
Table 3 Sequencing Primers
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Statistical analysis 
Comparison of seizure duration within the group was analyzed using the one-way 
analysis of variance (ANOVA) with the post test for linear trend, and comparison of 
seizure duration between the infected groups was performed using the unpaired t-test 
with the Welch’s correction. Body weights were analyzed using the repeated measures 
two-way ANOVA with the Tukey’s multiple comparisons test. Cognitive tests were 
analyzed using the two-way ANOVA with the Tukey’s multiple comparisons test. For 
rest of the parametric analysis, one-way ANOVA with the Tukey’s multiple 
comparisons test or the unpaired t-test with the Welch’s correction was used. For non-
parametric analysis, the unpaired Mann-Whitney rank sum test or Kolmogorov-Smirnov 
test was used. For nominal data (presence or absence of seizures), the Fisher’s exact test 
was used. For all cases, significance was determined when p ≤ 0.05. Statistical analysis 
was done using GraphPad Prism version 6.0d (Mac OS X, GraphPad Software, La Jolla, 
CA). 
Results 
Seizures induced by infection with DA-DS were significantly more frequent and more 
severe than those induced by DA-CL. 
Groups of 4-week-old C57BL/6 were infected with DA-CL, DA-Ds, or mock infected by 
I.C. injection as described in Materials and Methods.  To efficiently record seizures, we 
observed mice twice a day (mornings and evenings) for a week following infection. 
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During the first 7 days of infection mice infected with the DA-DS variant had a much 
higher incidence of seizures (31/33 mice) than the DA-CL variant (4/33) (Figure 5A) and 
this difference reached a high level of statistical significance (Fisher’s exact test, 
p<0.0001). No seizures were found in the control group (not shown).  
The infected mice usually seized within the first few minutes of observation, suggesting 
that handling-associated stress played an important role in triggering seizures. Seizures 
occurred both in the mornings and in evenings indicating that there was no association 
between seizures and circadian rhythm. Moreover, 64% of the DA-DS-infected mice 
experienced more than one seizure during the day, compared to only 3% in the DA-CL- 
infected group. Additionally, seized mice were individually monitored for the total 
number of seizures (frequency) during the acute phase (Figure 5B) the seizure frequency 
was significantly higher in the DA-DS-infected group compared to that in the DA-CL-
infected group (Unpaired t test with Welch’s correction, p<0.0001).  
The intensity of seizures was greater in DA-DS-infected mice with approximately 88% 
of the mice exhibiting Racine stage 5 level seizure activities, whereas only 9% of the 
DA-CL-infected mice had seizures of that severity. These severe seizures started with 
head nodding and rapidly progressed to tonic-clonic seizures. Seizures in the DA-DS-
infected group started from day 2 p.i., the majority of seizures occurred on days 3, 4 and 
5 p.i., and seizures completely ceased after day 7 p.i. (Figure 5D). In comparison, 
seizures in the DA-CL-infected group occurred only on day 3 p.i., The duration of 
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seizures in the DA-DS-infected group significantly increased over time and showed a 
significant linear trend (Figure 5C) (One-way ANOVA with post test for linear trend, 
p<0.0001). However, the duration of seizures that occurred on day 3 p.i. was not 
significantly different between the DA-DS- and DA-CL-infected groups (Figure 5E) 
(Unpaired t test with Welch’s correction, p=0.6511).  
 
To confirm our findings, we video-recorded two cages of mice from each infected group 
24/7 for a week, and analyzed videos in a blinded-fashion. As expected, we did not find 
any seizures in the DA-CL-infected groups, while a total of 8 seizure episodes, at the 
Racine stage 4 or 5, were recorded in the DA-DS-infected groups during the acute phase. 
To investigate for occurrence of delayed seizures or epileptic episodes, we examined 
three cages of mice per infected group for chronic phase (day 8 till week 5 or 11 p.i.) 
studies. We did not observe any seizures in any of the infected groups during the chronic 
phase. However, this does not rule out the possibility of the development of epilepsy in 
the infected mice, since epileptic seizures are sporadic and in our study, mice were not 
video monitored during the chronic phase.  
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Figure 5 Seizures induced by infection with DA-DS were significantly more frequent and more 
severe than those induced by DA-CL. (A) Significantly higher number of mice developed seizures 
following DA-DS infection. In contrast, the DA-CL plaque-variant failed to induce seizures in most of the 
infected mice (**** p<0.0001 by Fisher’s exact test). The % of seized mice in each group was calculated 
as (number of seized mice/total number of infected mice) x 100. (B) The seizure frequency was 
significantly higher due to infection by DA-DS than DA-CL (**** p<0.0001 by unpaired t test with 
Welch’s correction). The data are only from seized mice in DA-CL and DA-DS groups, N= 4 and 31, 
respectively. (C) In the DA-CL group, most of the mice (denoted as %) did not seize and hence, were given 
Racine score 0, while very few mice exhibited Racine stage 4 or 5 seizures.  In comparison, in the DA-DS 
group the majority of mice (denoted as %) exhibited seizures of Racine stage 5, and few mice had seizures 
of Racine stage 3 and 4. (D) Seizures in DA-CL group were only seen on day 3 p.i., while seizures in DA-
DS group began from day 2 p.i. and lasted till day 7 p.i. with most mice seizing on days 3, 4 and 5 p.i. (E) 
The duration of seizures that occurred on day 3 p.i. were not significantly different between the groups. 
However, the duration of seizures in the DA-DS group showed a significant linear trend over days p.i. 
(**** p<0.0001 by one-way ANOVA with post test for linear trend). Graphs (A, B, C and D) show pooled 
results from four separate experiments expressed as number/ percent/ mean ± SEM, N=33 per infected 
group. Graph (E) shows pooled results from three separate experiments expressed as mean ± SEM, N=23 
per infected group. 
Mice infected with DA-DS plaque variant displayed severe non-epileptic clinical signs in 
the acute phase. 
We evaluated the effects of plaque-variant infection on non-epileptic clinical signs 
during the acute phase. Most mice developed hunched backs, ruffled fur, and/or ataxia 
post-infection. However, encephalitis-like signs were more prominent among DA-DS-
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infected mice compared to DA-CL-infected mice. As shown in Figure 6, we found 
significant differences in clinical scores between the groups on days 1, 2, 5, 6 and 7 p.i. 
(Mann-Whitney rank sum test, p=0.0439 on day 1 p.i., p=0.0005 on day 2 p.i., p=0.1056 
on day 3 p.i., p=0.0630 on day 4 p.i., p<0.0001 on days 5 and 6 p.i., and p=0.0028 on 
day 7 p.i.). Furthermore, four of the DA-DS- and two of the DA-CL-infected mice 
developed flaccid paralysis of hind limb(s) during the acute phase. DA-DS-infected mice 
that developed flaccid paralysis also exhibited seizures.  
Figure 6 Mice infected with DA-DS plaque variant displayed severe non-epileptic clinical signs in the 
acute phase. Mice were observed daily for signs of non-epileptic clinical disease during the acute phase. 
Both the virus infected groups showed clinical signs, but clinical scores were significantly higher in DA-
DS-infected group compared to that in DA-CL-infected group (* p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001 by Mann-Whitney rank sum test). The clinical scores lowered in DA-CL group, but they 
remained persistently high in DA-DS group. Graph shows pooled results from four separate experiments 
expressed as mean ± SEM, N=33 per infected group. 
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Mice infected with DA-DS plaque variant had a significant delay in their recovery. 
Weight is one of the parameters used to monitor the health of mice. All mice lost weight 
following i.c. injection, but the weight loss was less marked in the control group and 
highest in the DA-DS-infected group as illustrated in Figure 7A. Control mice gained 
weight after day 2 p.i., while mice in the infected groups continued to lose weight during 
the acute phase of infection. (Repeated Measures two-way ANOVA with Tukey’s 
multiple comparisons test; for control vs. DA-CL groups- p<0.0001 on days 1, 4, 5, 6, 7 
p.i., p=0.0002 on day 2 p.i. and p=0.0001 on day 3 p.i.; for control vs. DA-DS groups-
p<0.0001 on days 1 till 7 p.i.; for DA-CL vs. DA-DS groups- p=0.0030 on day 1 p.i. and 
p<0.0001 on days 2 till 7 p.i.).  
The mice in the DA-CL-infected group began to gain weight during week 2 p.i., and 
were equal to the weights of control mice by week 3 p.i. The mice in DA-DS-infected 
group started gaining weight during week 3 p.i., but their weights remained significantly 
lower than the other groups until week 4 p.i. (Figure 7B). (Repeated Measures two-way 
ANOVA with Tukey’s multiple comparisons test; for control vs. DA-CL groups- 
p<0.0020 on week 1 p.i., p=0.0091 on week 2 p.i., p=0.8467 on week 3 p.i., p=0.5349 on 
week 4 p.i., and p=0.9892 on week 5 p.i.; for control vs. DA-DS groups- p<0.0001 on 
weeks 1 and 2 p.i., p=0.0010 on week 3 p.i., p=0.0079 on week 4 p.i., and p=0.5601 on 
week 5 p.i.; for DA-CL vs. DA-DS groups- p=0.0004 on week 1 p.i., p<0.0001 on weeks 
2 and 3 p.i., p=0.0132 on week 4 p.i., and p=0.2071 on week 5 p.i.). Thus, compared to 
other groups, recovery in DA-DS-infected group was significantly delayed.  
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Figure 7 Mice infected with DA-DS plaque variant had a significant delay in their recovery. Mice 
from the control and infected groups were weighed daily until day 7 p.i. and then once weekly until week 
5 p.i. (A) We found that the infected mice lost weight following infection during the acute phase, but the 
highest weight loss was found in the DA-DS-infected group. (B) DA-CL-infected mice recovered by week 
3 p.i., while recovery among DA-DS-infected mice was not seen until week 5 p.i. (* p<0.05, **/## p<0.01, 
***/### p<0.001, ****/#### p<0.0001 by Repeated Measures two-way ANOVA with Tukey’s multiple 
comparisons test). Graph A shows pooled results from four separate experiments expressed as mean ± 
SEM, N=4 in control group and N=32 per infected group. Graph B shows pooled results from two separate 
experiments expressed as mean ± SEM, N=4 in control group and N=13 per infected group. 
DA-DS infection induced significant neuro-edema in mice.  
To assess the impact of plaque-variants on neuro-edema, we compared wet brain weights 
from infected and control groups at day 7 p.i. As depicted in Figure 8, mouse brains 
from the DA-DS group weighed significantly more than the brains from control or DA-
CL group. However, brain weights from DA-CL and control groups were not found 
statistically different (One-way ANOVA with Tukey’s multiple comparisons test; 
control vs. DA-DS group-p=0.0003; control vs. DA-CL group-p=0.0838; DA-CL vs. DA-
DS group-p=0.0007). Our results indicate that only DA-DS plaque variant was able to 
induce neuro-edema in mice. 
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Figure 8 DA-DS infection induced significant neuro-edema in mice. To determine the effects of plaque-
variants on neuro-edema, brains from infected and control mice were collected and weighed at day 7 p.i. 
The brains from DA-DS-infected group weighed significantly more compared to that from control or DA-
CL-infected group. (*** p<0.001 by One-way ANOVA with Tukey’s multiple comparisons test). Graph 
shows pooled results from two separate experiments expressed as mean ± SEM, N=3 in control group and 
N=19 per infected group. 
Increased viral burden in mice infected with DA-DS plaque-variant.  
We used brain and spinal cord homogenates from day 7 p.i. to assess viral burden in the 
infected groups. As shown in Figure 9, we found that viral titers in the brains from DA-
DS-infected mice were approximately five times higher than that in the brains from DA-
CL-infected mice (Unpaired t test with Welch’s correction p=0.0010). However, viral 
titers in the spinal cords were found to be similar between the infected groups (Unpaired 
t test with Welch’s correction p=0.8721).  
We also found significant differences between the viral titers in brain vs. spinal cords 
from the DA-DS-infected group (Unpaired t test with Welch’s correction p=0.0004), 
while no such differences were found in the DA-CL-infected group (Unpaired t test with 
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Welch’s correction p=0.1964). Our plaque assay results from day 7 p.i. show that viral 
burden remained high in mice infected with DA-DS plaque-variant. 
Figure 9 Increased viral burden in mice infected with DA-DS plaque-variant. At day 7 p.i., brains 
from DA-DS-infected mice had significantly higher viral titers than DA-CL-infected mice. Viral load was 
also detected in their spinal cords at this time point, but no significant difference was observed between 
the groups. (*** p<0.001 by Unpaired t test with Welch’s correction). Graph shows mean ± SEM, N=10 in 
DA-CL group and N=11 in DA-DS group. 
Increased number of viral-antigen positive cells in the hippocampus of DA-DS-infected 
mice.  
We analyzed coronal sections of mouse brain from the infected groups for virus 
localization in the hippocampus. At day 7 p.i., viral-antigen was mainly found in the 
CA1 and CA2 pyramidal layers, while it was completely absent from the CA3 pyramidal 
layer and the granule cell layer of dentate gyrus (Figure 10A and B). We enumerated the 
number of virus-antigen positive cells in the hippocampi and found that there was a 
significantly higher number of virus-infected neurons in DA-DS-infected mice compared 
to DA-CL-infected mice (Figure 10C) (Unpaired t test with Welch’s correction 
p=0.0033). In addition to virus-antigen positive cells in the hippocampus, viral infection 
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was noted in the cortex. But in both the infected groups, the virus-antigen spread was 
limited to the cortical area nearest to the CA1 and CA2 hippocampal regions. 
Figure 10 Increased number of viral-antigen positive cells in the hippocampus of DA-DS-infected 
mice. At day 7 p.i., (A and B) viral-antigen was primarily detected in the CA1 and CA2 pyramidal layers 
(white arrows) of the hippocampus in both the infected groups. Some of the cortical neurons surrounding 
the CA1 and CA2 pyramidal layers also stained positive for viral-antigen. (C) The number of viral-antigen 
positive cells in the hippocampus was significantly higher in the DA-DS-infected group than that in the 
DA-CL-infected group. (** p<0.01 by Unpaired t test with Welch’s correction). Graph shows mean ± 
SEM, N=4/infected group. Cornu ammonis1 (CA1), Cornu ammonis2 (CA2), Cornu ammonis3 (CA3), 
and dentate gyrus (DG). 
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Heterogeneous astroglial pathology among infected mice. 
Astrogliosis is a characteristic finding in several neurological diseases including epilepsy 
95,96. At day 7 p.i., we examined brain sections from infected mice for the number and 
morphology of astrocytes in the hippocampus. In general, we found an increase in the 
number of astrocytes in DA-DS-infected mice. However, the astrocyte count was not 
significantly different between the infected groups (Figure 11C) (Unpaired t test with 
Welch’s correction p=0.1564). This could be because of the small sample size and/or 
pooled results from seized and non-seized mice in the DA-CL-infected group. 
Interestingly, the non-seized mice in DA-CL-infected group had less astrocytes 
compared to the seized mice in the DA-DS and DA-CL-infected groups.  
In comparison to the non-reactive/ resting astrocytes, reactive astrocytes exhibit 
increased GFAP expression and hypertrophy of the cell body and cellular processes 96. 
In our study, the astrocytes in the hippocampus showed variability in the extent of GFAP 
expression and hypertrophy between and within the infected groups. Most astrocytes 
from the DA-DS-infected mice were found highly activated and hypertrophied, while the 
morphology of astrocytes varied from mildly activated to highly activated among the 
DA-CL-infected mice. Apart from astrogliosis, we found loss of astrocytes in some of 
the infected mice in the CA1 and CA2 regions, except for the stratum lacunosum-
moleculare area (SLM), of the hippocampus (Figure 11B). Although astrogliosis has 
previously been reported in hippocampus following TMEV infection 81, this is the first 
report of loss of astrocytes in this model.  
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Figure 11 Heterogeneous astroglial pathology among infected mice.  (A) Schematic diagram of the 
coronal section of hippocampus depicting different areas of CA1 field. (B) In comparison to the control 
mice that express resting/quiescent astrocytes, viral-infected mice exhibit reactive astrocytes that appear 
hypertrophied and have increased expression of GFAP protein. Among the infected mice, the CA1 region 
of the hippocampus showed varied astroglial pathology. In both the infected groups, activated astrocytes 
were found at the SLM area of CA1. The astrocytes were also found lining the PVCs at SLM. At the CA1-
A area of the hippocampus, we found activated, but fewer astrocytes (possible astroglial degeneration) 
near the damaged CA1 pyramidal layer in both groups. At the CA1-B area, astrocytes were more reactive 
in the DA-DS-infected group than that in the control or DA-CL-infected group. Images were taken under 
200x magnification. (C) The total astrocyte count within the hippocampus was not found to be 
significantly different between the infected groups (Unpaired t test with Welch’s correction). Graph shows 
mean ± SEM, N=4/infected group. Cornu ammonis1 (CA1), dentate gyrus (DG) and stratum lacunosum-
moleculare (SLM). 
Extensive inflammation and neuronal damage in the hippocampus of mice infected with 
DA-DS variant.  
To evaluate the effects of DA plaque-variants on pathology in the hippocampus, we 
examined H&E stained coronal sections of brain for inflammation and neuronal damage 
at varying time points. The preliminary data from day 3 p.i. showed that when compared 
to controls (Figure 12A), infected mice developed inflammation at the alveus, 
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hippocampal fissure and stratum lacunosum-moleculare (SLM) area of CA1 and CA2 
regions, while only the DA-DS-infected mice showed neuronal loss at CA1 and CA2 
pyramidal layers (Figure 12B and F). By day 7 p.i., the neuronal damage was also found 
in the DA-CL-infected group along with the existent inflammation (Figure 12C). In 
contrast, there was a marked increment in the intensity of inflammation and CA1 and 
CA2 neuronal loss in the DA-DS-infected group (Figure 12G). The extent of acute 
neuronal loss (Mann-Whitney test. Sum of ranks, p=0.0079) and inflammation 
(Unpaired t test with Welch’s correction, p=0.0199) were significantly greater following 
DA-DS-infection compared to DA-CL-infection (Figure 12J and K). In the chronic phase, 
the inflammation mostly subsided and no further neuronal damage was found in the DA-
CL-infected mice (Figure 12D and E), while the inflammation was exacerbated in the 
DA-DS-infected mice by week 5 p.i. (Figure 12H) and persisted at week 11p.i., which 
was the latest time-point at which histological analysis was performed (Figure 12I). 
Moreover, we did not find any damage to the dentate gyrus and CA3 neurons in either of 
the infected groups, which is consistent with other studies using the DA strain 81.  
Our results show that both plaque variants are capable of inducing inflammation in the 
hippocampus, but the intensity of inflammation is much more severe following DA-DS-
infection compared to DA-CL-infection. In the chronic phase, inflammation resolves 
following DA-CL-infection, while it continues to increase following DA-DS-infection. 
The DA-DS variant also induces an early and severe onset of neuronal damage, as most 
mice lose almost all of their CA1 and CA2 neurons by day 7 p.i. On the contrary, the 
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DA-CL variant causes minimal neuronal loss in the acute phase, which does not progress 
in the chronic phase. 
Figure 12 Extensive inflammation and neuronal damage in the hippocampus of mice infected with 
DA-DS variant. (A) H&E stained coronal section of hippocampus from control mice. Hippocampal 
regions from the infected groups were analyzed at days 3 (B and F) and 7 (C and G) and weeks 5 (D and 
H) and 11 (E and I) p.i. for histopathology. B-E are the representative images from DA-CL-infected group
and F-I are the representative images from DA-DS-infected group. By day 3 p.i., both the infected groups 
(B and F) showed increase in cellularity and PVCs at alveus, hippocampal fissure and stratum lacunosum-
moleculare area of CA1 and CA2 regions. However, the loss of CA1 and CA2 pyramidal neurons was 
found only in the DA-DS-infected group at this time-point. At day 7 p.i., both the inflammation, and CA1 
and CA2 neuronal loss, were extremely severe in the (G) DA-DS-infected mice and greater than that in the 
(C) DA-CL-infected mice. (C) A representative section of hippocampus from DA-CL-infected group 
presenting CA1-CA2 damage score 2. (G) A representative section of hippocampus from DA-DS-infected 
group presenting CA1-CA2 damage score 10. By week 5 p.i., the inflammation mostly resolved in the (D) 
DA-CL-infected mice, while it remained high in the (H) DA-DS-infected mice. At week 11 p.i., no 
inflammation was found in the (E) DA-CL-infected group and the intensity of inflammation appeared to 
decrease in the (I) DA-DS-infected group. The arrowheads depict neuronal loss and the asterisks depict 
inflammation in the images. All images were taken under 100X magnification. At day 7 p.i., (J) the 
damage to the CA1 and CA2 pyramidal layers (** p<0.01 by Mann-Whitney test. Sum of ranks) and (K) 
the intensity of inflammation (* p<0.05 by Unpaired t test with Welch’s correction) were found to be 
significantly higher in the DA-DS-infected group in comparison to that in the DA-CL-infected group. 
Graphs show mean ± SEM, N=5 per infected group. Cornu ammonis1 (CA1), cornu ammonis2 (CA2), 
cornu ammonis3 (CA3), dentate gyrus (DG), alveus (Av.), hippocampal fissure (HF) and stratum 
lacunosum-moleculare (SLM). 
51 
Acute inflammation was more pronounced at the lumbar segment of spinal cord 
following DA-DS-infection.  
Unlike SJL mice, the DA infection fails to cause demyelinating lesions in the spinal cord 
of C57BL/6 mice 72. To study the impact of DA plaque variants on spinal cord disease in 
C57BL/6 mice, we analyzed H&E stained spinal cord sections for damage at acute (days 
3 and 7 p.i.) and chronic (weeks 5 and 11 p.i.) phases of infection.  
At day 3 p.i., no significant lesions were observed in the spinal cords of any of the 
infected mice in comparison to control mice. By day 7 p.i., both the infected groups 
developed meningitis, PVC, inflammatory foci, and/or possible neuronal degeneration at 
the ventral and/or lateral horns of the gray matter of spinal cord. In some mice, 
inflammation even extended to the dorsal horn of the gray matter, and ventral and lateral 
columns of the white matter.  
The magnitude of inflammation was similar at the cervical and thoracic segments 
between the infected groups, but the lumbar and sacral segments of the DA-DS-infected 
group showed higher neuropathology than the DA-CL-infected group.  In the DA-DS-
infected group, lesions were found in 6/6 mice at the lumbar segment and 4/6 mice at the 
sacral segment, while in the DA-CL-infected group, lesions were only found in 2/5 mice 
at the lumbar and sacral segments (Figure 13A-D).  
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Upon comparing the cumulative distribution of the scores, we found that DA-DS plaque 
variant induced significantly more lesions at the lumbar segment in comparison to the 
DA-CL plaque variant (Figure 13E) (Kolmogorov-Smirnov test; for cervical and thoracic 
segments-p>0.9999; for lumbar segment-p=0.0390; and for sacral region-p=0.2424).  
By week 5 p.i., the inflammation subsided in both the infected groups. In addition, we 
did not find demyelinating lesions in any of the infected mice at week 5 or 11 p.i. Our 
results show that although DA-CL-and DA-DS plaque variants induce acute 
inflammation in the spinal cord, they fail to cause chronic demyelinating disease in 
C57BL/6 mice. Nonetheless, the deleterious effects of DA-DS plaque variant were more 
prominent than that of DA-CL plaque variant, specifically at the lumbar segment of the 
spinal cord. 
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Figure 13 Acute inflammation was more pronounced at the lumbar segment of spinal cord following 
DA-DS-infection. H&E stained lumbar segments from the (A and C) control group, (B) DA-CL-infected 
group, and (D) DA-DS-infected group. (A and C) No lesions were found in the control group. (B and D) 
The most affected lumbar segments showing meningitis, PVC, and inflammatory foci in the gray and 
white matter, and representing scores 3. (E) The degree of inflammation was similar at the cervical, 
thoracic and sacral segments, while the lumbar segments from the DA-DS-infected group were found 
significantly more inflamed than that in the DA-CL-infected group (* p<0.05 by Kolmogorov-Smirnov 
test). All images were taken under 100X magnification. Graph shows mean ± SEM, N=5 in DA-CL group 
and N=6 in DA-DS group. Arrowhead indicates possible neuronophagia and arrows indicate inflammation. 
Increased immune cell infiltration into the CNS of mice following DA-DS-infection.  
TMEV infection stimulates the activation of resident immune cells and infiltration of 
peripheral immune cells into the CNS 21,81,97. To immuno-phenotype leukocyte 
populations, we harvested brain leukocytes from control and infected mice at day 3 p.i., 
as seizures peak at this time point. We found a significant increase in the expression 
levels of CD45.2+ (which includes microglia, macrophages/monocytes, neutrophils, T 
cells, B cells, etc.) in the cells isolated from the CNS of the DA-Ds-infected group 
compared to control mice. However, the expression levels of CD45.2+ cells were not 
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found to be statistically different between the controls and DA-CL groups, and between 
the DA-CL and DA-DS groups (Figure 14A) (One-way ANOVA with Tukey’s multiple 
comparisons test; control vs. DA-DS group-p=0.0246; control vs. DA-CL group-
p=0.3975; DA-CL vs. DA-DS group-p=0.1366).  
Upon further analysis, we found that the expression levels of CD45.2intermediate (int) 
cells were similar in all groups (Figure 14B) (One-way ANOVA with Tukey’s multiple 
comparisons test; control vs. DA-DS group-p=0.8870; control vs. DA-CL group-
p=0.9958; DA-CL vs. DA-DS group-p=0.8668), but the expression levels of CD45.2high 
(hi) cells were DA- DS > DA- CL > control group (Figure 14C) (One-way ANOVA with 
Tukey’s multiple comparisons test; control vs. DA-DS group-p=0.0003; control vs. DA-
CL group-p=0.0425; DA-CL vs. DA-DS group-p=0.0385). To differentiate between 
microglia and macrophage/monocyte/granulocyte populations, we gated cells based on 
their CD45.2 and CD11b expression. As depicted in Figure 14D, we did not find any 
significant differences in the expression levels of CD45.2int CD11b+ cells (microglia) 
between the groups (One-way ANOVA with Tukey’s multiple comparisons test; control 
vs. DA-DS group-p=0.7105; control vs. DA-CL group-p=0.9256; DA-CL vs. DA-DS 
group-p=0.8420). Interestingly, the expression levels of CD45.2hi CD11b+ cells 
(macrophage/monocyte/granulocyte) in the DA-DS-infected group were found 
significantly higher than that in control or DA-CL group, Figure 14E (One-way ANOVA 
with Tukey’s multiple comparisons test; control vs. DA-DS group-p=0.0014; control vs. 
DA-CL group-p=0.1335; DA-CL vs. DA-DS group-p=0.0374). Figure 14F shows a 
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significant increase in the expression levels of CD45.2+ Gr1+ cells in the DA-DS-
infected group compared to the control group, but not the DA-CL group (One-way 
ANOVA with Tukey’s multiple comparisons test; control vs. DA-DS group-p=0.0052; 
control vs. DA-CL group-p=0.2092; DA-CL vs. DA-DS group-p=0.0775).  
Our results indicate that DA-DS plaque-variant had a significant impact on the 
infiltration of peripheral innate immune cells into the CNS. On one hand, the 
inflammatory response is crucial for protection against virus infection, but on the other 
hand, the dysregulated inflammation initiates widespread hippocampal damage, leading 
to seizure development.  
Figure 14 Increased immune cell infiltration into the CNS of mice following DA-DS-infection. Brain 
leukocytes from control and infected mice were collected at day 3 p.i. and stained for cell specific 
markers. (A) Our results showed that DA-DS infection significantly increased the expression levels of 
CD45.2+ in the brain. Upon further analysis, we found that (B and D) neither of the plaque-variants 
significantly altered CD45.2int and CD45.2int CD11b+ expression levels, while (C) the expression levels 
of CD45.2hi were DA-DS > DA-CL > control group, and (E and F) DA-DS plaque variant significantly 
increased the expression levels of CD45.2hi CD11b+ and CD45.2hi Gr1+ in mice brains during the acute 
phase. Graphs show pooled results from five separate experiments expressed as mean ± SEM, N=5 in 
control group and N=13 per infected group. (* p<0.05, ** p<0.01, *** p<0.001 by One-way ANOVA with 
Tukey’s multiple comparisons test). 
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Behavioral and cognitive tests  
In addition to recurrent seizures, epilepsy is often associated with neuropsychological 
dysfunction, such as impaired memory and attention, depression, anxiety, etc. 98,99.  
Mice with DA-DS infection developed anxiety-like behavior in the chronic phase. 
We conducted EPMT to determine the effects of plaque-variants on the development of 
anxiety-like behavior in mice. This test is based upon the principle that mice have a 
natural disinclination for open and elevated spaces and preference for dark and enclosed 
spaces. However, mice also exhibit curiosity for novel environments. Hence, this test is 
truly a balance between both aspects of mouse behavior. The less curious mice would 
stay in the closed arms and have fewer visits to the open arms 90.  
As shown in Figure 15A, we found no statistical differences in the number of closed arm 
entries between the groups suggesting similar locomotor activity among all mice. (One-
way ANOVA with Tukey’s multiple comparisons test; control vs. DA-CL group-
p=0.9602; control vs. DA-DS group-p=0.9774; and DA-CL vs. DA-DS group-p=0.8312). 
However, we saw significantly fewer open arm entries in the DA-DS-infected group 
compared to the DA-CL-infected group (Figure 15B). The number of open arm entries 
was not statistically different between the controls and infected mice. This could be 
because of the smaller sample size of the control group. Our findings suggest that 
anxiety-like behavior was only induced among mice following DA-DS infection (One-
57 
way ANOVA with Tukey’s multiple comparisons test; control vs. DA-CL group-
p=0.3403; control vs. DA-DS group-p=0.7249; and DA-CL vs. DA-DS group-p=0.0370). 
Figure 15 Mice with DA-DS infection developed anxiety-like behavior in the chronic phase. (A) 
Neither of the plaque-variants affected locomotor activity, but (B) only DA-DS plaque-variant induced 
anxiety-like symptoms as infected mice hesitated to enter open arms of the elevated plus maze. Graphs 
show results expressed as mean ± SEM, N=4 in control group and N=8 per infected group. (* p<0.05 by 
one-way ANOVA with Tukey’s multiple comparisons test). 
The two plaque-variants had no effect on the context-associated memory, but they 
significantly impaired spatial-associated memory in mice. 
We conducted NORT and NOLT to examine whether plaque-variants had any effect on 
context and/or spatial-based memory in mice. NORT is based upon the inclination of 
mice to explore a novel object over a familiar object, while NOLT is based upon the 
inclination of mice to explore an object in a novel location (displaced) over an object in 
a familiar location (non-displaced) 100.  
We started with NORT, and found that both the control and infected mice displayed an 
increase in the discrimination index (DI) in the test phase when compared to that in the 
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familiar phase (Figure 16A), but we did not find DI to be statistically different between 
and within the groups (Two-way ANOVA with Tukey’s multiple comparisons test, 
control fam vs. DA-CL fam group-p=0.9991; control fam vs. DA-DS fam group-p>0.9999; 
DA-CL fam vs. DA-DS fam group-p=0.9995; control test vs. DA-CL test group-p=0.9723; 
control test vs. DA-DS test group-p=0.9978; DA-CL test vs. DA-DS test group-p=0.9986; 
control fam vs. control test group-p=0.5054; DA-CL fam vs. DA-CL test group-p=0.3670; and 
DA-DS fam vs. DA-DS test group-p=0.3247).  
As shown in Figure 16B, we found no significant differences in the novel object 
exploration time among the groups (Two-way ANOVA with Tukey’s multiple 
comparisons test, control fam vs. DA-CL fam group-p=0.9974; control fam vs. DA-DS fam 
group-p>0.9999; DA-CL fam vs. DA-DS fam group-p=0.9959; control test vs. DA-CL test
group-p=0.2269; control test vs. DA-DS test group-p=0.4709; DA-CL test vs. DA-DS test 
group-p=0.9917; control fam vs. control test group-p=0.0664; DA-CL fam vs. DA-CL test
group-p=0.4506; and DA-DS fam vs. DA-DS test group-p=0.4031). Our findings suggest 
that neither of the plaque-variants had any significant effect on the context-associated 
memory in mice.  
Our results from NOLT experiments showed that both the control and infected mice 
displayed an increase in the discrimination index (DI) in the test phase when compared 
to that in the familiar phase (Figure 16C), although this difference was found to be the 
least in the DA-DS-infected group. Moreover, we did not find the DI to be statistically 
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different between and within the groups (Two-way ANOVA with Tukey’s multiple 
comparisons test, control fam vs. DA-CL fam group-p=0.9969; control fam vs. DA-DS fam 
group-p>0.9999; DA-CL fam vs. DA-DS fam group-p=0.9768; control test vs. DA-CL test
group-p=0.9945 control test vs. DA-DS test group-p=0.8557; DA-CL test vs. DA-DS test 
group-p=0.9722; control fam vs. control test group-p=0.6261; DA-CL fam vs. DA-CL test
group-p=0.2928; and DA-DS fam vs. DA-DS test group-p=0.9864). 
However, (Figure 16D) we found that only the control mice preferred the displaced 
(novel location) object to the non-displaced (familiar location) object, and the 
exploration time for the displaced object was significantly lower among the infected 
groups than that among the control group (Two-way ANOVA with Tukey’s multiple 
comparisons test, control fam vs. DA-CL fam group-p=0.6526; control fam vs. DA-DS fam 
group-p=0.5478; DA-CL fam vs. DA-DS fam group-p>0.9999; control test vs. DA-CL test
group-p=0.0272; control test vs. DA-DS test group-p=0.0066; DA-CL test vs. DA-DS test 
group-p=0.9838; control fam vs. control test group-p=0.3566; DA-CL fam vs. DA-CL test
group-p=0.9804; and DA-DS fam vs. DA-DS test group-p=0.9999). Our findings suggest 
that both the plaque-variants significantly impaired the spatial-associated memory in 
mice, but this effect was more pronounced following DA-DS infection.  
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Figure 16 The two plaque-variants had no effect on the context-associated memory, but they 
significantly impaired spatial-associated memory in mice. The results from cognitive tests conducted in 
the chronic phase showed that (A and B) DI and exploration time (novel object) in NORT remained 
unaffected following viral infection. (C) DI in NOLT was relatively lower following DA-DS-infection, but 
(D) both DA-CL and DA-DS plaque-variants significantly decreased exploration time of the displaced 
object in NOLT. Graphs show results expressed as mean ± SEM. N=4 in control group and N=8 per 
infected group. (* p<0.05, ** p<0.01 by Two-way ANOVA with Tukey’s multiple comparisons test). 
Discrimination index (DI), novel object recognition test (NORT), and novel object location test (NOLT).  
Genetic Differences between viral strains. 
Total RNA was extracted from DA-CL and DA-DS infected L2 cells and cDNAs 
representing overlapping amplicons spanning nts 137-3’poly(A) tail (nt positions are all 
relative to Genbank Accession M20301 83) were synthesized by RT-PCR, purified by 
agarose gel electrophoresis and sequenced as described in Materials and Methods. A list 
of the overlapping amplicons can be found in Table 2. The nucleotide sequences of the 
DA-CL and DA-DS variants and the translated proteins were aligned and compared to 
each other and to the three other TMEV-DA complete genomes in Genbank (Genbank 
Accessions M20301, JX443418, and KF680264) 83 with Clustal Omega. Sequence 
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differences are summarized in Table 4. There are three nucleotide differences between 
DA-CL and DA-DS. The first is a T1244C change in DA-CL compared to both DA-DS 
and the three sequences for the DA strain of TMEV that are present in Genbank. This 
change results in a M60T amino acid change in the DA- CL leader protein and a W56R 
change in the L* protein relative to both DA-DS and the Roos lab strain of TMEV-DA. 
The second is in the coding sequence for the helicase domain of protein 2C, where DA-
DS contains a T5030C change relative to DA-CL and the Genbank sequences. This 
produces a corresponding I133T mutation in the DA-DS 2C protein relative to the 2C 
protein encoded in DA-CL and the other three TMEV-DA sequences in Genbank. The 
third nucleotide difference between the DA-CL and DA-DS variants is coding silent at 
position 6054, where DA-DS and the three other viruses we analyzed contain an A at this 
position and the DA-CL virus contains a G.   
There are three additional sites where the DA-CL and DA-DS sequences differ from all 
of the complete genomes in Genbank. In the 5’ untranslated region (5’UTR) there is a C 
at position 475 in the DA-CL and DA-DS sequences and a T is present in all three TMEV 
genome sequences in Genbank. Nucleotide7813 is a G in both DA-CL and DA-DS 
whereas all three of the Genbank Accessions contain a C at this position. This difference 
results in an alanine at amino acid 410 in the DA-CL and DA-DS 3D proteins, whereas 
the other 3 viruses encode a proline at this position. A third difference is present at 
nucleotide 1929 where both DA-CL and DA-DS contain a C, whereas a T is present in 
Genbank Accession JX443418 and a G is present in Genbank Accessions M20301 and 
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KF680264.  This nucleotide difference is coding silent relative to the translation of 
M20301 and KF680264 and is thus unlikely to be significant. There are approximately 
40 other sites where the DA-CL and DA-DS sequences are discordant from one or two of 
the three complete TMEV-DA genome sequences but are identical to at least one 
TMEV-DA genome sequence in Genbank (not shown). The vast majority of these 
correspond to coding silent polymorphisms amongst the three TMEV genomes in 
Genbank. 
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Nucleotide 
Position 
DA-DS DA-DS 
amino 
acid 
DA- CL DA- CL 
amino 
acid 
Genbank 
M20301 
Genbank 
M20301 
amino acid 
Genbank 
JX443418 
Genbank 
JX443418 
amino acid 
Genbank 
KF680264 
Genbank 
KF680264 
amino acid 
475 C NA C NA T NA T NA T NA 
1244 T L protein 
60M 
L*protei
n 56W 
C L protein 
60T 
L*protei
n 56R 
T L protein 
60M 
L*protein 
56W 
T L protein 
60M 
L*protein 
56W 
T L protein 
60M 
L*protein 
56W 
1929 C VP2 
protein 
141K 
C VP2 
protein 
141K 
G VP2 protein 
141K 
T VP2 protein 
141N 
G VP2 protein 
141K 
5030 C 2C 
protein 
133T 
T 2C 
protein 
133I 
T 2C protein 
133I 
T 2C protein 
133I 
T 2C protein 
133I 
6054 A 3C 
protein 
40Q 
G 3C 
protein 
40Q 
A 3C protein 
40Q 
A 3C protein 
40Q 
A 3C protein 
40Q 
7813 G 3D 
protein 
A410 
G 3D 
protein 
A410 
C 3D protein 
A410 
C 3D protein 
A410 
C 3D protein 
A410 
Table 4 Summary of sequence differences between DA-CL and DA-DS and Genbank Accessions M20301, JX443418, and KF680264. 
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Discussion 
 
Fujinami and co-workers were the first to characterize the TMEV-induced epilepsy 
model. They found that C57BL/6 mice infected with the DA strain of TMEV exhibit 
symptomatic seizures in the acute phase, recover from viral infection within a month, but 
after an unspecified latent phase develop unprovoked recurrent seizures (epilepsy). In 
this infection-driven model, the lesions are mainly concentrated in the CA1 and CA2 
regions of the hippocampus. In the chronic phase, the neuronal loss and gliosis worsens 
to cause hippocampal atrophy and glial scarring, termed hippocampal sclerosis (HS) 
34,38,101-103. HS is also the hallmark neuropathology of mesial temporal lobe epilepsy 
(MTLE), the most prevalent form of human epilepsy 104 105,106. Since DA-infection 
shares similarities with MTLE, it serves as an excellent model to study epileptogenesis 
and epilepsy.  
 
Our current work is an extension of the TMEV-induced epilepsy studies. Here, we 
investigated the independent roles of the large (DA-CL) and small (DA-DS) plaque-size 
variants of DA strain of TMEV in the development of seizures. The in vivo studies 
revealed a striking contrast between the phenotypes of the DA-CL and DA-DS plaque 
variants. We found that the percentage of seized mice was significantly higher following 
DA-DS-infection (~94%) compared to DA-CL-infection (~12%). We recorded repeated 
seizures in the DA-DS-infected group that began on day 2 and ceased after day 7 p.i., 
whereas seizures in the DA-CL-infected group were only observed on day 3 p.i. 
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Additionally, the frequency and severity (Racine stage 4 or 5) of seizures in the DA-DS-
infected group peaked on day 3 p.i. and remained high until day 5 p.i. The previous 
study, where similar titers (2.5 x 105 pfu) of the DA strain were used and mice were 
examined twice daily, showed acute seizures in ~57% of the infected C57BL/6 mice 107. 
The phenotypic variability between the DA strain and the plaque variants indicate that 
the neuro-virulence is DA-DS-plaque variant>DA strain>DA-CL-plaque variant.  
 
Furthermore, we monitored clinical illness including weight loss and non-epileptic 
clinical signs in mice following infection. Compared to DA-CL, the DA-DS plaque 
variant caused severe illness (ruffling, hunched back and ataxia) in mice during the acute 
phase. However, the severity of clinical illness was variable within the group. In 
addition, the acute weight loss was highest in the DA-DS-infected mice, and their 
weights remained significantly lower than the control or DA-CL-infected mice until one-
month p.i. This implies that there was significant delay in the recovery among DA-DS-
infected mice.  
 
The plaque assay studies at day 7 p.i. revealed that viral titers remained significantly 
higher in the brains of DA-DS- infected mice compared to those of DA-CL-infected 
mice. Similar to the DA infection 81, we also detected virus-antigen positive cells in the 
hippocampus at day 7 p.i. Within the hippocampus, the virus-antigen was localized in 
the CA1 and CA2 pyramidal neurons, but the neurons in dentate gyrus and CA3 region 
were not affected. The number of viral-antigen positive cells was significantly higher in 
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the DA-DS-infected group compared to the DA-CL-infected group. These findings 
confirm that the DA-DS-, but not DA-CL-, plaque variant could efficiently replicate in 
vivo. 
Since viral-antigen positive cells were mainly confined to the CA1 and CA2 pyramidal 
layers of the hippocampus, we examined these regions for neuronal loss. By day 7 p.i., 
the DA-DS-infected group had wide-spread loss of CA1 and CA2 neurons, and increased 
presence of PVCs and inflammatory foci in the hippocampal fissure and near CA1 and 
CA2 pyramidal layers. In contrast, neuronal loss in the DA-CL-infected group was 
patchy, with significantly fewer PVCs and inflammatory foci. In the chronic phase, mice 
from the DA-DS-infected group developed evident anatomical changes at CA1 and CA2 
regions of hippocampus. The extensive loss of pyramidal neurons in the DA-DS-infected 
group may have emanated from the high viral burden, inflammation, and/or seizures 
from the acute phase.    
Moreover, we detected viral burden and inflammation in the spinal cords of infected 
mice at day 7 p.i. The magnitude of inflammatory lesions varied within the spinal cord 
segments of the same mouse and between the infected mice. However, the most marked 
lesions were found in the lumbar segment of the spinal cord among DA-DS-infected 
mice. Mice also developed ataxia/ flaccid paralysis of the hind limb(s) during the first 
week, which was more pronounced following DA-DS-infection. Therefore, we suggest 
that mice develop short-lived hind limb deficits, the intensity of which depends upon the 
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severity of spinal cord lesions. Nonetheless, the intensity and duration of inflammation 
and viral burden was much higher in the brains than the spinal cords of the infected 
mice. 
TMEV-infection triggers a significant host immune response, including the activation of 
resident (glia) and the infiltration of peripheral immune cells into the CNS. The immune 
response is extremely crucial for protecting the CNS against viral infection, but also 
leads to massive neuronal destruction in the process. The neuronal damage (particularly 
CA1 and CA2 pyramidal neurons) and seizures begin very early following TMEV (DA 
strain)-infection (day 2-3 p.i.), the time-point at which the adaptive immune response is 
not significant, implying that these events are mainly mediated by the innate immune 
response 21,81,97,103. Here, we found that at day 3 p.i, which is the peak time for seizures 
in our study, the expression levels of infiltrating innate immune cells (such as, 
monocytes, macrophages and granulocytes), but not resident immune cells (microglia), 
were significantly higher in the DA-DS-infected group compared to the control and DA-
CL-infected groups. Our findings imply that the excessive levels of infiltrated innate 
immune cells are detrimental to the hippocampal neurons and result in seizures 
following DA-DS-infection, while microglia may not be a critical factor here. These 
results align with the previous studies using DA-infected mice, where the hippocampal 
damage and seizure frequency were significantly reduced after blocking or depleting 
granulocytes and more specifically, inflammatory monocytes. However, the authors did 
not rule out the role of microglia in causing seizures 20,97. 
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Astrocytes play crucial and diverse roles in maintaining the healthy state of the CNS, 
while reactive astrocytes may be a direct cause of disease or may contribute to disease 
progression.  Upon molecular, cellular and/or functional alterations, the reactive 
astrocytes can lose their normal functions or gain atypical functions. On the contrary, 
reactive astrocytes may have beneficial roles in the diseased state. For instance, the glial 
scarring by astrocytes may be a mechanism to limit the spread of infection, insult or 
inflammation 96. Here, we found the dual and region-specific astroglial pathology in the 
hippocampus at day 7 following DA plaque variants infection. In general, infected mice 
displayed reactive astrocytes, and seized mice had higher number of astrocytes than the 
non-seized mice. In addition, we found the loss of astrocytes near CA1 and CA2 
pyramidal layers in some of the infected mice. The missing astrocytes could be a 
consequence of glial degeneration mediated by viral infection, acute inflammation, or 
adjacent neuronal damage. The loss of astrocytes is also a characteristic finding in 
Rasmussen’s encephalitis, a form of inflammation-induced human epilepsy 108.  Thus, 
the dysfunctional or lost astrocytes may cause excitotoxicity, neurotoxicity, seizures and 
epilepsy.  
Neuropsychological issues, such as mood disorders, anxiety, depression, impaired 
cognition, etc. are common sequelae of epilepsy 98,99. In fact, these deficits are more 
prevalent among people with epilepsy than the general population 109,110. Therefore, we 
examined infected mice for behavioral and cognitive deficits at one-month p.i. Our 
results showed that mice developed anxiety-like symptoms following DA-DS-infection, 
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but not DA-CL-infection. The ventral hippocampus and amygdala are the two main 
regions of the brain involved in regulating emotional behavior. However, their roles are 
quite distinctive, as the amygdala affects fear-based situations, while ventral 
hippocampus contributes to anxiogenic situations 111,112. This suggests that the DA-DS 
plaque variant provoked anxiety-like symptoms in mice by causing functional alterations 
in the hippocampus. The anxiety-like symptoms are also seen among mice following 
DA-infection 38.  
 
The results from memory tasks showed that both the infected groups had significant 
decline in spatial-based memory, and this deficit was more pronounced among DA-DS-
infected mice. However, context-based memory was spared in both the infected groups. 
In their review, Ciernia and Wood 100 discussed the roles of distinct regions of rodent 
brain in partaking different types of memory. They note that the hippocampus, in 
particular the dorsal CA1 region, is critical for spatial-based memory. Whereas, insular 
cortex, perirhinal cortex, ventromedial prefrontal cortex, and maybe the hippocampus 
are important for forming context-based memory. The previous study using DA-infected 
mice showed that the extent of hippocampal damage, but not cortical damage, regulates 
spatial-based memory in mice 102. In our present study, we report that like the DA strain 
38,102,103; both plaque-variants could induce spatial-based memory deficits in mice 
probably due to CA1 neuronal damage. The infected mice in our study had intact 
context-based memory, though another group has reported context-based memory 
deficits using DA-infected mice 103.  These varied findings could be because of the 
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differences in the test setup (short vs. long delay phase) or in the neuro-virulence of the 
DA strain and plaque-variants.  
Cardioviruses such as TMEV translate their genomes as a 7kb polyprotein precursor that 
subsequently undergoes autoproteolytic cleavage to yield 12 viral proteins, one of which 
is the 76 amino acid leader protein 113-116. The demyelinating strains of TMEV such as 
TMEV-DA also express an 18-kDA L* protein from an alternate open reading frame 2 
first identified by Kong and Roos 117. The leader protein contains an N-terminal Zinc 
binding Cys-His-Cys-Cys (C-H-C-C) motif that is essential for this protein’s ability to 
inhibit IFN-α/β production, allowing for viral persistence 118-122. Part of the mechanism 
for this inhibition of interferon induction has been linked to leader protein binding to 
nucleoporins and blocking mRNA nuclear export 123,124. The Leader protein also 
contains an acidic domain, a serine/threonine rich domain which in TMEV contains two 
phosphorylation sites, and a C-terminal TMEV-specific domain that plays a role in 
cellular localization and trafficking between the nucleus and cytoplasm 124,125. L* is 
synthesized from an overlapping ORF 13 nucleotides downstream from the AUG start 
codon for the polyprotein 122,126 and has been shown to inhibit the interferon-inducible 
OAS/RNase L pathway allowing for the evasion of host innate immunity 121. The ability 
to impair the innate host immune response in certain cell types by either Leader or L* 
contributes to viral evasion of the host immune response and viral persistence 
118,123,124,126,127. Mutations in leader result in significantly less neurovirulence as indicated 
by decreased viral persistence in the CNS 120. Our data show that the thymine to cytosine 
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mutation at position 1244 in DA-CL compared to both DA-DS and the three TMEV 
Genbank sequences results in a methionine to threonine amino acid change at position 
60 in the DA- CL leader protein and a tryptophan to arginine change at position 56 for 
the L* protein. Interestingly, mutation of leader methionine 60 to valine, leucine, or 
isoleucine blocks binding to nucleoporins, RNA export from the nucleus, interferon 
induction in vitro, and viral persistence in vivo 122,124. Thus, we postulate that these 
mutations in the leader and L* proteins of DA-CL lead to the attenuating phenotype of 
the DA-CL variant in the C57BL/6 mouse model of epilepsy. Compared to the DA-DS 
variant, infection with the DA-CL variant resulted in to less neuro-edema, less viral 
burden and less neuro-inflammatory burden in the hippocampus of our DA-CL infected 
mice. The overall result was better recovery of mice infected with the DA-CL variant 
versus the DA-DS and significantly fewer and less severe episodes of seizure activity in 
DA-CL infected mice. Our data are consistent with previous findings that mutations in 
the leader protein 118 and the L* protein 113,124 both reduce viral neurovirulence and virus 
persistence in macrophages in vitro, and in the brain and spinal cord in  mice 113,127,128. 
Experiments are ongoing to elucidate the relative importance of the mutation in leader 
versus L*, as current research has yielded somewhat controversial claims as to the 
importance of each protein in viral persistence 113,121. The sequence differences between 
DA-CL and DA-DS at nucleotides 5030 and 6054, respectively, appear to be unlikely to 
contribute to the attenuation of DA-CL. The first because the nucleotide at this position 
is identical to that in the other three TMEV stains in Genbank and identical to the DA-CL 
sequence, and the latter because it is coding silent. 
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The H-2D MHC class I locus strongly influences the susceptibility of the inbred mouse 
strains to the demyelinating disease or epilepsy. C57BL/6 mouse strain (H-2b haplotype) 
is resistant to the demyelinating disease but susceptible to epilepsy, whereas the SJL 
mouse strain (H-2s haplotype) is susceptible to the demyelinating disease but do not 
develop epilepsy 82,129-131. Our findings in C57BL/6 mice together with the previous 
study by Oleszak and group in SJL mice 80 corroborate that both the C57BL/6 and SJL 
mouse strains develop severe neuro-pathological lesions, clinical disease, and viral 
burden following DA-DS-infection, while the magnitude of the clinical disease in both 
the mouse strains is minimal following DA-CL-infection. Hence, the neuro-virulence of 
DA-DS and DA-CL plaque-variants is independent of the H-2D MHC class I locus in 
C57BL/6 and SJL mouse strains. This is in contrast to the recent paper published on two 
naturally occurring variants of the BeAn strain of TMEV, (BeAn-1 and BeAn-2). They 
found that BeAn-1 was neuro-virulent in only the SJL mouse strain causing 
demyelinating disease (MS), while BeAn-2 was neuro-virulent in only the C57BL/6 
mouse strain causing acute seizures. Thus, the neuro-virulence of the BeAn variants, 
unlike the DA variants, depends upon the genotype of C57BL/6 and SJL mice. 
Although, they do not show if the BeAn variants formed different sized-plaques as the 
DA variants do in vitro 132.  
 
To conclude, we found that the DA-DS plaque variant was extremely neuro-virulent and 
caused marked structural and functional alterations in the hippocampus of C57BL/6 
mice, while the DA-CL plaque variant had attenuated neuro-virulence. The previous 
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study from SJL mice 80 along with our current study in C57BL/6 mice indicate that the 
neuro-virulence of DA-DS plaque variant is significantly higher than the DA-CL plaque 
variant in the viral-induced models of two distinct neurological diseases, MS and 
epilepsy.  
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CHAPTER III  
THE NLRC5 GENE IS CRITICAL FOR INNATE IMMUNITY AND SEIZURE 
DEVELOPMENT IN TMEV-INDUCED EPILEPSY MODEL 
Introduction 
Theiler’s murine encephalomyelitis virus (TMEV) is a single stranded RNA virus that 
belongs to Picornaviridae family. TMEV-infected C57BL/6 mice develop an 
unregulated innate immune response (activation of microglia/monocytes, astrocytes, 
etc.) invoking seizures within a week post infection (p.i.), and adaptive immune response 
(mainly MHC class I-dependent cytotoxic T cell activation) mediating viral clearance 
within a month p.i. In addition, the development of “bystander” hippocampal damage 
makes infected mice susceptible to recurrent spontaneous seizures (epilepsy). Although, 
TMEV infection culminates in epilepsy in C57BL/6 mice 21,34,36, the T cell-mediated 
viral clearance prevents them from developing chronic demyelinating disease of the 
central nervous system (CNS) that resembles multiple sclerosis. TMEV infection-driven 
murine epilepsy recapitulates the attributes of medial temporal lobe epilepsy (mTLE); 
hence, serves as an efficient model to study acute inflammatory triggers and 
pathophysiology of seizures 34,43.  
Nucleotide-binding oligomerization domain-like receptors (NLRs) form an essential part 
of the innate immune system. They are intracellular pattern recognition receptors (PRRs) 
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that recognize conserved microbial motifs called pathogen-associated molecular patterns 
(PAMPs) and/or endogenous danger signals called danger-associated molecular patterns 
(DAMPS). Among the PRRs, NLRs form the biggest family with 22 members in 
humans and 34 members in mice 133. NLRs have recently gained immense attention due 
to their diverse immunological functions in numerous autoimmune disorders, 
neurological diseases, viral and bacterial infections (Reviewed by: Biswas and 
Kobayashi 134; Coutermarsh-Ott et al. 135; Kong et al. 136).  
The NLR family, caspase activation and recruitment (CARD) domain containing 5 
(NLRC5), also named NOD27, or CLR16.1 133, is the largest protein of the NLR family 
possessing the molecular mass of 204 kDa. It consists of a tripartite domain structure, 
which includes an atypical caspase activation and recruitment domain (CARD) located 
at the N-terminal, a nucleotide-binding domain (NBD) located at the center, and a 
leucine-rich repeat domain (LRR) located at the C-terminal 137. NLRC5 is located on 
chromosome 16q13 in humans 133,137, and chromosome 8 in mice 133. NLRC5 protein in 
humans and mice share 64% of the amino acid sequence, suggesting that it is 
biologically conserved 56.  
NLRC5 has a well-established role as the transactivator of major histocompatibility 
complex (MHC) class I (H2-D and H2-K) gene and the genes involved in MHC class I 
antigen processing and presentation, such as β2-microglobulin (β2m), transporter 
associated with antigen processing 1 (TAP1), and large multifunctional proteases 2 
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(LMP2) 45,49,50. Apart from regulating MHC class I expression, NLRC5 has also been 
reported to contribute to immune signaling pathways (nuclear factor kappa-light-chain-
enhancer of activated B cells [NF-κB]- and interferon [IFN]-dependent responses) 
following viral infection. However, most of these studies are conducted in in vitro and ex 
vivo systems, and the results pertaining to the function of NLRC5 as positive or negative 
regulator of anti-viral immunity are still inconclusive 49,53,54,56-58,137,138. Since, NLRC5 
contributes to both innate (by recognizing PAMPs) and adaptive (by MHC class I-
dependent activation of cytotoxic T cell) immune responses, it is a common mediator for 
both arms of the immune system.  
The objective of our current study is two-fold. The first objective is to delineate the 
function of Nlrc5 in regulating immune responses and inducing seizures in TMEV-
induced model of epilepsy. The second objective is to investigate whether Nlrc5-
dependent MHC class I expression determines the resistance of C57BL/6 mice to 
demyelinating disease following TMEV infection. For this, Nlrc5 deficient (Nlrc5-/-) 
mice (on C57BL/6 background) and wild type C57BL/6 mice were infected with TMEV, 
examined for clinical signs of seizures and demyelinating disease, brain and spinal cord 
pathology, and inflammation. The acute phase (day 0-7 p.i.) results showed that Nlrc5 
deficiency caused a significant reduction in the frequency of seizures, and reduced 
hippocampal pathological condition among the infected mice. Besides, we found a 
significant decrease in the inducible expression of MHC class I and its related genes, and 
pro-inflammatory mediators in the brain due to Nlrc5 deficiency. Additionally, Nlrc5-/- 
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infected mice showed a significant decrease in the expression of Natural Killer cells 
(NK) in the brain, with variable expression of other leukocyte subtypes in comparison to 
wild type infected mice. We observed a significant decrease in astrocytes, specifically at 
the CA1 and dentate gyrus regions of the hippocampus in Nlrc5-/- infected mice. The 
chronic phase (day 8-52 p.i.) results showed no signs of demyelinating disease or spinal 
cord lesions in Nlrc5-/- and wild type mice. Taken together, our results show that Nlrc5 
gene promotes inflammation and seizures in C57BL/6 mice, without affecting their 
resistance to demyelinating disease following TMEV infection. To our knowledge, this 
is the first study to report in vivo functions of Nlrc5 as a promoter of epilepsy.  
Materials and Methods 
Mice 
Four-to-six-week-old female Nlrc5-/- (Nlrc5 deficient mice on C57BL/6 background) 
mice were generously provided by Dr. Koichi K. Kobayashi, Department of Microbial 
Pathogenesis and Immunology, Texas A&M University, TX.  Age-matched female 
C57BL/6 wild type mice were purchased from Taconic (Germantown, NY). Upon 
arrival, mice were assigned to one of four experimental groups; Nlrc5-/- /sham-infected 
control, wild type/ sham-infected control, Nlrc5-/- virus-infected, and wild type virus-
infected. Mice were placed in a pathogen-free facility, with 12 hours of light and dark 
cycle and controlled room temperature and humidity. They were given free access to 
food and water throughout the duration of the experiment. All animal experiments were 
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approved by the Institutional Animal Care and Use Committee (IACUC) of Comparative 
Medicine Program at Texas A&M University, TX. 
Virus 
The BeAn strain of TMEV (ATTC) was initially propagated in baby hamster kidney 
(BHK) cells. Culture supernatant containing virus particles was collected and stored at -
80°C, and later used for infections 85. 
Infection  
Mice were habituated to the facility for a week prior to infection. Mice in the infected 
groups were injected intracerebrally (I.C.) with 5.0 x 104 plaque forming unit (PFU) of 
BeAn strain in 20μl of Dulbecco’s modified eagle medium (DMEM) (Sigma, Life 
Science, St. Louis, MO), whereas mice in the control group were either sham-infected 
I.C. with 20μl of 1x Phosphate Buffered Saline (PBS) or remained untreated. All 
injections were performed under isoflurane (Isoflo, North Chicago, IL) anesthesia. 
Body weight measurement 
During the acute phase, mice (n=4/control and n=26/infected group) body weights were 
recorded daily until day 6 p.i. % weight loss was calculated as ([mouse weight on day nth 
p.i.- mouse weight on day 0 p.i.]/mouse weight on day 0 pi) *100.
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Clinical scores 
During the acute phase, mice were examined twice daily between 9 AM to 6 PM for 
seizures (n=4/control group and n=30-37/infected group) and non-epileptic clinical signs 
(n=4/control group and n=41/infected group) until day 6 p.i. and once on day 7 p.i. For 
seizures, mice were scored on a Racine scoring scale: (1) Mouth and facial movements, 
(2) Head nodding, (3) Forelimb clonus, (4) Rearing, and (5) Rearing and falling 
progressing to tonic-clonic seizure 139. For non-epileptic clinical signs, mice were scored 
based upon the severity of sickness, where score (0) indicated no clinical signs; score (1) 
indicated mild ruffling, hunched back, and/or ataxia; score (2) indicated moderate 
ruffling, hunched back, and/or ataxia; score (3) indicated severe ruffling, hunched back, 
and/or ataxia; score (4) indicated paralysis; and score (5) indicated moribund. One cage 
of mice (n=4/control group and n=5/infected group) from each group was examined 
once weekly during the chronic phase (day 8-52 p.i.) for clinical signs of seizures and 
demyelinating disease. 
Tissue isolation 
To obtain tissues, mice were euthanized with 150mg/kg beuthanasia-D special 
(Schering-Plough Animal Health Corp. Union, NJ) and perfused intracardially using 10 
ml of 1x PBS. Brains collected on day 7 p.i. were split into right and left halves, and 
each half was either used for quantitative real time PCR (qRT-PCR) assay or 
immunohistochemistry (IHC). For qRT-PCR, brains were snap frozen and stored at -
80°C until use. For IHC, brains were immediately placed in freshly prepared 4% 
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paraformaldehyde (PFA) solution for 24-48 h at 4°C. For histology, spinal cords were 
retrieved on day 52 p.i., brains were instantly placed in 4 % PFA for 24-48 hours at 4°C, 
and spinal cords in 10% formaldehyde for 5 days at room temperature. For flow 
cytometry, brains and cervical lymph nodes (CLNs) were collected on day 3 p.i. in ice-
cold RPMI 1640 (Gibco, Life Technologies, Grand Island, NY), and individually 
processed to analyze leukocyte populations.  
 
Flow cytometry 
For collecting leukocytes from brain: The whole brains (n=3/ infected group) were 
gently homogenized using 70-micron (μm) FALCON cell strainer (21008-952; VWR, 
Sugarland, TX) and suspended in RPMI 1640 containing 5% fetal bovine serum (FBS). 
The cell suspensions containing brain homogenates were collected in individual 50 ml 
conical tubes, and centrifuged at 500 x g for 5 min at room temperature. After discarding 
the supernatant, each pellet was suspended in 10 ml of 30% Percoll (17-0891-01; GE 
healthcare, Uppsala, Sweden) in PBS. This solution was gently overlaid onto 2 ml of 
70% Percoll in PBS, and centrifuged at 500 x g for 30 min at 18°C. The leukocytes were 
collected from the 30% and 70% Percoll interphase, suspended in PBS, and centrifuged 
at 500 x g for 7 min at 18°C. The supernatants were discarded, and pellets were re-
suspended in 3 ml of ice-cold flow buffer containing 3% BSA and 0.1% sodium azide in 
PBS.  
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For collecting leukocytes from CLNs: The CLNs (n=3-4/infected group) were 
homogenized by gently grinding them with sterile microscopic slides. Then, the cell 
suspensions containing CLN homogenates were filtered using sterile, 70-μm nylon 
mesh. The filtrates containing leukocytes were collected in individual 15 ml conical 
tubes, and centrifuged at 350 x g for 5 min at 4°C. The supernatants were discarded, and 
each pellet was suspended in 2 ml of flow buffer containing 3% BSA and 0.1% sodium 
azide in PBS. The cells were washed, re-suspended in flow buffer and maintained at 
4°C. 
Staining procedure: Leukocytes from brain and CLNs were treated with anti-mouse 
CD16/CD32 (1:100, 14-0161-82; eBioscience, San Diego, CA) for 10 min at 4°C to 
prevent any non-specific binding. For phenotyping, cells were stained with the anti-
mouse antibodies as indicated below for 30 min at 4°C, washed and fixed with 2% PFA 
prior to flow cytometric analysis on BD FACSAria II. Data was analyzed using 
FlowJo® software V10.0.8r1 (Mac OS X, FlowJo, LLC, Ashland, OR). Ly-6G (Gr-1) 
was detected with clone RB6-8C5 (1:500, 12-5931-82; eBioscience, San Diego, CA). 
CD11c was detected with clone N418 (1:250, 17-0114-81; eBioscience, San Diego, CA). 
NK1.1 was detected with clone PK136 (1:500, 12-5941-63; eBioscience, San Diego, 
CA). CD11b was detected with clone M1/70 (1:500, 101224; BioLegend, San Diego, 
CA). CD45.2 was detected with clone 104 (1:100, 109805; BioLegend, San Diego, CA). 
CD8a was detected with clone 53-6.7 (1:250, 100711; BioLegend, San Diego, CA). CD4 
was detected with clone GK1.5 (1:500, 100428; BioLegend, San Diego, CA). B220 was 
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detected with clone RA3-6B2 (1:500, 17-0452-83; eBioscience, San Diego, CA). CD69 
was detected with clone H1.2F3 (1:500, 12-0691-82; eBioscience, San Diego, CA). 
CD80 was detected with clone 16-10A1 (1:500, 12-0801-82; eBioscience, San Diego, 
CA) 89,140. 
Immunohistochemistry 
Post-fixation, brains (n=7-9/infected group) were cryopreserved in 30% sucrose at 4°C 
for 3 days. After which, brains were embedded in optimum cutting temperature (OCT) 
compound (Tissue-Tek 4583, Torrance, CA), and cut on a cryostat (Leica CM 1950) to 
obtain 10-micron (μm) coronal sections. The serial sections, comprising of dorsal 
hippocampus, starting -1.7 mm from bregma were collected on plus-charged coated 
microscopic slides (12-550-17; Fisherbrand, Fisher Scientific). For each marker, rostro-
caudally matched cryosections were selected from the groups.  
The cryosections were hydrated, then blocked for 1 hour with 5% goat serum (16210-
064; Gibco, Life Technologies, Grand Island, NY) in PBS containing 0.1% Triton X-100 
(9002-93-1; Sigma-Aldrich, St. Louis, MO) for surface and cellular markers and 0.3% 
Triton X-100 for viral-antigen markers. The sections were incubated overnight at 4°C in 
primary antibodies, rabbit anti-ionized calcium-binding adapter molecule1 (IBA1) [019-
19741; Wako Chemicals USA, Inc., Richmond, VA, 1:200] for macrophages/microglia, 
rabbit anti-glial fibrillary acidic protein (GFAP) [180063; Invitrogen, Life Technologies, 
Eugene, OR, 1:200] for astrocytes, or mouse anti-TMEV [Welsh lab:1:50] for TMEV-
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antigen positive cells. The following day, sections were incubated at room temperature 
for 1 hour with secondary antibodies (1:1000), Alexa-Fluor 488 goat anti-rabbit IgG 
(A11034; Invitrogen, Life Technologies, Eugene, OR) for IBA, Alexa-Fluor 594 goat 
anti-rabbit IgG (A11037; Invitrogen, Life Technologies, Eugene, OR) for GFAP, and 
Alexa-Fluor 594 goat anti-mouse IgG (A11032, Invitrogen, Life Technologies, Eugene, 
OR) for viral-antigen. Later, cryosections were washed, counterstained with Hoechst 
33342, trihydrochloride, trihydrate [1:1000, H3570; Life Technologies, Eugene, OR] 
and mounted with Fluoromount-G (0100-01; SouthernBiotech, Birmingham, AL).  
 
To enumerate IBA- and GFAP-positive cells in the hippocampus, two-matched, but non-
overlapped areas (400x field/area) from CA1, CA3 and dentate gyrus (DG) each were 
selected from the infected groups. Average cell count/area was used for comparison 
between the infected groups. The TMEV-stained sections were analyzed for the presence 
and localization of viral-antigen positive cells in the hippocampus. All images were 
acquired using a HRD076-NIK camera attached to OLYMPUS VANOX AHBS3 
microscope. 
 
Histology: brain  
To determine acute neuronal loss and lesions in the hippocampus, 10 μm cryosections 
(n=3/infected group) were hydrated, and then stained in 0.5% cresyl violet for 5 min. 
After being rinsed with water, the sections were dehydrated in increasing concentrations 
of ethanol (75%-90%-100%), cleared in xylene, and coverslipped on the slides. All 
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images were acquired using a HRD076-NIK camera attached to OLYMPUS VANOX 
AHBS3 microscope. 
Histology: spinal cord  
Four μm paraffin-embedded sections from the spinal cords (n=4/control and n=4/ 
infected group) were stained with H&E. At least one transverse section from each spinal 
cord segment was examined for the presence of inflammatory foci, axonal/neuronal 
degeneration, and/or meningitis. All images were acquired using a HRD076-NIK camera 
attached to OLYMPUS VANOX AHBS3 microscope. 
Quantitative real-time PCR (qRT-PCR) 
Mouse brains (n=1-4/control group and n=3-5/infected group) were gently homogenized 
using Kinematica Inc, HOMOGEN KINMATICA PT 1200E electronic homogenizer 
(05-400-261, Fisher Scientific). Total RNA was isolated from each brain homogenate 
using Trizol-chloroform reagents, and purified using the TURBO DNA-free kit 
(AM1907, Invitrogen, Life Technologies). For each sample, one microgram (μg) of total 
RNA was reverse transcribed to cDNA using the qScript Flex cDNA Synthesis kit 
(95049-025, Quanta Biosciences) and following manufacturer’s instructions. RNA 
expression was quantified on the 7300 Real-Time PCR System (Applied Biosystems) 
using the PerfeCTa SYBR Green SuperMix with ROX (Quanta Bio- sciences). The 
following primers were used for amplification, and the expression of target genes was 
determined by ratio of the number of target mRNA to β-actin mRNA 49.  
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Gene name Primer sequence 
Nlrc5 5’- CTTCCCGCCTCTCCTTCCACAAT -3’ (forward) 
5’- CTCCACCTGCCCACATCCTACCA -3’ (reverse) 
TMEV 5’- TGACTAAGCAGGACTATGCCTTCC -3’ (forward) 
5’- CAACGAGCCACATATGCGGATTAC -3’ (reverse) 
Ifn-γ 5’- TGCATCTTGGCTTTGCAGCTCTTC -3’ (forward) 
5’- GGGTTGTTGACCTCAAACTTGGCA -3’ (reverse) 
Ifn-β 5’- CAGCTCCAAGAAAGGACGAAC -3’ (forward) 
5’- GGCAGTGTAACTCTTCTGCAT -3’ (reverse) 
H2-Kb 5’- GTGATCTCTGGCTGTGAAGT -3’ (forward) 
5’- GTCTCCACAAGCTCCATGTC -3’ (reverse) 
H2-Aα 5’- CAACCGTGACTATTCCTTCC -3’ (forward) 
5’- CCACAGTCTCTGTCAGCTC -3’ (reverse) 
Ciita 5’- CCCTGCGTGTGATGGATGTC -3’ (forward)  
5’- ATCTCAGACTGATCCTGGCAT -3’ (reverse) 
β2m 5’- CCCCACTGAGACTGATACATACG -3’ (forward) 
5’- CGATCCCAGTAGACGGTCTTG -3’ (reverse) 
Tap1 5’- GGACTTGCCTTGTTCCGAGAG -3’ (forward) 
5’- GCTGCCACATAACTGATAGCGA -3’ (reverse) 
Il-6 5’- CCAGAAACCGCTATGAAGTTCC -3’ (forward) 
5’- TTGTCACCAGCATCAGTCCC -3’ (reverse) 
Tnf-α 5’- ACAGAAAGCATGATCCGCG -3’ (forward) 
5’- GCCCCCCATCTTTTGGG -3’ (reverse) 
Il-1β 5’- AAGGAGAACCAAGCAACGACAAAA -3’ (forward) 
5’- TGGGGAACTCTGCAGACTCAAACT -3’ (reverse) 
Tgf-β 5’-TGCGCTTGCAGAGATTAAAA -3’ (forward) 
5’- CGTCAAAAGACAGCCACTCA -3’ (reverse) 
Mip-1 5’- GGCTAACTGACCTGGAAAGG -3’ (forward) 
5’- GCACATCAGGTACGATCCAG -3’ (reverse) 
Mcp-2 5’- TTAAGGCATCACAGTCCGAG -3’ (forward) 
5’- TGAATGTGAAGTTGACCCGT -3’ (reverse) 
Rantes 5’- GGAATTCCTGCCGCGGGTACCATGAAG -3’ (forward) 
5’- CATGCCATGGTACAGGGTCAGAATCAAG -3’ (reverse) 
β-Actin 5’- GCTGTGCTGTCCCTGTATGCCTCT -3’ (forward) 
5’- CTTCTCAGCTGTGGTGGTGAAGC -3’ (reverse) 
Table 5 Primer sequences for target genes. 
Elevated Plus Maze Test (EPMT) 
EPMT is one of the most common behavioral tests to determine anxiety-like symptoms 
in rodents. This test is based upon an intricate balance between two main characteristics 
of mice behavior, their natural aversion for open and elevated spaces and preference for 
dark and enclosed spaces, and their inherent curiosity for exploring novel environments. 
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We followed the standard protocol from Komada et al. 90 with few modifications. The 
elevated plus maze was made of black Plexiglass. It consisted of two perpendicularly 
placed open (25 x 5 x 0.5 cm3) and closed (25 x 5 x 16 cm3) arms, with a platform (5 x 5 
x 0.5 cm3) at the intersection of the arms. The maze was kept elevated at a height of 50 
cm above the floor. EPMT was conducted at one-month p.i. in an isolated room with 
dim lightings to minimize environmental distractions. Prior to testing, mice were 
acclimated to the room for 30 min. The test does not require former training. 
Experiments were performed during the day between 8:00 AM and 6:00 PM.  
 
To test for anxiety, each mouse (n=3-4/control group and n=5/infected group) was 
individually placed at the central platform with its head facing the same closed arm. 
Mice were given 5 min of test period to freely explore the maze. During this period, the 
number of entries in open and closed arms, and % time spent in open arms were 
recorded for each mouse. An arm entry was defined as the placement of all four paws of 
the mouse in that arm of the maze. The time spent on the central platform was included 
with the time spent in the closed arms. The percentage (%) of time spent in open arms 
was calculated as [(time spent in open arms/total test time) x 100]. The number of entries 
and % time spent in open arms were used as a measure of anxiety-like behavior. The 
number of closed arm entries was used to determine locomotor activity. The maze was 
cleaned with 70% (vol/vol) ethanol between the tests to remove any feces, urine or 
animal odor. 
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Statistical analysis 
qRT-PCR results were analyzed using the two-way analysis of variance (ANOVA) with 
the Tukey’s multiple comparisons test or unpaired t-test with the Welch’s correction. For 
rest of the parametric analysis, one-way ANOVA with the Tukey’s multiple 
comparisons test or the unpaired t-test with the Welch’s correction was used. For non-
parametric analysis, the unpaired Mann-Whitney rank sum test was used. For nominal 
data (presence or absence of seizures), the Fisher’s exact test was used. For all cases, 
significance was determined when p ≤ 0.05. Statistical analysis was done using 
GraphPad Prism version 6.0d (Mac OS X, GraphPad Software, La Jolla, CA). 
Results 
TMEV-induced acute seizures were significantly reduced due to Nlrc5 deficiency.  
During the acute phase, mice were monitored for seizures twice a day until day 6 p.i. and 
once on day 7 p.i.  The results from daily examination of mice showed that 
approximately 75% (28/37) of mice seized in the wild type infected group, while only 
30% (9/30) of mice seized in the Nlrc5-/- infected group (Figure 17A) (Fisher’s exact 
test, p<0.0001). As expected, no seizures were found in any of the control groups.  
Mice in the wild type infected group had seizures beginning on day 2 until day 6 p.i., 
with highest seizures recorded on day 3 p.i. Mice in the Nlrc5-/- infected group had a 
slight delay in seizure occurrence, as seizures in this group started on day 3 p.i. The daily 
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phenotypic comparison between the infected groups showed that significantly fewer 
mice seized in the Nlrc5-/- group than in the wild type group on days 2, 3, 4 and 5 p.i. 
The Nlrc5-/- infected mice showed an unexpected increase in seizures on day 6 p.i., 
nevertheless, the % seized mice were not significantly different between the infected 
groups (Figure 17B) (Fisher’s exact test, p=0.0140 on day 2 p.i., p<0.0001 on day 3 p.i., 
p=0.0052 on day 4 p.i., p=0.0447 on days 5 p.i., and p=0.4570 on day 6 p.i.). 
We also found that most seized mice, whether in the wild type or the Nlrc5-/- infected 
groups, developed tonic-clonic seizures, and so attained the highest Racine score (Figure 
17C and D). Moreover, the seizure frequency (total number of seizures/mouse) 
(Unpaired t test with Welch’s correction, p=0.3817) and duration of seizure (Unpaired t 
test with Welch’s correction, p=0.7227 on day 3 p.i., p=0.7091 on day 5 p.i., p=0.5923 
on day 6 p.i.) were not significantly different between the seized mice from the wild type 
and Nlrc5-/- infected groups (Figure 17E and F). During weekly examinations of mice 
during the chronic phase (day 8 till 52 p.i.), we did not observe seizures in any of the 
infected groups. 
Thus, we found that knocking out Nlrc5 gene significantly reduced the number of seized 
mice and delayed seizure occurrence following TMEV infection. Although, the affected 
mice from wild type and Nlrc5-/- infected groups did not show any differences in seizure 
intensity. Taken together our results show a critical role of Nlrc5 gene in TMEV-induced 
seizures. 
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Figure 17 TMEV-induced acute seizures were significantly reduced due to Nlrc5 deficiency. (A) 
Acute phase results revealed a significant decrease in the proportion of Nlrc5-/- infected mice with seizures 
in comparison to wild type infected mice. The % seized mice in each group was calculated as (number of 
seized mice/total number of infected mice) x 100. No seizures were observed in the control groups. (B) 
Daily examinations of mice showed that Nlrc5-/- infected group had significantly fewer seizures than wild 
type infected group from days 2-5 p.i. The % seized mice per day was calculated as (number of seized 
mice in a day /total number of infected mice) x 100. (C and D) In both the infected groups, seizures were 
mostly of highest intensity, i.e. stage 5, while few mice had seizures of stage 3 and 4 on the Racine scale. 
(**** p<0.0001, ** p<0.01, * p<0.05 by Fisher’s exact test). Graphs (A, B, C, D and E) show pooled 
results from six separate experiments expressed as percent or mean ± SEM, N=4 per control group and 
N=30-37 per infected group. Graph F shows pooled results from three separate experiments expressed as 
mean ± SEM, N=12 in wild type infected group and N=3 in Nlrc5-/- infected group. 
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Knocking out Nlrc5 gene alleviates non-epileptic clinical disease following TMEV 
infection. 
Apart from seizures, mice were monitored for clinical signs of acute sickness, including 
ruffling, hunched back, and ataxia. Daily examination of mice showed that TMEV 
infection led to acute illness in mice. However, the mice deficient of Nlrc5 gene 
exhibited lower clinical scores than the wild type mice in the acute phase. Significant 
differences were seen between the wild type and Nlrc5-/- infected groups on days 1, 2, 3, 
and 4 p.i. (Figure 18) (Mann-Whitney rank sum test, p=0.0324 on day 1 p.i., p=0.0009 
on day 2 p.i., p=0.0002 on day 3 p.i., p=0.0347 on day 4 p.i., p=0.1976 on days 5 p.i., 
and p=0.1542 on day 6 p.i.). We did not find any sickness behavior among the control 
mice following PBS injection (data not shown).  
Figure 18 Knocking out Nlrc5 gene alleviates non-epileptic clinical disease following TMEV 
infection. Mice were observed daily for signs of non-epileptic clinical disease during the acute phase. 
Both the wild type and Nlrc5-/- infected groups showed clinical signs of illness, but clinical scores were 
significantly lower in Nlrc5-/- infected group compared to that in wild type infected group (* p<0.05, *** 
p<0.001 by Mann-Whitney rank sum test). Graph shows pooled results from six separate experiments 
expressed as mean ± SEM, N=30-41 per infected group. 
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The Nlrc5 gene had a significant effect on body weight following infection. 
In comparison to controls, we observed significant weight loss among TMEV-infected 
mice in both the wild type and Nlrc5-/- groups during the acute phase (wild type control 
vs.   Nlrc5-/- control: Unpaired t test with Welch’s correction, p=0.1674 on day 1 p.i., 
p=0.1450 on day 2 p.i., p=0.2523 on day 3 p.i., p=0.2693 on day 4 p.i., p=0.1902 on day 
5 p.i., p=0.1194 on day 6 p.i.), (wild type control vs. wild type infected: Unpaired t test 
with Welch’s correction, p<0.0001 from days 1 to 6 p.i.), (Nlrc5-/-control vs. Nlrc5-/- 
infected: Unpaired t test with Welch’s correction, p=0.0002 on day 1 p.i., p=0.0008 on 
day 2 p.i., p=0.0051 on day 3 p.i., p=0.0211 on day 4 p.i., p=0.0109 on day 5 p.i., 
p=0.0058 on day 6 p.i.). However, upon comparing the infected groups, Nlrc5-/- mice 
had significantly lower weight loss than the wild type mice on days 1, 2 and 3 p.i. 
(Figure 19) (Wild type infected vs. Nlrc5-/- infected: Unpaired t test with Welch’s 
correction, p=0.0046 on day 1 p.i., p=0.0024 on day 2 p.i., p=0.0222 on day 3 p.i., 
p=0.9539 on day 4 p.i., p=0.8741 on day 5 p.i., p=0.8134 on day 6 p.i.). Hence, Nlrc5 
deficiency significantly reduced the extent of weight loss in TMEV-induced seizure 
model. Notably, the time-points for differences in weight loss correspond with the time-
points for differences in seizure phenotype between the infected groups.  
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Figure 19 The Nlrc5 gene had a significant effect on mice weights following infection. To determine 
recovery post infection, mice from the control and infected groups were weighed daily until day 6 p.i. 
Both the infected groups exhibited significant weight loss immediately following TMEV infection in 
comparison to their respective controls. However, the body weight comparisons between the infected 
groups showed that Nlrc5-/- mice weighed significantly more than the wild type mice at earlier time-points, 
indicating better recovery among Nlrc5-/- infected mice. (Between wild type control and infected groups: 
δδδδ p<0.0001; between Nlrc5-/- control and infected groups: # p<0.05, ## p<0.01, ### p<0.001; between 
wild type and Nlrc5-/- infected groups: * p<0.05, ** p<0.01 by Unpaired t test with Welch’s correction). 
Graph shows pooled results from five separate experiments, expressed as mean ± SEM, N=4/control group 
and N=26/infected group. 
The Nlrc5 gene had variable effects on different leukocyte populations in the brain and 
CLNs. 
Since day 3 p.i. was the peak time for seizures, we chose this time-point to analyze 
different leukocyte populations in the brain and CLNs from infected mice. The results 
from the brains showed increased expression levels of innate immune cells compared to 
that of adaptive immune cells on day 3 p.i. Upon comparing the infected groups, we 
found a significant reduction in the expression levels of CD45.2 high(hi) NK1.1+ cells 
(natural killer [NK] cells), and a mild reduction in the expression of CD45.2 high 
CD11c+ cells (dendritic cells) in the Nlrc5-/- group compared to the wild type group. 
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However, we found an increasing, but insignificant trend in the expression levels of 
CD45.2 high CD11b+ cells (monocytes, macrophages, granulocytes, etc.) and CD45.2 
high Gr1+ cells (granulocytes) in the Nlrc5-/- infected mice when compared with the 
wild type infected mice (Figure 20A). (Unpaired t test with Welch’s correction, 
p=0.7153 for CD45.2 int CD11b+ cells, p=0.1206 for CD45.2 hi CD11b+ cells, 
p=0.1217 for CD45.2 hi Gr1+ cells, p=0.0144 for CD45.2 hi NK1.1+ cells, p=0.0649 for 
CD45.2 hi CD11c+ cells, p=0.6060 for CD45.2 hi CD8+ cells, p=0.4127 for CD45.2 hi 
CD4+ cells, and p=0.4912 for CD45.2 hi B220+ cells). 
 
Previous studies have reported that Nlrc5 deficient mice exhibit impaired in the 
activation of cytotoxic T cells upon intracellular bacterial infection 49,50, therefore we 
next analyzed the cytotoxic and helper T cells for their activation levels. Our results 
showed that there was a slight decrease in the levels of CD45.2 high CD4+ CD69+ cells 
(activated helper T cells) in the brains of Nlrc5-/- infected mice when compared with the 
wild type infected mice (Figure 20B), while the deficiency of Nlrc5 gene did not affect 
the expression of CD45.2 intermediate(int) CD11b+ CD80+ cells (activated microglia) 
and CD45.2 high CD11b+ CD80+ cells (activated monocytes, macrophages, 
granulocytes, etc.) (Figure 20C). (Unpaired t test with Welch’s correction, p=0.2047 for 
CD45.2 hi CD8+ CD69+ cells, p=0.0556 for CD45.2 hi CD4+ CD69+ cells, p=0.7486 
for CD45.2 int CD11b+ CD80+ cells, and p=0.1428 for CD45.2 hi CD11b+ CD80+ 
cells). This suggests that Nlrc5 gene has variable effects on the leukocyte populations in 
the brain. 
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In contrast to the leukocyte profile in the brain, we did not find any significant 
differences in the expression levels of leukocyte populations in the CLNs of Nlrc5-/- 
infected mice than wild type infected mice (Figure 20D and E) (Unpaired t test with 
Welch’s correction, p=0.1206 for CD45.2 hi CD11b+ cells, p=0.6165 for CD45.2 hi 
Gr1+ cells, p=0.9743 for CD45.2 hi NK1.1+ cells, p=0.1159 for CD45.2 hi CD11c+ 
cells, p=0.0766 for CD45.2 hi CD8+ cells, p=0.2768 for CD45.2 hi CD4+ cells, 
p=0.5746 for CD45.2 hi B220+ cells, p=0.4708 for CD45.2 hi CD8+ CD69+ cells, and 
p=0.5756 for CD45.2 hi CD4+ CD69+ cells).  
Figure 20 The Nlrc5 gene had variable effects on different leukocyte populations in the brain and 
CLNs. To examine the extent of inflammation at the time of peak seizures, we analyzed the expression of 
leukocyte subsets in the brain and CLNs at day 3 p.i. In the brain, the deficiency of Nlrc5 gene caused a 
significant reduction in the expression of CD45.2hi NK1.1+ (NK) cells, and mild reduction in the 
expression of CD45.2hi CD11c+ cells (dendritic cells) and CD45.2hi CD4+ CD69+ cells (activated T 
helper cells), while it led to a slight increase in the expression of CD45.2hi CD11b+ cells 
(monocytes/macrophages, granulocytes, etc.) and CD45.2hi Gr1+ cells (granulocytes). In the CLNs, the 
deficiency of Nlrc5 gene only mildly downregulated the expression of CD45.2hi CD8+ cells (cytotoxic T 
cells). (* p<0.05 by Unpaired t test with Welch’s correction). Graphs (A-E) show results expressed as 
mean ± SEM, N=3 per infected group. 
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Nlrc5 deficiency induced a significant reduction in the number of GFAP+ cells, but not 
IBA+ cells, following infection. 
Acute immune response comprises of the activation and proliferation of both resident 
and infiltrated immune cells. Here, we enumerated the infiltrated and resident IBA+ cells 
(macrophage/microglia) and GFAP+ cells (astrocytes) in different regions of the 
hippocampus among the infected groups.  
On day 7 p.i., we found activated astrocytes in the hippocampus of both infected groups, 
but the number of astrocytes was significantly decreased in the hippocampus from the 
Nlrc5-/- infected group compared to the wild type infected group. The proliferation of 
astrocytes was found to be region-specific, with significant differences recorded at CA1 
and dentate gyrus regions of the hippocampus (Figure 21A-G) (Unpaired t test with 
Welch’s correction, p=0.0065 for total cells, p=0.0245 for cells at CA1, p=0.3719 for 
cells at CA3, and p=0.0001 for cells at dentate gyrus [DG]). Moreover, we found an 
increase in the number of macrophages and microglia in the hippocampus from both 
infected groups. The activated cells adopted varying morphologies, such as rod-shape, 
and amoeboid-like shape. Within the hippocampus, the highest number of cells were 
found in the CA1 region and near the CA1-CA3 junction, while the dentate gyrus had 
least number of cells in both infected groups. However, the number of macrophages and 
microglia was not significantly different between infected groups (Figure 21H-N) 
(Unpaired t test with Welch’s correction, p=0.3638 for total cells, p=0.2941 for cells at 
CA1, p=0.6764 for cells at CA3, and p=0.6225 for cells at dentate gyrus [DG]). Taken 
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together our results show that Nlrc5 gene is a positive regulator of the activation and 
proliferation of astrocytes, while it may not have a critical role in macrophage and 
microglial proliferation at least on day 7 p.i.  
In addition, we found TMEV-antigen positive cells in the hippocampus of both the 
infected groups at day 7 p.i. The virus mostly infected the CA1 and CA2 pyramidal 
neurons, while CA3 and dentate gyrus neurons were found uninfected (Figure 21O and 
P). This suggests that Nlrc5 deficiency had no effect on viral replication during the acute 
phase of infection. 
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Figure 21 Nlrc5 deficiency induced a significant reduction in the number of GFAP+ cells, but not 
IBA+ cells, following infection. To assess the effect of Nlrc5 deficiency on the proliferation and 
activation of astrocytes, microglia/macrophages, and virus-infected cells in the hippocampus, we stained 
10 μm coronal sections of fixed brain with antibody against GFAP, IBA, and TMEV-antigen, respectively. 
(A-F) are the representative images (400x) of CA1, CA3, and DG regions of hippocampus showing 
GFAP+ astrocytes. (G) The number of astrocytes was significantly reduced in the hippocampus, 
specifically in the CA1 and dentate gyrus regions, of Nlrc5-/- infected mice than wild type infected mice. 
(H-M) are the representative images (400x) of CA1, CA3, and DG regions of hippocampus showing IBA+ 
macrophages/microglia. (N) The infected groups had no significant differences in the number of 
macrophages and microglia in the hippocampus. (O and P) are the representative images (100x) from 
infected groups showing that TMEV-antigen positive cells were mainly localized in the CA1 and CA2 
pyramidal neurons, while TMEV-antigen was not detected in the DG and CA3 neurons. (* p<0.05, ** 
p<0.01, **** p<0.0001 by Unpaired t test with Welch’s correction). Graphs (G and N) show results 
expressed as mean ± SEM, N=7-9 per infected group. Cornu ammonis1 (CA1), cornu ammonis2 (CA2), 
and dentate gyrus (DG). 
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Nlrc5 deficiency mitigates hippocampal damage in TMEV-induced seizure model. 
At day 7 p.i., we found marked inflammation near the hippocampal fissure, and neuronal 
damage in the CA1 region of hippocampus for both infected groups. Our preliminary 
data, showed a decrease in the extent of neuronal damage at CA1 region in Nlrc5-/- 
infected mice when compared to wild type infected mice. This suggests a detrimental 
role of Nlrc5 gene in TMEV-induced seizure model (Figure 22A-C).  
Figure 22 Nlrc5 deficiency mitigates hippocampal damage in TMEV-induced seizure model. To 
determine the effect of Nlrc5 on the extent of inflammation and damage in the hippocampus following 
infection, we compared the cresyl violet-stained 10 μm coronal sections of fixed brain. (A-C) are the 
representative images (20x) from wild type control, wild type infected and Nlrc5-/- infected group, 
respectively. The preliminary results indicate that TMEV-infection induced CA1 neuronal damage was 
less severe in Nlrc5-/- than that in wild type infected mice. Cornu ammonis1 (CA1), cornu ammonis2 
(CA2), dentate gyrus (DG), and hippocampal fissure (HF). 
Knocking out Nlrc5 gene did not alter the resistance to TMEV-induced demyelinating 
disease. 
 SJL mice are susceptible to TMEV-induced demyelinating disease and develop white 
matter lesions in their spinal cord within a month or two p.i. 31,42. In contrast to SJL 
mice, none of the infected C57BL/6 and Nlrc5-/- mice in the current study exhibited 
meningitis, inflammatory foci, or demyelinating lesions in their spinal cords. Our results 
indicate that the impairment of Nlrc5-mediated MHC class I expression does not affect 
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the resistance of C57BL/6 mouse strain to TMEV-induced demyelinating disease 
(Figure 23A-D). 
Figure 23 Knocking out Nlrc5 gene did not alter the resistance to TMEV-induced demyelinating 
disease. To investigate whether Nlrc5 gene affects the resistance of C57BL/6 mice to TMEV-induced 
demyelinating disease, we compared the H&E-stained four μm transverse sections from cervical, thoracic, 
lumbar and sacral segments of spinal cords from infected mice and compared the histological condition 
with their respective controls. At day 52 p.i., we did not find active inflammation or demyelinating lesions 
in the spinal cords from any of the infected mice. (A-D) are the representative images (100x) from thoracic 
segment of the spinal cord from wild type control, Nlrc5-/- control, wild type infected and Nlrc5-/- infected 
groups.  
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Expression of target genes in the brain following TMEV infection: 
a) TMEV-infected wild type mice showed an increase in the mRNA expression of
Nlrc5. 
It has been established previously that Nlrc5-/- mice exhibit significantly lower or 
minimal levels for Nlrc5 mRNA in splenocytes in response to intracellular infection 49. 
Here, we found baseline expression of Nlrc5 gene in the brains of wild type control 
mice, while there was a significant increase in the expression of Nlrc5 gene in wild type 
infected mice at day 7 p.i., implying that TMEV infection effectively upregulates Nlrc5 
gene expression in the brain (Figure 24A) (Unpaired t test with Welch’s correction, 
p=0.0036).  
b) Comparative expression of TMEV mRNA in the brain.
At day 7 p.i., we found a slight, but insignificant decrease in the TMEV mRNA 
expression in Nlrc5-/- infected mice than the wild type infected mice. This denotes that 
Nlrc5 deficiency has no significant effect on viral replication at least during the acute 
phase (Figure 24B) (Unpaired t test with Welch’s correction, p=0.4010). 
c) Nlrc5 exclusively affects MHC Class I-antigen processing and presentation
machinery in the brain. 
As expected, virus infection significantly upregulated expression of MHC class I (H2-
Kb) mRNA in the brains of wild type mice. However, Nlrc5 deficiency abrogated this 
effect, as expression of H2-Kb was significantly lower in Nlrc5-/- infected mice 
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compared to wild type infected mice (Figure 24C). Similar findings were noted in β2m 
and Tap1 expression (Figure 24D and E). In case of the genes involved in MHC class II 
pathway, virus infection significantly upregulated the expression of MHC class II (H2-
Aa) (Figure 24F) and MHC class II transactivator (Ciita) (Figure 24G) in both wild type 
and Nlrc5-/- mice. Our results corroborate past studies showing that NLRC5 upregulates 
the expression of MHC class I and its associated genes, and has no effect on the 
expression of MHC class II genes (H2-Kb: Two-way ANOVA with Tukey’s multiple 
comparisons test, p>0.9999 for wild type control vs. Nlrc5-/- control, p<0.0001 for wild 
type control vs. wild type infected, p=0.7620 for Nlrc5-/- control vs. Nlrc5-/- infected, 
p<0.0001 for wild type infected vs. Nlrc5-/- infected) (β2m: Two-way ANOVA with 
Tukey’s multiple comparisons test, p>0.9999 for wild type control vs. Nlrc5-/- control, 
p<0.0001 for wild type control vs. wild type infected, p=0.0760 for Nlrc5-/- control vs. 
Nlrc5-/- infected, p=0.0004 for wild type infected vs. Nlrc5-/- infected) (Tap1: Two-way 
ANOVA with Tukey’s multiple comparisons test, p>0.9999 for wild type control vs. 
Nlrc5-/- control, p=0.0031 for wild type control vs. wild type infected, p=0.6848 for 
Nlrc5-/- control vs. Nlrc5-/- infected, p=0.0446 for wild type infected vs. Nlrc5-/- infected) 
(H2-Aa: Two-way ANOVA with Tukey’s multiple comparisons test, p>0.9999 for wild 
type control vs. Nlrc5-/- control, p=0.0106 for wild type control vs. wild type infected, 
p=0.0017 for Nlrc5-/- control vs. Nlrc5-/- infected, p=0.5935 for wild type infected vs. 
Nlrc5-/- infected) (Ciita: Two-way ANOVA with Tukey’s multiple comparisons test, 
p=0.9664 for wild type control vs. Nlrc5-/- control, p=0.0025 for wild type control vs. 
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wild type infected, p=0.0112 for Nlrc5-/- control vs. Nlrc5-/- infected, p=0.8203 for wild 
type infected vs. Nlrc5-/- infected).  
d) Virus-induced type I interferon expression was significantly reduced in the
brains due to Nlrc5 deficiency. 
Virus infection increased mRNA levels for Ifn-β in wild type mice, but significantly 
lower mRNA levels of it were evident in Nlrc5-/- mice (Figure 24H). In contrast, Nlrc5 
deficiency did not affect the virus-induced expression of type II interferon (Ifn-γ) (Figure 
24I). (Ifn-β: Two-way ANOVA with Tukey’s multiple comparisons test, p=0.9832 for 
wild type control vs. Nlrc5-/- control, p=0.0691 for wild type control vs. wild type 
infected, p=0.9758 for Nlrc5-/- control vs. Nlrc5-/- infected, p=0.0479 for wild type 
infected vs. Nlrc5-/- infected) (Ifn-γ: Unpaired t test with Welch’s correction, p=0.3862 
for wild type infected vs. Nlrc5-/- infected) 
e) Nlrc5 deficiency resulted in a significant decrease in the inducible expression of
pro-inflammatory mediators. 
In wild type mice, virus infection induced a significant increase in the mRNA expression 
levels of pro-inflammatory cytokines, such as interleukin (Il)-1β, Il-6 and tumor necrosis 
factor (Tnf)-α. In contrast, Nlrc5 deficiency significantly abated the increase in the 
mRNA levels for Il-1β, and to an extent for Il-6, while Tnf-α expression remained 
unaffected among the infected mice (Figure 24J-L). The mRNA expression level for the 
anti-inflammatory cytokine, tumor growth factor (Tgf)-β, was only slightly elevated in 
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wild type mice, but it was significantly increased in Nlrc5-/- mice following infection 
(Figure 24M). In case of the chemokines, TMEV-infected wild type mice showed a 
significant increase in the mRNA levels for monocyte chemoattractant protein-1 (Mcp-
1), and regulated upon activation, normally T-expressed, and presumably secreted 
(Rantes); and had very high expression levels for macrophage inflammatory protein 2 
(Mip-2) following infection. Nlrc5 deficiency showed no effect on the mRNA levels for 
Rantes, and only slighted decreased the expression of Mcp-1 and Mip-2 in the infected 
group (Figure 24N-P). In addition, the expression levels for inducible nitric oxide 
synthase (iNOS) mRNA levels were significantly increased with infection in wild type 
group, but lower levels were noted in Nlrc5-/- group (Figure 24Q). (Il-1β: Two-way 
ANOVA with Tukey’s multiple comparisons test, p>0.9999 for wild type control vs. 
Nlrc5-/- control, p=0.0026 for wild type control vs. wild type infected, p=0.9122 for 
Nlrc5-/- control vs. Nlrc5-/- infected, p=0.0082 for wild type infected vs. Nlrc5-/- infected) 
(Il-6: Two-way ANOVA with Tukey’s multiple comparisons test, p=0.9924 for wild 
type control vs. Nlrc5-/- control, p=0.0443 for wild type control vs. wild type infected, 
p=0.9365 for Nlrc5-/- control vs. Nlrc5-/- infected, p=0.1936 for wild type infected vs. 
Nlrc5-/- infected) (Tnf-α: Two-way ANOVA with Tukey’s multiple comparisons test, 
p=0.9246 for wild type control vs. Nlrc5-/- control, p<0.0001 for wild type control vs. 
wild type infected, p=0.0006 for Nlrc5-/- control vs. Nlrc5-/- infected, p=0.3736 for wild 
type infected vs. Nlrc5-/- infected) (Tgf-β: Two-way ANOVA with Tukey’s multiple 
comparisons test, p=0.9974 for wild type control vs. Nlrc5-/- control, p=0.0696 for wild 
type control vs. wild type infected, p=0.0024 for Nlrc5-/- control vs. Nlrc5-/- infected, 
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p=0.1480 for wild type infected vs. Nlrc5-/- infected) (Mcp-1: Two-way ANOVA with 
Tukey’s multiple comparisons test, p>0.9999 for wild type control vs. Nlrc5-/- control, 
p=0.0188 for wild type control vs. wild type infected, p=0.7924 for Nlrc5-/- control vs. 
Nlrc5-/- infected, p=0.1143 for wild type infected vs. Nlrc5-/- infected) (Rantes: Two-way 
ANOVA with Tukey’s multiple comparisons test, p>0.9999 for wild type control vs. 
Nlrc5-/- control, p=0.0003 for wild type control vs. wild type infected, p=0.0009 for 
Nlrc5-/- control vs. Nlrc5-/- infected, p=0.9998 for wild type infected vs. Nlrc5-/- infected) 
(Mip-2: Two-way ANOVA with Tukey’s multiple comparisons test, p>0.9999 for wild 
type control vs. Nlrc5-/- control, p=0.1626 for wild type control vs. wild type infected, 
p>0.9999 for Nlrc5-/- control vs. Nlrc5-/- infected, p=0.1651for wild type infected vs. 
Nlrc5-/- infected) (iNos: Two-way ANOVA with Tukey’s multiple comparisons test, 
p=0.9895 for wild type control vs. Nlrc5-/- control, p=0.0054 for wild type control vs. 
wild type infected, p=0.1346 for Nlrc5-/- control vs. Nlrc5-/- infected, p=0.4004 for wild 
type infected vs. Nlrc5-/- infected). 
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Figure 24 Expression of target genes in the brain following TMEV infection: To assess the effects of 
Nlrc5 deficiency on the expression of virus and inflammatory mediators, we compared the mRNA levels 
of target genes from the brains of infected mice at day 7 p.i. The comparisons between control and 
infected groups, and between wild type and Nlrc5-/- infected groups showed that (A) TMEV infection 
caused a significant increase in the expression of Nlrc5 in wild type mice. (B) The mRNA levels for virus 
were similar between the infected groups. (C-E) Nlrc5 deficiency caused a significant reduction in the 
expression of MHC class I and its associated genes, (F-G) while it did not affect the expression of MHC 
class II and its related genes following TMEV infection. Nlrc5 deficiency significantly downregulated the 
expression of pro-inflammatory cytokines, (H) Ifn-β, (J) Ifn-β, but had minimal or no effects on the 
expression of (I) Ifn-γ, (K) Il-6, and (L) Tnf-α. (M) The expression of anti-inflammatory cytokine, Tgf-β 
was only mildly increased in wild type infected mice, but Nlrc5 deficiency significantly upregulated its 
expression following infection. The mRNA levels of chemokines, (N) Mcp-1, (O) Rantes, and (P) Mip-2, 
were highly upregulated in wild type infected mice, but Nlrc5 deficiency only slightly decreased the 
expression of Mcp-1 and Mip-2 following infection. (Q) When compared to the controls, the expression of 
iNos was significantly increased in wild type infected mice, but not in Nlrc5-/- infected mice. (Between 
control and infected groups: # p<0.05, ## p<0.01, ### p<0.001, #### p<0.0001; between wild type and Nlrc5-/- 
infected groups: * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 by Unpaired t test with Welch’s 
correction or Two-way ANOVA with Tukey’s multiple comparisons test). Graphs (A-Q) show results 
expressed as mean ± SEM, n=1-4/control group and n=3-5/infected group.  
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Mice did not exhibit anxiety-like symptoms following infection.  
We did not find any significant differences in the number of entries in open and closed 
arms, and % time spent in open arms between the control and infected groups or 
between the wild type and Nlrc5-/- infected groups (Number of entries in open arms: 
One-way ANOVA with Tukey’s multiple comparison test, p=0.9569 for wild type 
control vs. Nlrc5-/- control, p=0.6622 for wild type control vs. wild type infected, 
p=0.9854 for Nlrc5-/- control vs. Nlrc5-/- infected, p=0.4223 for wild type infected vs. 
Nlrc5-/- infected) (Number of entries in closed arms: One-way ANOVA with Tukey’s 
multiple comparison test, p=0.4609 for wild type control vs. Nlrc5-/- control, p=0.9955 
for wild type control vs. wild type infected, p=0.5544 for Nlrc5-/- control vs. Nlrc5-/- 
infected, p=0.9991 for wild type infected vs. Nlrc5-/- infected) (% time spent in open 
arms: One-way ANOVA with Tukey’s multiple comparison test, p=0.8342 for wild type 
control vs. Nlrc5-/- control, p=0.8231 for wild type control vs. wild type infected, 
p=0.9926 for Nlrc5-/- control vs. Nlrc5-/- infected, p=0.3508 for wild type infected vs. 
Nlrc5-/- infected). However, one of the wild type infected mice explored the open arms 
more than the other mice, suggesting the development of aberrant emotional behavior 
(Figure 25A-C). 
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Figure 25 Mice did not exhibit anxiety-like symptoms following infection. To determine the effects of 
neuronal damage and Nlrc5 gene on the development of anxiety-like symptoms in mice, we conducted 
EPMT at one-month p.i. (A) % time spent in open arms, (B) number of entries in open arms, and (C) 
number of entries in closed were similar among the groups, suggesting that the infected mice did not show 
any behavioral or locomotor abnormality, with the exception of one wild type infected mouse. The % time 
spent in open arms was calculated as (time spent in open arms/time spent in open and closed arms) x 100. 
The number of entries in open and closed arms was recorded manually at the time of the experiment. 
(One-way ANOVA with Tukey’s multiple comparisons test). Graphs (A-C) show results expressed as 
mean ± SEM, N=3-4 per control group and N=5 per infected group. 
 
Discussion 
 
NLRC5 is a unique member of the NLR family, as it has the ability to shuttle between 
the cytoplasm and nucleus in a cell. The expression of NLRC5 varies based upon the 
tissue, cell type, and inflammatory condition 54. It is highly expressed by immune-related 
tissues, such as spleen, thymus, lymph nodes, bone marrow, and tonsils; and immune 
cells, such as T cells, B cells, monocytes/ macrophages, and dendritic cells 54,137,141. Its 
expression has also been reported in brain 52,55 and more specifically in cells that form 
the blood-brain barrier, such as pericytes 142, and cerebral endothelial cells (CECs) 143. 
Moreover, it can be induced in response to various PAMPs, such as type I IFN (IFN-β) 
and type II IFN (IFN-γ) 45,55,137, lipopolysaccharide (LPS) 56,58,137, 
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polyinosinic:polycytidylic (poly [I:C]) 54,56,58,137, viruses (Newcastle disease virus [NDV] 
58, respiratory syncytial virus [RSV] 144, vesicular stomatitis virus [VSV] 57, human 
rhinovirus [HRV] 138, etc.), and bacteria (Listeria monocytogenes 49,50,58). 
NLRC5 is a well-known transactivator of MHC class I and its associated genes, while it 
has been shown to have no effect on the transcription of MHC class II genes. The 
NLRC5-dependent MHC class I expression is more pronounced in T cells, NK cells and 
Natural Killer T (NKT) cells than in B cells, macrophages, and dendritic cells (antigen 
presenting cells) 49,51,57,141. Since MHC class I presenting cytosolic peptide complex is 
essential for the activation of cytotoxic T cells, previous studies have shown that 
NLRC5, in extension, can also regulate the activation, proliferation and cytotoxicity of 
cytotoxic T cells in response to Listeria monocytogenes infection 49,50.  
In addition, the function of NLRC5 in anti-viral immunity has been extensively studied 
in in vitro and ex vivo systems. The activated NLRC5 may respond to viral infection by 
regulating the expression of signaling pathways (NF-κB-, IFN-dependent pathways) 
55,56,58, by interacting with other PRRs (such as retinoic acid inducible gene I [RIG-I] 144, 
NLRP3 59,138) , and/or by forming multi-protein complex called inflammasome 59,138. 
Nonetheless, these studies have failed to reach a consensus regarding the positive, 
negative, or dispensable effects of NLRC5 in viral-induced inflammation. The 
conflicting results from previous studies are suggested to be a result of the use of 
different cell lines, variable expression levels of NLRC5 in different cell types, cell type-
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specific signaling pathways, different treatments, and/or different Nlrc5 gene deletion 
strategies. 
 
To resolve the discrepancies about the role of NLRC5 in viral infection and to delineate 
its effect in epilepsy, we infected Nlrc5-/- mice with TMEV and compared the disease 
pathogenesis with wild type mice in vivo. Our acute phase results showed that Nlrc5 
ablation significantly decreased seizures, non-epileptic clinical disease, weight loss, and 
reduced the extent of hippocampal damage among the infected mice. In accordance with 
earlier studies 41, we found that TMEV infection significantly upregulates MHC class I 
expression in the brains of wild type mice. In contrast to wild type, Nlrc5-/- infected mice 
had significant reduction in the inducible expression of MHC class I, β2m and Tap1. Past 
studies show that β2m deficiency results in impaired MHC class-I-mediated cytotoxic T 
cell responses upon TMEV infection. β2m deficient mice (on predominantly C57BL/6 
background) develop demyelinating lesions in spinal cords and show compensatory 
increase in T helper cell-mediated viral clearance, however they do not exhibit clinical 
signs of demyelinating disease (waddling gait, spastic paralysis) 42. This is partly in 
agreement with our study, where infected Nlrc5 deficient mice, with impaired expression 
of MHC class I and β2m, neither presented clinical signs of demyelinating disease nor 
developed demyelinating lesions in spinal cord. 
 
We also documented a significant but variable effect of Nlrc5 deficiency on the 
expression of different immune cells in the brain and CLNs following infection. In the 
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brain, Nlrc5 deficiency induced a significant decrease in CD45.2 high NK1.1+ cells (NK 
cells), and mild increase in CD45.2hi CD11c+ cells, while it led to no significant 
changes in CD45.2 high CD11b+ cells (monocytes, macrophages, granulocytes, etc.) and 
CD45.2 high Gr1+ cells (granulocytes) expression levels. In the CLNs, Nlrc5 deficiency 
induced a mild decrease in CD45.2 high CD8+ cells (cytotoxic T cells). Furthermore, we 
found significantly reduced astrocyte numbers in the hippocampus of Nlrc5-/- infected 
mice than that in wild type infected mice. The Nlrc5-mediated differences in TMEV-
induced activation of immune cell types may be due to differential expression of Nlrc5 
in different cell types, or cell type-specific regulatory effects of Nlrc5.  
The gene expression studies revealed that TMEV infection could effectively induce 
Nlrc5 expression in vivo. Besides, we found that Nlrc5 deficiency significantly 
downregulated the expression levels for Ifn-β, and Il-β; but had minimal or no effect on 
the expression levels for Ifn-γ, Il-6, Tnf-α, Mcp-1, Mip-2, Rantes, and iNOS upon TMEV 
infection. The gene expression studies were conducted at day 7 p.i. (the time-point when 
seizures generally cease), so future studies from day 3 p.i. (peak time for seizures) would 
better depict the contribution of pro-inflammatory mediators in TMEV-induced seizures. 
Nevertheless, we saw a significant role of Nlrc5 as the positive regulator of IFN-β and 
IL-β following viral infection. In contrast to our results, previous study showed that 
Nlrc5-/- mice develop increased amounts of IFN-β in their sera, without significantly 
affecting the viral titers and mice survival rates following VSV infection. Such 
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differences could be a result of different gene deletion techniques, or different virus 
treatments used 57.   
The behavioral test to determine anxiety-like symptoms in mice did not show any 
significant difference due to Nlrc5 deficiency. However, we found that one of the 
infected wild type mice displayed an aberrant behavior (anxiolytic) after a month p.i., 
which could be due to pronounced hippocampal pathology. 
The other members of the NLR family, such as NLR family pyrin domain containing 1 
(NLRP1) have previously been implicated in epilepsy. Increased expression of NLRP1 
was found in resected hippocampus from patients with mTLE. NLRP1 was also found to 
contribute in neuronal death and chronic seizure activity in amygdala kindling-induced 
rat model of epilepsy. However, silencing of NLRP1 inflammasome did not lower acute 
seizures in rats, implying that NLRP1 has a role in late phase of the disease 145. Since 
NLRC5 can interact with other NLRs (NLRP3), and form inflammasome 59,138, the 
TMEV-induced inflammation and seizures could be a collaborative effect of Nlrc5 and 
other inflammasome forming NLRs. Future studies are required to investigate the 
interactions between Nlrc5 and inflammasome forming NLRs in this model. 
Although, inflammation is crucial for viral clearance, excessive and unregulated 
inflammation contributes to hippocampal pathology and seizures in TMEV-induced 
epilepsy model. Therefore, treatments limiting neuroinflammation would be beneficial to 
prevent seizure development and neuronal loss following infection. From our current 
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study, we found that Nlrc5 deficiency alleviates immune-mediated seizures in C57BL/6 
mice upon TMEV infection, signifying that Nlrc5 intensifies inflammation, positively 
regulates anti-viral immunity, and contributes to seizure development. Therefore, 
inhibiting the acute elevation of NLRC5 or its downstream signaling molecules (such as 
IL-1β) could prove to be promising therapeutic targets for treating epilepsy. 
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CHAPTER IV  
NLRC3: A NOVEL DOWNREGULATOR INVOLVED IN TMEV-INDUCED 
EPILEPSY MODEL 
Introduction 
Epilepsy is one of the most common diseases of the central nervous system (CNS). It is 
characterized by two or more unprovoked seizures occurring more than 24 hours apart, a 
single unprovoked seizure with high risks of subsequent seizures in the future, or 
diagnosis of an epilepsy syndrome 2. Currently, 70 million people worldwide are 
diagnosed with epilepsy 5, and one-third of the affected population is refractory to drugs. 
Moreover, there is no existent cure for epilepsy and the available anti-epileptic drugs 
provide symptomatic treatment only. Therefore, identifying novel therapeutic strategies 
to extenuate epilepsy is much needed 14.  
Intracerebral (I.C.) infection of Theiler’s murine encephalomyelitis virus (TMEV) 
triggers an overzealous innate immune response, seizures and neuronal damage within a 
week post infection (p.i.), subsequently leading to epilepsy in C57BL/6 mice. Hence, the 
TMEV-induced model of epilepsy proves to be beneficial in understanding the 
pathophysiology of both acute and chronic forms of seizures. The dysregulated innate 
immune response is the key attribute of this experimental model, and previous 
researchers have primarily focused on the pro-inflammatory part of the immune system. 
114 
However, we are left with the partial picture of the disease mechanism without 
investigating the role of the adaptive immune response or anti-inflammatory aspects. 
21,34,36. 
Nucleotide-binding oligomerization domain-like receptors (NLRs) are an integral part of 
the innate immune system. They are important in both infection and injury by 
recognizing conserved microbial motifs, pathogen-associated molecular patterns 
(PAMPs) such as nucleic acid, and/or danger-associated molecular patterns (DAMPs) 
which are endogenous danger signals released from necrotic cells, such as adenosine 
triphosphate (ATP).  There are 22 identified NLRs in humans and 34 in mice. The NLRs 
are multi-faceted and they contribute to innate immunity by acting as either pro- or anti-
inflammatory mediators, thereby aiding in microbial clearance and wound healing 135. 
The NLR family, caspase activation and recruitment (CARD) domain containing 3 
(NLRC3), alternatively named as NOD3 or CLR16.2, is an under researched member of 
the NLR family. Similar to other NLRs, it has a tripartite domain; which includes a less 
well-defined CARD domain at the N-terminal, a nucleotide-binding domain (NBD) at 
the center, and a leucine-rich repeat domain (LRR) at the C-terminal. The NLRC3 gene 
is located on chromosome 16, and the protein encoded by this gene is localized in the 
cell cytoplasm. NLRC3 is mainly expressed by cells and tissues of the immune system, 
with highest expression reported in T lymphocytes, in both humans and in mice. It is 
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also highly expressed in natural killer cells (NK) and moderately expressed in B 
lymphocytes in humans 61, 60.  
 
The limited studies focused on NLRC3 describe its role in negatively regulating 
inflammation under pathological conditions and maintaining homeostasis in absence of 
immune challenge. NLRC3 has been reported to constitute a negative-feedback 
mechanism to monitor immune responses and cellular proliferation by attenuating T cell- 
61, Toll-like receptor 4 (TLR4)- 66, stimulator of interferon genes (STING)- 67, and 
mechanistic target of Rapamycin (mTOR)- 68 dependent signaling pathways. This 
consequently suppresses the activation and signaling by downstream transcriptional 
factors (e.g. nuclear factor kappa-light-chain-enhancer of activated B cells [NF-κB] and 
interferon regulatory factor 3 [IRF3]), and production of interferon (IFN) and pro-
inflammatory cytokines (such as tumor necrosis factor [TNF], interleukin-6 [IL-6]). 
Furthermore, NLRC3 may inhibit the formation of inflammasomes, multi-protein 
complexes that mediate caspase-1 activation and IL-1β and IL-18 production, by other 
NLR members (e.g. NLR family, pyrin domain containing 3 [NLRP3], NLR family, 
CARD domain containing 4 [NLRC4]) 60, 146.  
 
In our current study, we investigated the effect of Nlrc3 in the TMEV-induced murine 
model of epilepsy. For this, Nlrc3 deficient (Nlrc3-/-) mice (on C57BL/6 background) 
and wild type C57BL/6 mice were infected with TMEV, and examined for clinical signs 
of acute and chronic seizures, weight loss, seizures-associated behavioral abnormality, 
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leukocyte infiltration in the brain and cervical lymph nodes (CLNs), and demyelinating 
lesions in the spinal cord. The clinical examination of mice showed that the absence of 
Nlrc3 gene increased the susceptibility of infected mice to acute seizures (day 3-7 p.i.), 
and chronic seizures (day 8-week 30 p.i.). We further established that the increase in the 
occurrence of epileptic seizures in Nlrc3-/- group was not mediated by the infiltration of 
peripheral immune cells in the brain during chronic phase. We also found that the Nlrc3 
gene did not affect the resistance of C57BL/6 mice to TMEV-induced demyelinating 
disease as none of the infected Nlrc3-/- mice developed spinal cord lesions or exhibited 
clinical signs of the demyelinating disease in the chronic phase. In addition, we found 
that Nlrc3 deficiency led to significantly increased mobility and excitability (signs of 
behavioral abnormalities), but slightly faster recovery among mice following infection, 
while no behavioral abnormalities were detected in control mice due to Nlrc3 deficiency. 
Taken together, our results show that the Nlrc3 gene contributes in attenuating acute 
seizures and epilepsy in C57BL/6 mice following TMEV infection, but may require the 
involvement of other gene(s) to completely inhibit seizure activity.  
Materials and Methods 
Mice 
Six-to-nine-week-old female Nlrc3-/- mice were generously provided by Dr. Koichi K. 
Kobayashi, Department of Microbial Pathogenesis and Immunology, Texas A&M 
University, TX.  Age-matched female C57BL/6 wild type mice were purchased from 
117 
Taconic (Germantown, NY). Upon arrival, mice were assigned to one of four 
experimental groups, Nlrc3-/- sham-infected control, wild type sham-infected control, 
Nlrc3-/- virus-infected, and wild type virus-infected. Mice were placed in a pathogen-free 
facility, with 12 hours of light and dark cycle and controlled room temperature and 
humidity. Mice were provided with ad libitum food and water throughout the duration of 
the experiment. All animal experiments were approved by the Institutional Animal Care 
and Use Committee (IACUC) of Comparative Medicine Program at Texas A&M 
University, TX. 
Virus 
The BeAn strain of TMEV (ATCC) was initially propagated in baby hamster kidney 
(BHK) cells. Culture supernatant containing virus particles was collected and stored at -
80°C, and later used for infection 85. 
Infection  
After a week of acclimatization, mice in the infected groups were injected intracerebrally 
(I.C.) with 5.0 x 104 plaque forming unit (PFU) of BeAn strain in 20μl of Dulbecco’s 
modified eagle medium (DMEM) (Sigma, Life Science, St. Louis, MO). Mice in the 
control groups were injected I.C. with 20μl of 1x phosphate buffer saline (PBS). All 
injections were performed under isoflurane (Isoflo, North Chicago, IL) anesthesia. 
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Clinical scores 
During the acute phase, mice (n=4/control group and n=23-24/infected group) were 
examined for seizures twice daily between 9 AM to 6 PM until day 6 p.i. and the once 
on day 7 p.i. For epileptic seizures, control mice (n=4/group) and infected mice 
(n=12/group) were examined once weekly during the chronic phase (day 8 till week 30 
p.i.). Mice were scored on a Racine scoring scale: (1) Mouth and facial movements, (2) 
Head nodding, (3) Forelimb clonus, (4) Rearing, and (5) Rearing and falling progressing 
to tonic-clonic seizure 139.  
 
Body weight measurement 
During the acute phase, mice (n=4/control group and n=22-23/infected group) body 
weights were recorded daily until day 6 p.i. % weight loss was calculated as ([mouse 
weight on day nth p.i.- mouse weight on day 0 p.i.]/mouse weight on day 0 p.i.) *100.  
 
Elevated Plus Maze Test (EPMT) 
EPMT is one of the most common behavioral tests to determine behavioral anomalies 
such as anxiety-like symptoms in rodents. We followed the standard protocol from 
Komada et al. 90 with few modifications. The elevated plus maze was made of black 
Plexiglass. It consisted of two perpendicularly placed open (25 x 5 x 0.5 cm3) and closed 
(25 x 5 x 16 cm3) arms, with a platform (5 x 5 x 0.5 cm3) at the intersection of the arms. 
The maze was kept elevated at a height of 50 cm above the floor.  
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To determine the effects of mouse genotype, seizures, and time-interval p.i., EPMT was 
conducted at two different time-points, day 17 and day 34 p.i. The experiments were 
performed in two different isolated rooms to maintain novel environmental conditions. 
Mice were given 30 min to acclimate to the room prior to any testing. Experiments were 
performed during the day between 8:00 AM and 6:00 PM.  
To test for anxiety, each mouse (n=4/control group and n=5/infected group) was 
individually placed at the central platform with its head facing the same closed arm. 
Mice were given 5 min of test period to freely explore the maze. During this period, the 
number of entries in open and closed arms, and percentage (%) time spent in open arms 
were recorded for each mouse. An arm entry was defined as the placement of half of the 
mouse body mass in that arm of the maze. The % of time spent in open arms was 
calculated as [(time spent in open arms/total test time) x 100]. The number of entries and 
% time spent in open arms were used as a measure of anxiety-like behavior. The number 
of closed arm entries was used to determine locomotor activity. The maze was cleaned 
with 70% (vol/vol) ethanol between the tests to remove any feces, urine or animal odor. 
Tissue isolation 
To obtain tissues, mice were euthanized with 150mg/kg beuthanasia-D special 
(Schering-Plough Animal Health Corp. Union, NJ) and perfused intracardially using 10 
ml of 1x phosphate buffered saline (PBS). For histology, spinal cords were retrieved at 
week 30 p.i., and fixed in 10% formaldehyde for 5 days at room temperature. For flow 
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cytometry, brains and cervical lymph nodes (CLNs) were collected at week 30 p.i. in 
ice-cold RPMI 1640 (Gibco, Life Technologies, Grand Island, NY), and individually 
processed to analyze leukocyte populations.  
Flow cytometry 
To collect leukocytes from the brain, whole brains (n=3/ infected group) were gently 
homogenized using 70-micron (μm) FALCON cell strainer (21008-952; VWR, 
Sugarland, TX) and suspended in RPMI 1640 containing 5% fetal bovine serum (FBS). 
The cell suspensions containing brain homogenates were collected in individual 50 ml 
conical tubes, and centrifuged at 500 x g for 5 min at room temperature. After discarding 
the supernatant, each pellet was suspended in 10 ml of 30% Percoll (17-0891-01; GE 
healthcare, Uppsala, Sweden) in PBS. This solution was gently overlaid onto 2 ml of 
70% Percoll in PBS, and centrifuged at 500 x g for 30 min at 18°C. The leukocytes were 
collected from the 30% and 70% Percoll interphase, suspended in PBS, and centrifuged 
at 500 x g for 7 min at 18°C. The supernatants were discarded, and pellets were re-
suspended in 3 ml of ice-cold flow buffer containing 3% BSA and 0.1% sodium azide in 
PBS.  
To collect leukocytes from CLNs, the CLNs (n=3/infected group) were homogenized by 
gently grinding them with sterile microscopic slides. Then, the cell suspensions 
containing CLN homogenates were filtered using sterile, 70-μm nylon mesh. The 
filtrates containing leukocytes were collected in individual 15 ml conical tubes, and 
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centrifuged at 350 x g for 5 min at 4°C. The supernatants were discarded, and each pellet 
was suspended in 2 ml of flow buffer containing 3% BSA and 0.1% sodium azide in 
PBS. The cells were washed, re-suspended in flow buffer and maintained at 4°C. 
 
Staining procedure: Leukocytes from brain and CLNs were treated with Anti-Mouse 
CD16/CD32 (1:100, 14-0161-82; eBioscience, San Diego, CA) for 10 min at 4°C to 
prevent any non-specific binding. For phenotyping, cells were stained with the anti-
mouse antibodies as indicated below for 30 min at 4°C, washed and fixed with 2% PFA 
prior to flow cytometric analysis on BD FACSAria II. Data was analyzed using 
FlowJo® software V10.0.8r1 (Mac OS X, FlowJo, LLC, Ashland, OR). Ly-6G (Gr-1) 
was detected with clone RB6-8C5 (1:500, 12-5931-82; eBioscience, San Diego, CA). 
CD11c was detected with clone N418 (1:250, 17-0114-81; eBioscience, San Diego, CA). 
NK1.1 was detected with clone PK136 (1:500, 12-5941-63; eBioscience, San Diego, 
CA). CD11b was detected with clone M1/70 (1:500, 101224; BioLegend, San Diego, 
CA). CD45.2 was detected with clone 104 (1:100, 109805; BioLegend, San Diego, CA). 
CD8a was detected with clone 53-6.7 (1:250, 100711; BioLegend, San Diego, CA). CD4 
was detected with clone GK1.5 (1:500, 100428; BioLegend, San Diego, CA). B220 was 
detected with clone RA3-6B2 (1:500, 17-0452-83; eBioscience, San Diego, CA) 89,140.  
 
Histology: spinal cord  
Four μm paraffin-embedded sections from the spinal cords (n=7/ infected group) were 
stained with H&E. At least one transverse section from each spinal cord segment was 
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examined for the presence of inflammatory foci, axonal/neuronal degeneration, and/or 
meningitis. All images were acquired using a HRD076-NIK camera attached to 
OLYMPUS VANOX AHBS3 microscope. 
Statistical analysis 
For parametric analysis, one-way analysis of variance (ANOVA) with the Tukey’s 
multiple comparisons test or the unpaired t-test with the Welch’s correction was used. 
Body weights were analyzed using repeated measures two-way ANOVA with the 
Tukey’s multiple comparisons test. For nominal data (presence or absence of seizures), 
the Fisher’s exact test was used. For all cases, significance was determined when p ≤ 
0.05. Statistical analysis was done using GraphPad Prism version 6.0d (Mac OS X, 
GraphPad Software, La Jolla, CA). 
Results 
Nlrc3 deficiency aggravated susceptibility to TMEV-induced epilepsy. 
Corroborating previous studies, our acute phase results showed that TMEV infection 
resulted in ~71% (17/24) of wild type mice exhibiting seizures. In contrast to wild type 
mice, 100% (23/23) of Nlrc3-/- mice succumbed to acute seizures following infection 
(Fisher’s exact test, p<0.0001) (Figure 26A). Clinical examinations, conducted twice 
daily, showed that in wild type infected group, seizures began on day 3 p.i. and ceased 
after day 6 p.i., with highest number of seizures recorded on day 4 p.i. In the case of 
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Nlrc3-/- infected mice, a similar pattern of acute seizures was noted but seizures in this 
group lasted a day longer than the wild type infected group (until day 7 p.i.). We also 
found an increase in the number of seizures recorded per day in Nlrc3-/- group in 
comparison to the wild type group, with significant differences observed on days 3, 4 
and 7 p.i. (Fisher’s exact test, day 3: p=0.0009; day 4: p=0.0005; day 5: p=0.4665; day 6: 
p=0.8868; and day 7: p=0.0015) (Figure 26B). In both infected groups, the majority of 
seizures were of the highest intensity depicting tonic-clonic seizures, hence were given a 
score of 5 on the Racine scale (Figure 26C and D). As expected, no seizures were 
observed in any of the control groups. 
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Figure 26 Nlrc3 deficiency increased the susceptibility of mice for TMEV-induced seizures. (A) 
Acute phase results revealed a significant increase in the proportion of Nlrc3-/- infected mice with seizures 
in comparison to wild type infected mice. The % seized mice in each group was calculated as (number of 
seized mice/total number of infected mice) x 100. No seizures were observed in the control groups. (B) 
Daily examinations of mice showed that Nlrc3-/- infected group had significantly more seizures that lasted 
a day longer than wild type infected group. The % seizures per day was calculated as (number of seizures 
in a day /total number of infected mice) x 100. (C and D) In both the infected groups, seizures were mostly 
of highest intensity, i.e. stage 5, while few mice had seizures of stage 3 and 4 on the Racine scale. (**** 
p<0.0001, *** p<0.001, ** p<0.01 by Fisher’s exact test). Graphs (A, B, C, and D) show pooled results 
from four separate experiments expressed as percent, N=4 per control group and N=23-24 per infected 
group. 
During the weekly examination of the mice in the chronic phase, we observed two 
unprovoked behavioral seizures in ~8 % (1/12) of the wild type infected mice on week 
28 p.i. In comparison to the wild type group, ~42% (5/12) of Nlrc3-/- infected mice 
experienced behavioral seizures in the chronic phase. In the Nlrc3-/- infected group, 
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epileptic seizures occurred randomly. Seizures were documented as early as week 3 p.i. 
and were recorded until the day of termination (Figure 27). Moreover, the epileptic 
seizures observed per mouse varied from one to six in Nlrc3-/- group during the chronic 
phase. As expected, no seizures were observed in any of the control groups during either 
the acute or chronic phase. Collectively, our results show that knocking out Nlrc3 gene 
exacerbated TMEV-induced epilepsy. Conversely, the Nlrc3 gene moderately protected 
mice from developing acute seizures and epilepsy following CNS infection. 
Figure 27 Nlrc3-/- infected mice had increased susceptibility to TMEV-induced epilepsy compared to 
wild type infected mice. Weekly examinations of the mice showed that chronic seizures in Nlrc3-/- 
infected group started as early as week 2 p.i. and were recorded until the termination of mice, i.e. week 30 
p.i. In contrast to Nlrc3-/- mice, chronic seizures were only documented at week 28 p.i. in the wild type 
infected group. The seizure frequency in each group was calculated as number of seizures per week during 
chronic phase. Graph shows pooled results from two separate experiments expressed as seizure frequency, 
N=12 per infected group. 
Infected Nlrc3-/- mice showed faster recovery than infected wild type mice. 
To assess the effects of virus infection and genotype, mice from all four groups were 
weighed daily during the acute phase and once per week during the chronic phase. 
Changes in the weights of mice were similar between control groups, which indicates 
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that Nlrc3-/- mice do not show any growth abnormalities (Repeated measures two-way 
ANOVA with Tukey’s multiple comparisons test, day 0: p>0.9999; day 1: p=0.9976; 
day 2: p=0.9993; day 3: p=0.9372; day 4: p=0.8891; day 5: p=0.9890; and day 6: 
p=0.9925). Significant weight loss was evident in both infected wild type and Nlrc3-/- 
mice compared to their respective controls during the acute phase. Although, the weight 
change was not significantly different between the infected Nlrc3-/- group and the control 
Nlrc3-/- group on day 6 p.i., implying that infected Nlrc3-/- mice started to regain weight 
at this time-point (Repeated measures two-way ANOVA with Tukey’s multiple 
comparisons test between wild type control vs. wild type infected, day 0: p>0.9999; day 
1: p=0.0061; day 2 till day 6: p<0.0001; between Nlrc3-/-control and Nlrc3-/- infected, 
day 0: p>0.9999; day 1: p=0.0058; day 2 till day 4: p=<0.0001; day 5: p=0.0054; and 
day 6: p=0.1225). Both infected groups began to regain weight at day 3 p.i. and 
completely recovered by day 21 p.i., but the weight gain was significantly higher in 
Nlrc3-/- mice than wild type mice on days 5 and 6 p.i. (Repeated measures two-way 
ANOVA with Tukey’s multiple comparisons test, day 0: p>0.9999; day 1: p=0.9791; 
day 2: p=0.5336; day 3: p=0.2822; day 4: p=0.4155; day 5: p=0.0350; and day 6: 
p<0.0001 chronic phase) (Figure 28). Our results signify that although Nlrc3-/- mice 
experienced more seizures, they showed better recovery than wild type mice in terms of 
improvement in weight. 
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Figure 28 Nlrc3-/- infected mice showed better recovery than wild type infected mice. Mice from the 
control and infected groups were weighed daily until day 6 p.i. and then once weekly until day 56 p.i. Both 
the infected groups exhibited significant weight loss immediately following TMEV infection in 
comparison to their respective controls. However, Nlrc3-/- infected mice started to regain weight earlier 
than wild type infected group, indicating faster recovery in Nlrc3-/- infected group. Both the infected 
groups showed complete recovery by day 21 p.i., when their weights matched with those of their 
respective controls. (Between wild type control and infected groups: δδ p<0.01, δδδδ p<0.0001; between 
Nlrc3-/- control and infected groups: ## p<0.01, #### p<0.0001; between Nlrc3-/- infected and wild type 
infected groups: * p<0.05, **** p<0.0001 by Repeated Measures two-way ANOVA with Tukey’s 
multiple comparisons test). Graph shows pooled results from acute phase (days 0-6 p.i.) and chronic phase 
(days 14-56 p.i.) studies, expressed as mean ± SEM. During acute phase, results are from four separate 
experiments, N=22-23 per infected group, during chronic phase, result is from one experiment, N=6-7 per 
infected group. For control groups, N=4 during acute and chronic phase. 
Nlrc3 deficient mice developed aberrant emotional behavior following TMEV infection. 
We observed that infected Nlrc3-/- mice displayed hypermobility and excitable behavior 
even after seizures ceased. Therefore, we conducted EPMT to compare locomotor 
activity and behavioral differences between control and infected groups after seizures 
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resolved. EPMT is based upon an intricate balance between two main characteristics of 
mouse behavior, their natural aversion for open and elevated spaces and preference for 
dark and enclosed spaces, and their inherent curiosity for exploring novel environments 
90.  
Results from day 17 p.i. demonstrated significantly increased activity among infected 
Nlrc3-/- mice not only in the open arms, but also in the closed arms as indicated by open 
and closed arm entries (Figure 29B and C) (One way ANOVA with Tukey’s multiple 
comparisons test-open arms entries, between wild type control and Nlrc3-/- control: 
p=0.9605; between wild type control and wild type infected: p=0.9648; between Nlrc3-/- 
control and Nlrc3-/- infected: p=0.0010; and between wild type infected and Nlrc3-/- 
infected: p=0.0039) (One way ANOVA with Tukey’s multiple comparisons test-closed 
arms entries, between wild type control and Nlrc3-/- control: p=0.2918; between wild 
type control and wild type infected: p=0.8430; between Nlrc3-/- control and Nlrc3-/- 
infected: p=0.0040; and between wild type infected and Nlrc3-/- infected: p=0.0235). As 
shown in figure 29A, infected Nlrc3-/- mice also spent significantly more time in the 
open arms than control Nlrc3-/- mice and infected wild type mice (One way ANOVA 
with Tukey’s multiple comparisons test-% time spent on open arms, between wild type 
control and Nlrc3-/- control: p=0.9910; between wild type control and wild type infected: 
p=0.9906; between Nlrc3-/- control and Nlrc3-/- infected: p=0.0018; and between wild 
type infected and Nlrc3-/- infected: p=0.0035). To confirm our findings, we repeated the 
test on day 34 p.i. The second EPMT showed similar results with respect to significantly 
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increased activity among infected Nlrc3-/- mice in the open arms (Figure 29D and E) 
(One way ANOVA with Tukey’s multiple comparisons test-open arms entries, between 
wild type control and Nlrc3-/- control mice: p=0.9917; between wild type control and 
wild type infected mice: p=0.9903; between Nlrc3-/- control and Nlrc3-/- infected mice: 
p=0.0531; and between wild type infected and Nlrc3-/- infected mice: p=0.0385) (One 
way ANOVA with Tukey’s multiple comparisons test-% time spent on open arms, 
between wild type control and Nlrc3-/- control mice: p=0.9947; between wild type 
control and wild type infected mice: p=0.9846; between Nlrc3-/- control and Nlrc3-/- 
infected mice: p=0.0427; and between wild type infected and Nlrc3-/- infected mice: 
p=0.0252). As shown in figure 29F, the activity of infected Nlrc3-/- mice in the closed 
arms was not different in comparison to mice from other groups (One way ANOVA with 
Tukey’s multiple comparisons test-closed arms entries, between wild type control and 
Nlrc3-/- control: p=0.4690; between wild type control and wild type infected: p=0.6393; 
between Nlrc3-/- control and Nlrc3-/- infected: p=0.0801; and between wild type infected 
and Nlrc3-/- infected: p=0.1210). Thus, our results showed that Nlrc3-/- mice developed 
aberrant emotional behavior (anxiolytic) and increased locomotor activity following 
infection. 
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Figure 29 Nlrc3 deficient mice developed aberrant emotional behavior following TMEV infection. 
We conducted EPMT to determine behavioral abnormalities among infected mice during chronic phase. 
Graphs A-C are from study conducted on day 17 p.i., and graphs D-F are from study conducted on day 34 
p.i. The EPMT results show that Nlrc3-/- infected mice spent significantly more time exploring the open 
arms, and had significantly higher open and closed arms entries than the other groups, indicating 
hypermobility and development of anxiolytic behavior. The % time spent in open arms was calculated as 
(time spent in open arms/time spent in open and closed arms) x 100. The number of entries in open and 
closed arms was recorded manually at the time of the experiment. Graphs show results expressed as mean 
± SEM, N=4 per control group and N=5 per infected group. (* p<0.05, ** p<0.01, *** p<0.001 by one-
way ANOVA with Tukey’s multiple comparisons test). 
Seizures in the chronic phase were not mediated by neuro-inflammation. 
Previous studies reported that activation and infiltration of innate immune cells into the 
CNS may contribute to the development of acute seizures 21, 97. Therefore, we wanted to 
determine whether chronic inflammation played a role in instigating epileptic seizures. 
For this purpose, we analyzed leukocyte populations in the brain and CLNs at week 30 
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p.i. In both infected groups (Figure 30A), the leukocyte profile from the brain showed 
minimal or no activation of peripheral immune cells (Unpaired t test with Welch’s 
correction, CD45.2 intermediate CD11b+: p=0.1748; CD45.2 high CD11b+: p=0.3600; 
CD45.2 high Gr1+: p=0.6368; CD45.2 high NK1.1+: p=0.2596; CD45.2 high CD11c+: 
p=0.5029; CD45.2 high CD8+: p=0.7768; CD45.2 high CD4+: p=0.3304; and CD45.2 
high B220+: p=0.3767). In the case of CLNs (Figure 30B), no significant differences 
were seen between the infected groups, but we found a higher expression of adaptive 
immune cells (CD45.2 high CD4+ [T helper cells], CD45.2 high CD8+ [Cytotoxic T 
cells], and CD45.2 high B220+ [B cells]) than other cell types in both groups (Unpaired t 
test with Welch’s correction, CD45.2 high CD11b+: p=0.0128; CD45.2 high Gr1+: 
p=0.7619; CD45.2 high NK1.1+: p=0.4597; CD45.2 high CD11c+: p=0.1389; CD45.2 
high CD8+: p=0.3393; CD45.2 high CD4+: p=0.0903; and CD45.2 high B220+: 
p=0.2279). Consequently, we eliminated the role of inflammation in causing epileptic 
seizures following TMEV infection. 
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Figure 30 Seizures in the chronic phase were not mediated by neuro-inflammation. To determine 
whether chronic inflammation contributed to epileptic seizures, innate and adaptive leukocyte populations 
were analyzed from brain and CLNs of infected mice at week 30 p.i. Surprisingly, we found minimal or no 
expression of peripheral immune cells in the brain during the chronic phase. In addition, the expression 
levels of leukocytes populations from brain and CLNs were similar between the infected groups, 
indicating that epileptic seizures were not the result of chronic inflammation. Graphs show results 
expressed as mean ± SEM, N=3 per infected group. (Unpaired t test with Welch’s correction). 
Nlrc3 deficient mice sustain their resistance to demyelinating disease following TMEV 
infection. 
Wild type mice are known to be resistant to TMEV-induced demyelinating disease of the 
CNS 43,130. To investigate whether infected Nlrc3-/- mice develop chronic inflammation 
or demyelinating lesions in the spinal cord, we compared spinal cord histology between 
the two infected groups at week 30 p.i. Like the wild type mice, no lesions or active 
inflammation was recorded from spinal cords of Nlrc3-/- mice in the chronic phase. Our 
results indicate that Nlrc3 gene did not alter the resistance of C57BL/6 mice to 
demyelinating disease of the CNS (Figure 31A and B). 
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Figure 31 Nlrc3 deficient mice sustain their resistance to demyelinating disease following TMEV 
infection. To assess the effect of the Nlrc3 gene on susceptibility of C57BL/6 mice to TMEV-induced 
demyelinating disease, the spinal cords from Nlrc3-/- mice were collected at week 30 p.i., stained with 
H&E and compared to that of wild type mice. A and B are the representative images (100x) of the thoracic 
segment of the spinal cord from wild type and Nlrc3-/- mice, respectively. Unlike in the susceptible SJL 
mice, we did not find any pathological condition in the spinal cords from either Nlrc3-/- or wild type group, 
indicating that the Nlrc3 gene does not regulate the resistance of C57BL/6 mice to TMEV-induced 
demyelinating disease. 
Discussion 
The immune system plays an important role in defense against microbial infection and 
wound healing. However, dysregulated and heightened immune activity in response to 
infection may cause inflammatory disorders and autoimmune diseases. Therefore, the 
right balance between the functions of pro- and anti-inflammatory mediators is vital for 
maintaining homeostasis. NLRs are intracellular pattern recognition receptors that play 
an essential part in innate immunity. Several NLRs (such as NLR, domain containing 2 
[NOD2]) initiate early, non-specific immune responses against infection, while others 
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(such as NLR family member X1 [NLRX1]) participate in restoring immune responses 
to basal levels after microbial clearance 135. 
Studies on NLRC3 have only recently been started and the current literature implicates 
its role in downregulating immune responses. Conti, Davis and colleagues 61 found that 
NLRC3 expression significantly reduces upon T-cell receptor (TCR)- and CD28-
dependent stimulation of primary T cells, while addition of exogenous NLRC3 
significantly downregulates the induction of signaling pathways (e.g. NF-κB, activator 
protein-1 [AP-1], and Nuclear factor of activated T-cells [NFAT]), and downstream 
inflammatory molecules (e.g. IL-2 and CD25) in activated T cells. Thus, they proposed 
that NLRC3 plays a role in limiting the activation and signaling of T cells. Schneider, 
Zimmermann et al. 66 demonstrated an inhibitory effect of NLRC3 on TLR-dependent 
signaling, which is mediated by impairing the activation of TRAF6, a TLR signaling 
adaptor molecule. They further found that wild type mice administered with 
lipopolysaccharide (LPS), a TLR4 ligand, have reduced expression of Nlrc3 mRNA in 
their peritoneal cells, but Nlrc3 expression levels return to basal levels at later time-
points. Furthermore, LPS-stimulated macrophages from Nlrc3-/- mice have increased 
production of TRAF6, NF-κB, and pro-inflammatory cytokines (TNF, IL-6, and IL-1β) 
compared to wild type macrophages at early time-points. This effect diminishes at later 
time-points. In vivo studies showed that LPS-treated Nlrc3-/- mice develop increased 
intensity of inflammation and clinical illness compared to wild type mice; thus, they 
showed a protective role for Nlrc3 in the LPS-induced mouse model of endotoxic shock. 
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Zhang, Mo and others 67 found that NLRC3 blocks the association between STING and 
TANK-binding kinase 1 (TBK1), thereby reducing the activation of STING-dependent 
innate immune signaling (NF-κB and IRF3) under basal conditions and in case of 
infection against cytosolic DNA, and DNA viruses. They also found that bone marrow-
derived macrophages (BMDMs) and mouse embryonic fibroblasts (MEFs) from Nlrc3 
deficient mice have increased production of type I IFN, IL-6 and TNF, and reduced viral 
load in response to DNA viruses such as Herpes simplex virus-1 (HSV-1). However, 
they did not find similar responses against RNA viruses, such as Sendai virus (SeV) and 
vesicular stomatitis virus (VSV). Moreover, HSV-1-infected Nlrc3-/- mice exhibit 
increased inflammation (increased production of IFN-1, TNF-a, IL-6), faster recovery in 
terms of body weight, and reduced viral load compared to wild type mice. Karki, Man, et 
al. 68 found that Nlrc3 expression significantly decreases in the tumor tissue of wild type 
mice with colitis-associated colorectal cancer. In addition, Nlrc3-/- mice show increased 
susceptibility to colitis and colorectal tumorigenesis as they develop pronounced weight 
loss, damage to the colon, tumor growth, and inflammation in comparison to wild type 
mice. Nlrc3-/- mice also have increased expression levels of innate immune cells 
(macrophages, NK cells, and neutrophils), pro-inflammatory cytokines (IL-1β, IL-6, 
TNF, etc.) and chemokines (macrophage chemoattractant protein-1 [MCP-1], monocyte 
inflammatory protein-1α [MIP-1α], etc.) and increased activation of immune signaling 
pathways in colon tissue. Thus, they proposed that Nlrc3 protects mice against colitis 
and colorectal tumorigenesis by reducing the activation of mTOR-signaling pathways at 
earlier time-points, thereby decreasing cellular proliferation and stem-cell-derived 
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organoid formation at later time-points. Since, wild type mice with normal expression of 
Nlrc3 are not completely tumor free, we assume that Nlrc3 provides partial protection 
against tumor development. In addition, Gültekin, Erin and Özören 60, 146 found that 
NLRC3 blocks the formation of NLRP3 and NLRC4 inflammasomes, thus decreases the 
production of IL-1β and IL-18 cytokines.  
 
Libbey, Kennett and group have reported that wild type mice develop acute seizures 
following TMEV infection, and the proportion of mice affected with seizures vary based 
on the amount of TMEV used 35. In the current study, we found that 5.0 x 104 pfu of 
BeAn strain of TMEV induced seizures in ~71% of wild type mice, while the same viral 
titers caused seizures in all Nlrc3-/- mice following infection. Stewart, Wilcox et al. 
further found that infected wild type mice are known to recover from acute symptomatic 
seizures after a week p.i. and clear virus within a month p.i., but video-
electroencephalogram (VEEG) monitoring has shown that 40-64% of them proceed to 
develop spontaneous behavioral seizures and 100% of them exhibit epileptiform activity 
during 2nd, 4th and 7th month p.i. 36. In our present study, the weekly examinations of 
mice during the chronic phase (until week 30 p.i.) showed that only one of the 12 
infected wild type mice displayed behavioral seizures, while Nlrc3 deficiency led to 
behavioral seizures in five of the 12 infected mice. Future studies using VEEG 
monitoring may help us provide results that are more accurate.  
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In line with past studies 34, we found that TMEV infection induced acute weight loss 
among wild type mice in comparison to their controls, and infected mice completely 
recovered by week 2 p.i. TMEV infection in Nlrc3-/- mice also resulted in significant 
acute weight loss compared to their controls. However, infected Nlrc3-/- mice had higher 
gain in body weight and therefore better recovery than infected wild type mice in spite of 
increased seizures occurrences.  
 
Using behavioral tests, such as open-field and light/dark box, Umpierre, et al. found that 
TMEV-infected wild type mice develop anxiety-like symptoms after acute seizures 
resolve 38. However, using a different behavioral test (EPMT) we were unable to find 
any behavioral or locomoter abnormality among wild type infected mice. The difference 
in results from infected wild type mice could be due to the use of different TMEV 
strains, behavioral tests, or time at which the tests were conducted. Furthermore, Nlrc3-/- 
mice displayed significant aberrations in locomotor activity and behavioral symptoms 
that resembled anxiolytic activity, signifying a peculiar role of Nlrc3 gene in regulating 
mouse behavior that is highlighted post infection. 
 
Moreover, we discovered that epileptic seizures were not the result of chronic 
inflammation in the CNS, as neither the wild type group nor the Nlrc3-/- group showed 
pertinent immune cell infiltration into the CNS at week 30 p.i. Additionally, the infected 
groups did not show any significant differences in the leukocyte populations draining the 
CLNs. Since acute seizures are largely mediated by acute elevation in the activation and 
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infiltration of innate immune cells in the CNS 21, our chronic phase results support the 
idea that the mechanisms of induction of acute and chronic seizures are different in this 
experimental model. Wild type mice exhibit hippocampal sclerosis and glial scarring in 
the chronic phase 36; hence, our next step would be to analyze the extent of neuronal 
damage and glial activation in the hippocampus of Nlrc3-/- mice in chronic phase. 
Examination of spinal cord histology at week 30 p.i. did not show demyelinating lesions 
in wild type or Nlrc3-/- mice, indicating that Nlrc3 gene does not alter the resistance of 
wild type mice to TMEV-induced demyelinating disease. 
 
Here we found that in contrast to wild type mice, all the Nlrc3-/- mice exhibited 
pronounced seizures in the acute phase and about half of them developed spontaneous 
seizures in the chronic phase. Our study showed that Nlrc3 protects mice from TMEV-
induced acute seizures and epilepsy to an extent. Acute pronounced inflammation 
contributes to initiation of acute seizures in wild type mice. Increased incidence of acute 
seizures in Nlrc3-/- mice could be due to suppression of the inhibitory role of Nlrc3 on 
acute inflammatory mediators, which requires further research. Taken together, our 
study identified an anti-inflammatory target in the innate immune system, which 
mitigates both acute seizures and epilepsy induced by TMEV infection. Future studies 
using Nlrc3 agonists may help to discover potential anti-epileptic drugs. 
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CHAPTER V  
CONCLUSIONS  
  
Epilepsy is a complex neurological disease characterized by unprovoked seizures 2, and 
is often associated with psychosocial impairments 98. There is no existing cure for 
epilepsy. Symptomatic treatment is available to suppress seizure frequency, but current 
medications still fail to prevent seizures in 30% of the affected population. Therefore, 
further studies are required to better understand the pathophysiology of seizures, and to 
delineate more promising therapeutic targets 6,7.  
 
TMEV-induced murine model of epilepsy 
 
The TMEV-induced epilepsy in C57BL/6 mice was first reported by the Fujinami group 
almost a decade ago 34. Since then, studies have been conducted to investigate the effects 
of distinct leukocytes subtypes, cytokines, and chemokines, etc. in the development of 
acute seizures and epilepsy. Past studies have revealed that the local glial cells 
(microglia and astrocytes) in the brain become activated in response to TMEV infection. 
Activated glial cells secrete pro-inflammatory cytokines and chemokines to activate and 
attract non-resident or peripheral immune cells to the site of insult (hippocampus). 
Although, the brain is considered as “immuno-privileged”, the dysregulated local 
immune responses disrupt the integrity of the BBB and cause leakage of peripheral 
immune cells into the CNS. The infiltrating immune cells such as macrophages, 
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granulocytes, etc. contribute to already heightened immune responses, pose a grave 
threat to the viability of neurons, and lead to acute seizures. The infected mice 
successfully clear virus from the CNS within a month p.i., but the overzealous acute 
inflammation, hippocampal damage and seizures themselves render mice susceptible to 
subsequent chronic seizures (epilepsy) 20,21,34,35,78,97.  
 
TMEV-induced demyelinating disease model 
 
TMEV infection induces a biphasic disease in SJL mice, where acute poliomyelitis-like 
symptoms appear in the early phase and demyelinating disease of the CNS occurs in the 
late phase. In the early phase, mice usually develop flaccid paralysis, while in the late 
phase of the disease, mice develop a waddling gait, body tremors, inactivity, impaired 
righting reflex, etc. Virus is mainly found in neurons in the early phase, while virus 
continues to persist in macrophages, astrocytes, and oligodendrocytes in the late phase of 
the disease 24,71,72,75,76. The increased activation and expansion of T regulatory cells 147, 
and increased expression of anti-inflammatory cytokine (IL-10) 148 in the CNS of SJL 
mice could contribute to the inefficiency of T cell responses in mediating viral clearance. 
The late phase of the disease is characterized by pronounced mononuclear cell 
infiltration in the leptomeninges and white matter accompanied with primary 
demyelination in the spinal cord 24,71. Since the clinical features of the demyelinating 
disease resemble with human multiple sclerosis (MS), TMEV-infected SJL mouse model 
has been extensively used to study the pathogenesis of MS.  
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To further analyze the virus-specific effects on the disease pathogenesis, Oleszak, 
Leibowitz et al. isolated and characterized two plaque-sized variants, DA-DS and DA-
CL, of the DA strain of TMEV. Both variants were found genetically stable but they had 
different growth kinetics and neurovirulence in SJL mice. They found that DA-DS 
plaque-sized variant was highly neurovirulent, had higher viral growth, and induced 
more severe demyelinating disease than the parental DA virus. In contrast to DA-DS and 
parental DA virus, the DA-CL plaque-sized variant yielded lower titers, and was unable 
to induce any clinical disease, even though it persisted in the CNS of SJL mice 80. 
 
Virulence and pathogenicity of plaque-sized variants of DA strain in epilepsy 
 
To determine the virus-specific effects in the pathogenesis of epilepsy, we infected 
C57BL/6 mice with either DA-DS or DA-CL, and compared the disease pathogenesis 
with sham-infected mice. We found that the DA-DS variant induced acute seizures in 
~94% of infected mice, while the DA-CL variant induced seizures in ~12% of infected 
mice Besides experiencing severe seizures, the DA-DS-infected mice also exhibited 
significantly higher sickness scores (non-epileptic clinical illness), and increased weight 
loss, viral burden in the CNS, neuro-edema, neuro-inflammation, hippocampal damage 
and anxiety-like symptoms than the DA-CL-infected mice. However, spatial-associated 
memory was found to be impaired in both DA-DS- and DA-CL- infected mice. Unlike 
the parental DA virus-infected mice, we found high seizure occurrence and minimal 
phenotypic variability among the DA-DS-infected mice. Therefore, we propose that the 
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DA-DS-induced epilepsy model would be better suited to understand the disease 
pathogenesis and to test potential therapeutic drugs for treating epilepsy. 
 
Moreover, upon comparing the genome sequences of DA-DS and DA-CL variants, we 
found three coding differences at the protein level, in the Leader (L), L*, and 2C 
proteins. The ability to impair the innate host immune response (IFN production) in 
certain cell types by either Leader or L* contributes to viral evasion of the host immune 
response and viral persistence 118,123,124,126,127. Thus, we suggest that the mutations in the 
Leader and L* proteins of DA-CL resulted in the attenuated phenotype of the DA-CL 
variant in the C57BL/6 mouse model of epilepsy. Further studies are required to 
understand the distinct effects of the leader and L* proteins. 
 
Implication of NLRs in neurological diseases 
 
The NLRs are the intracellular microbial sensors, broadly classified as pro-inflammatory 
or anti-inflammatory based upon their role in inflammation 48. Their expression has been 
found in brain cells, such as microglia 149, astrocytes 150, neurons 151, pericytes 142, and 
endothelial cells 143. Moreover, several NLRs have been implicated in neurological 
diseases; e.g. NLR family, pyrin domain containing 1 (NLRP1) 152 and NLR family, 
pyrin domain containing 3 (NLRP3) 153 in Alzheimer’s disease; NLRP3 in multiple 
sclerosis 154; NLR family, CARD domain containing 4 (NLRC4), absent in melanoma 2 
(AIM2) 155, and NLRP1 156 in stroke; NLRP1 in traumatic brain injury 157; NLRC5 in 
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bipolar disorder 158; etc. With respect to epilepsy, the NLRP1 inflammasome has been 
suggested to promote neuronal death and chronic spontaneous seizures in an electrically-
induced rat model of epilepsy. However, investigators did not find any changes in the 
occurrence of acute seizures upon NLRP1 silencing 145. Here, we studied the effects of 
Nlrc5 and Nlrc3 genes, in the pathogenesis of, and susceptibility to, TMEV (BeAn 
strain)-induced mouse model of epilepsy using Nlrc5-/- and Nlrc3-/- mice.  
 
The role of Nlrc5 gene in TMEV-induced experimental model of epilepsy 
 
The clinical studies showed that upon TMEV infection, Nlrc5-/- group showed a 
significant decrease in the proportion of mice suffering from seizures, and exhibited 
lower sickness scores and weight loss when compared with wild type mice. Flow 
cytometry studies from day 3 p.i. showed a significant increase in the expression levels 
of CD45.2 high CD11b+ cells (macrophages, granulocytes) and CD45.2 high Gr+ cells 
(granulocytes), but a significant reduction in the expression levels of CD45.2 high 
NK1.1+ cells (NK cells) in the brains from Nlrc5-/- infected mice compared to wild type 
infected mice. Using immunohistochemistry, we found a significant decrease in the 
number of astrocytes in the hippocampus of Nlrc5-/- infected mice than wild type 
infected mice on day 7 p.i. The gene expression studies using brains from Nlrc5-/- 
infected mice showed a significant reduction in the mRNA levels for the genes involved 
in the MHC class I pathway (H2-Kb, β2m, and Tap1), I1-1β, Ifn-β, and iNOS compared 
to the wild type infected mice on day 7 p.i. However, Nlrc5-/- and wild type infected 
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mice showed no differences in mRNA levels for the genes involved in the MHC class II 
pathway (H2-Aa, Ciita), TMEV, Il-6, Tnf-α, Ifn-γ, Mcp-1, Rantes, and Mip-2. In 
addition, wild type infected mice showed a significant increase in the mRNA expression 
of Nlrc5 compared to wild type control mice. Taken together, we found that in the wild 
type mice, the presence of intact Nlrc5 promotes seizures, sickness behavior, and weight 
loss by exacerbating neuroinflammation following infection with TMEV. As reported by 
other groups 54,55,57,59,138,144, activated Nlrc5 may modulate inflammation by regulating 
NF-κB - and IFN-signaling pathways and/or by regulating inflammasomes formed by 
other NLRs upon TMEV infection. However, further studies are required to understand 
these interactions. Nonetheless, our findings suggest a pro-inflammatory role of Nlrc5 
gene in in vivo model of TMEV-induced epilepsy. 
 
The role of Nlrc3 gene in TMEV-induced experimental model of epilepsy 
 
With regards to Nlrc3, our studies determined an anti-epileptic effect of Nlrc3 gene in 
TMEV-induced epilepsy. The clinical studies following infection showed that Nlrc3-/- 
mice had a significant increase in the susceptibility to TMEV-induced epilepsy. All 
Nlrc3-/- infected mice developed acute seizures, while ~30% of wild type infected mice 
remained seizure free during the first week p.i. In addition, Nlrc3-/- infected group had 
increase in the frequency of spontaneous seizures when compared with wild type 
infected group. We found minimal or no infiltration of peripheral leukocytes into the 
brain of wild type and Nlrc3-/- mice at week 30 p.i. Therefore, we suggest that unlike 
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acute seizures, chronic seizures do not correlate with the infiltration of peripheral 
leukocytes into the CNS. However, neuronal damage caused by acute phase 
inflammation may predispose mice to epilepsy. Additionally, we identified the 
development of aberrant behavior (anxiolytic) and hypermobility in Nlrc3-/- mice 
following infection, which was not found in wild type infected group.  
Karki, Man, et al. recently proposed a protective role of Nlrc3 in the mouse model of 
colitis and colorectal tumorigenesis by suppressing the activation of mTOR-signaling 
pathway, and subsequently downregulating cellular proliferation. They found that 
affected wild type mice showed reduced expression of Nlrc3 in their tumor tissue 
compared to control mice. However, the disease pathogenesis in Nlrc3-/- mice worsened 
as these mice developed more colon tumors and had increased damage to their colon. 
Furthermore, Nlrc3-/- mice showed a significant increase in the expression levels of 
innate immune cells (macrophages, NK cells, and neutrophils), pro-inflammatory 
cytokines (IL-1β, IL-6, TNF, etc.) and chemokines (macrophage chemoattractant 
protein-1 [MCP-1], monocyte inflammatory protein-1α [MIP-1α], etc.) and increased 
activation of immune signaling pathways in colon tissue in comparison to the wild type 
mice 68.  
Notably, mTOR signaling pathway was also found to be activated in the 
chemoconvulsant (kainic acid [KA])-induced rodent model of epilepsy by two different 
groups. Shacka, Lu and colleagues found an acute activation of mTOR pathway in the 
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hippocampi of mice treated with KA 159, while Zeng, Rensing et al. found a biphasic 
activation of mTOR pathway in rats following KA treatment. An early phase of mTOR 
activation was seen in hippocampi and neocortex immediately after the onset of acute 
seizures, and mTOR activation lasted roughly until the resolution of acute seizures. A 
delayed phase of mTOR activation occurred in hippocampus alone that coincided with 
the period of epileptogenesis. Furthermore, they found that affected rats that were 
pretreated with Rapamycin, a mTOR inhibitor, had reduced activation of mTOR in both 
early and delayed phases, which consequently decreased the frequency of spontaneous 
seizures, and reduced neuronal death, neurogenesis, and mossy fiber sprouting. The 
affected rats that were treated with rapamycin within 24 hours after the resolution of 
KA-induced status epilepticus, had reduced mTOR activation in the chronic phase and 
decreased development of mossy fiber sprouting and frequency of spontaneous seizures. 
In addition, pretreatment with Rapamycin did not affect the seizure phenotype in the 
acute phase 160. Like in the KA-induced model of epilepsy, the mTOR pathway could be 
of relevance in the TMEV-induced model of epilepsy. Since Nlrc3 strongly 
downregulates mTOR pathway, the hyper-susceptibility to TMEV-induced epilepsy seen 
among Nlrc3-/- infected mice could be a result of the inhibition of Nlrc3-mediated 
suppression of mTOR pathway. Future studies demonstrating the interaction between 
Nlrc3 and mTOR signaling pathway in TMEV infection would give us better insight into 
the role of Nlrc3 in the development of epilepsy.  
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Inflammation is essential for host defense against microbial infection and restoring 
homeostasis. Therefore, an appropriate balance is required between pro-inflammatory 
and anti-inflammatory mediators in response to injury or infection. However, 
dysregulated immune responses generated against TMEV infection lead to increased 
hippocampal pathology and seizures in C57BL/6 mice. Our findings suggest that 
mutated viruses may have altered neurovirulence, and can modulate host immune 
responses, causing subsequent alterations in disease pathogenesis. The differences 
between seized and non-seized mice following infection would aid in narrowing down 
the search for the critical factors that are of paramount importance in epilepsy. We also 
found unique and distinct effects of Nlrc5 and Nlrc3 genes in TMEV-induced epilepsy. 
The Nlrc5 gene was found to be pro-inflammatory, as its deficiency suppressed neuro-
inflammation and protected the infected C57BL/6 mice from seizures. On the other 
hand, the Nlrc3 gene was found to be anti-inflammatory, as its deficiency significantly 
increased the susceptibility of C57BL/6 mice to acute and chronic seizures. Here, we 
found two potential inflammatory targets that could mitigate epilepsy. Future trials to 
test treatments downregulating the effects of Nlrc5 gene or promoting the effects of 
Nlrc3 gene may prove beneficial in further controlling seizures.  
 
Future directions 
 
TMEV-induced epilepsy in C57BL/6 mice proves to be an excellent model to study 
epileptogenesis, and mechanism of acute and chronic forms of seizures. Using plaque-
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sized variants of DA strain, we found that mutated virus can significantly alter disease 
phenotype and can successfully modulate host inflammatory components. Therefore, 
future studies are required to investigate the specific effects of mutated viral proteins in 
regulating virulence and disease pathogenesis. We also identified the unique and 
contrasting roles of Nlrc5 and Nlrc3 in epilepsy development. We showed that Nlrc5 is a 
positive regulator of inflammation and seizures, while Nlrc3 serves as check-point to 
suppress both acute and chronic seizures. In addition, Nlrc3 regulates anxiolytic-
behavior in mice under pathological conditions. Future studies determining the temporal 
expression and localization of Nlrc5 and Nlrc3 in the CNS would help in clarifying the 
mechanism of action of NLRs in epilepsy. To conclude, we found that both the virus and 
inflammation generated in response to virus infection are critical for the development of 
seizures. However, the exact cause of seizure onset at day 3 p.i. and the abrupt cessation 
of seizures at day 7 p.i. needs to be further elucidated.   
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